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Breast cancer affects ~55,000 women in the UK annually. Key to the reliable management of the
disease is robust characterisation of an individual’s tumour, to best determine the most appropri-
ate treatment and likely prognosis. High-throughput measurement of gene expression has driven
recent developments in improved clinical patient stratification but difficulties in accuracy and sen-
sitivity persist. Key to producing — and validating — predictive signatures of disease response
and progression lies in utilising patient-derived material, to maximise a study’s relevance to clin-
ical practice. Traditionally, measurements taken at diagnosis or surgery have been correlated with
long-term outcomes, such as evidence of recurrence or metastasis. These post-operative studies
often take place over the course of decades and are understandably restricted in terms of speed, ef-
ficiency and cost. In contrast, the pre-operative neoadjuvant setting allows expedited, short course
studies that maximise the information available from a tumour whilst it is still in situ, allowingmul-
tiple characterisations of the tumour to be performed over time. The in situ nature of neoadjuvant
study has allowed phenotypic and molecular characterisation to be performed in concert, allowing,
for example, treatment response to be explained in terms of variation in gene expression. Sup-
porting these neoadjuvant studies are routine biobanking operations, facilitating repeated tumour
sampling and physiological characterisations. A happy side-effect of this indiscriminate sampling
strategy is the generation of cohorts that do not fit the traditional neoadjuvant model and offer the
potential to query alternative hypotheses. This thesis makes use of two of these cohorts to inves-
tigate each of (i) intra-tumour heterogeneity under conditions of no-treatment and (ii) long-term
latent treatment resistance. Key results include demonstrating a biopsy method-specific effect on
gene expression and revealing a role of epigenetic modification in endocrine treatment resistance,
respectively. In addition, a more generally applicable methodology to illustrate and quantify the as-
sociation of a continuous variable — such as gene expression — with outcome is described. Taken
together, these parallel threads depict the emerging utility of the neoadjuvant setting in portray-
ing difficult to model clinically relevant aspects of cancer treatment and response. The results will
likely prove to guide clinical best practice as well as inform future studies, with the novel datasets
generated allowing comparison, validation and further analysis.

Lay abstract
Just as the weather can be forecast using patterns of temperature, humidity and pressure, cancer
can be diagnosed bymeasuring patterns within our bodies. The hope is to be able to tell if a person’s
cancer will respond or not respond to treatment. Just like with a weather forecast, this allows us
to make decisions of how to act. We can both choose whether to treat when necessary (or wear a
raincoat), as well as when not to treat (so that we aren’t caught wearing three jumpers on the hottest
day of the year). Here we are forecasting the likely course of events but, as anyone caught in a sud-
den shower will know, weather forecasts, like cancer forecasts, are often not always reliable. More
recently, new technologies have enabled these measurements to be made on smaller and smaller
parts of us, even to the point of looking at what is happening within a single cell. It is hoped that
these finer measurements will allow for more accurate forecasts but, just as we would have to wait
a week or so to check whether a weather forecast is correct, we often have to wait decades to check
whether a cancer forecast is correct or not. This is like waiting to check if it rained or not by seeing
if a lake had formed 100 years in the future. The reason for this wait is because the tumour is re-
moved at the time the forecast is made and there is nothing left to check whether the treatment is
working or not. Not only is this delay far too long a time, the cost of running such a study is large.
For cancer, forecasting can be sped up by taking measurements earlier. Here we can look at how
these measurements compare to how the tumour responds whilst it is still in place. We can then
find the similarities between people whose tumours respond, and those between people whose tu-
mour did not respond. Knowing these similarities we can test a new cancer and predict whether
they are more similar to the responders or the non-responders. Unfortunately, cancer treatment is
more complicated than simply whether someone will respond or not, and patients often respond to
treatment at first before becoming resistant. In this thesis we will use early tumour measurements
to help guide how cancer forecasts should best be made, asking - (i) can resistant tumours be fore-
cast and (iii) what happens when we forecast tumours that are untreated. Together, these threads
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Cancer is a dysregulation of otherwise normal function necessary to develop and preserve
life.i It corrupts the same biochemical complexities that grant organisms greater diversity,
survival and fitness,ii complexity that ultimately provides opportunity for perturbation. In
simpler terms, the more complex the system becomes the more challenging it is to keep
the scales of growth, survival, and death balanced appropriately6. This is captured in the
widely cited cancer hallmarks7, with dysregulation of growth signalling, apoptosis, replica-
tion, angiogenesis, and tissue invasion all representing otherwise normal cellular functions
repurposed within an aberrant context. At the heart of this normality of tumourigenesis is
a treatment paradox — how are we able to treat a tumour in lieu of ourselves.
1.1 Cancer therapy
Treatment for solid tumours can be approached either locally — by surgery and radiother-
apy — as well as systemically, including chemo-, immuno- and hormone therapies. Sys-
temic chemotherapy has revolved around targeting inherent susceptibilities common to
a majority of cancers,iii taking advantage of characteristic high rates of proliferation and
impaired DNA damage repair pathways8. It is therefore at the point of DNA replication
and cellular division that tumour cells become most sensitive to the DNA damaging and
anti-mitotic agents that compose the bulk of chemotherapeutics. However, whilst these
agents are extremely effective at eliminating tumour cells, their off-target effects on other
susceptible tissues are severely debilitating9. This limits their use, with sub-optimal levels
defined by a ‘maximally tolerated dose’, necessary to balance effect and side-effect. We can
consider avoiding treatment-induced side-effects and achieving this balance by two com-
plimentary approaches: in the development of tumour-specific targeted therapies; and in
predicting response to treatment whilst avoiding over treatment. For the purposes of this
i“We have only seen our monster more clearly and described his scales and fangs in new ways – ways that
reveal a cancer cell to be, like Grendel, a distorted version of our normal selves”.4
iiIn fact, current understanding suggests that cancer has paralleled multicellularity since the earliest
metazoa.5




thesis we will consider the latter, emphasising the idea that targeted therapies are of little
use if we don’t know where to aim them.
1.2 Breast cancer
Over the course of the 21st century, breast cancer has stood out as emblematic in the devel-
opment of novel bioinformatics approaches towards prognosis and treatment prediction
for a number of reasons10. Not least amongst these are its high incidence, relative ease in
procuring biopsy material and popular research support from both charitable and govern-
mental funding bodies6. Together, these factors have enabled and encouraged extensive
sample collection, allowing increasingly bold studies to be realised11. In this way breast
cancer has pioneered advancements in high-throughput molecular methodology and fu-
elled its own molecular characterisation.
Figure 1.2.1: UK breast cancer incidence
and mortality rates per 100,000 women.
Source: Office for National Statistics.
As a disease, breast cancer presents as a
solid tumour in ~55,000 UK women per year.
Despite decreasing mortality, incidence contin-
ues to rise, leaving breast cancer responsible
for ~11,500 deaths annually, representing ~9%
of cancer-related deaths in the UK12. Improved
screening is understood to partially explain this
paradox of increasing incidence and decreas-
ing mortality, and is suggestive of two concepts
— that earlier characterisation of a tumour al-
lows better treatment, and that not all cancers
detected in situ progress to become invasive
and require treatment.i Disentanglingwhich tu-
mours are — or will become — invasive and/or recurrent/metastatic, and which will re-
main benign is critical to the full realisation of diagnostic screening efforts. Here again is
highlighted the concept of treating those tumours that require it, whilst avoiding over treat-
ing patients who do not. Decisions to treat or not treat, or how best to treat, have proven
challenging for many cancers, with stratification schemes consistently falling short in ac-
curacy. Even marginal shortfalls in the context of a highly prevalent disease can translate
to thousands of women being incorrectly treated per year, and have therefore motivated
continued attempts to improve prognostic and predictive accuracy.ii These attempts have
iH Gilbert Welch adds that mortality and incidence may be even more closely entangled, “the more overdiag-
nosis the test causes, the more popular it is because there are more survivors”.
iiPrognosis describes the likely disease course, irrespective of treatment. Prediction on the other hand de-
scribes the response to a specific treatment.
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largely sought to consider tumours with greater molecular resolution, in effect making use
of ever more abundant sources of data to more accurately classify a tumour with respect
to treatment. However, it remains important to note that counterbalancing these attempts
is a need for real-world clinical feasibility and accessibility.
1.3 Breast cancer classification
Attempts to realise classification and prediction in breast cancer have undergone a number
of re-inventions, from class prediction based on anatomical location, through assessment
of pathological presentation, immunohistochemical (IHC) molecular determination, to the
current state of high-throughput multi-omic research. Each has improved patient stratifi-
cation, though as-of-yet none has fully realised their potential in precisely assigning treat-
ment. Key to the concept of patient stratification, is relating descriptive characteristics to
clinical differences, be it response to a particular therapy or simply differences in survival.
Thoughmost early attempts relied on the anatomical location of the tumour, it has since be-
come apparent that, although breast cancers may more closely resemble one another than
they do gliomas, there remains considerable intra-class heterogeneity that location alone
fails to capture, a paradigm that has defined contemporary cancer research.
Early breakthroughs inmicroscopyi allowed solid tumours to be defined beyond simply
their location, by their clinical and histological presentation and imaging methodsii con-
tinue to be routine in breast cancer diagnosis. However, thesemethods are only suggestive
of a lesion and histological confirmation is necessary, including determination of grade,
size, vascularisation, lymphatic involvement and ability to invade surrounding tissues and
organs. TheWorld Health Organisation (WHO) continue to advise classification of invasive
breast cancer based on these factors14, and formal classification schemes, such as the Not-
tingham Prognostic Index (NPI), allow clinicians to systematically determine prognosis15–18.
However, the variation in clinical course between patients with similar presentation re-
mains high, accurate prediction of a response to therapy remains low and an ability to be
mechanistically informative is lacking. Critically, histological grading is subjective and fail-
ure to reliably classify tumours highlights not only the difficulty posed by true tumour het-
iJohannesMüller andRudolf Virchow first described the cellular origin of cancer bymicroscopy,moving away
from esoteric descriptions of dysregulated blastema and the bodies four humors — blood, phlegm, yellow
bile and black bile. Thomas Ramsden Ashworth would describe early tumour cells as “large and beautifully
pellucid” and successfully isolate cells from a patient’s blood closely resembling those of the primary tumour,
for the first time implicating the vascular system in metastatic spread. Alternative hypotheses had included
“irritations” travelling along lymphatic vessel walls and the nervous system invoking the ‘idea’ of a tumour
at a distal site. Ironically, an alterative hypothesis of spread by “morbid juices” proved to be closer to the
truth.
iiFour major diagnostic screening methods are employed: clinical examination, mammography, ultrasound
and magnetic resonance imaging.13
3
1 Introduction
erogeneity but also in perceived heterogeneity, typified by modest rates of inter-observer
agreement, and contention over the existence of some forms19. Tumour grading equally
fails to highlight driving features that may be clinically actionable, describing effect rather
than affect, and therefore remains a prognostic rather than predictive measure for hor-
mone therapies.
Currently only three predictive markers are routinely used in the clinic: the oestrogen,
progesterone and human epidermal growth factor receptors (ER, PR and HER2)20–23. Both
oestrogen and the oestrogen receptor have been associated with invasive breast cancer
for more than a century,i and these three molecules have largely defined breast cancer as
at least three different diseases — loosely defined as ER+/PR+/HER2-, ER-/PR-/HER2+, and
ER-/PR-/HER2-, though all permutations can present. Defining tumours by their driving
molecular features has facilitated the use of targeted therapies, to disrupt some facet of
the receptor signalling processes. In concert, these same molecules function as predictive
biomarkers able to be quantified by IHC staining and allow treatment to be prescribed on a
patient-by-patient basis. Unfortunately, however, whilst an absence of each of these mark-
ers preclude response to their corresponding therapies, presence only modestly correlates
with response25. Moreover, of the approximate 60% of early stage breast cancer receiv-
ing adjuvant chemotherapy only, a fraction display benefit26,27. This limited response to
therapy has fuelled an interest in whole-omic analysis, to transition from single molecule
biomarkers towards — in theory — increasingly sensitive and descriptive multigene signa-
tures.
1.4 High-throughput classification
The advent of gene expressionmicroarray technology revolutionised our understanding of
breast cancer as a disease of multiple transcriptionally distinct entities and influential 21st
century studies continue to inform our understanding of its inherent heterogeneity28,29.ii
Importantly, whilst these newly defined subtypes correlated with IHC-based approaches,
they additionally redefined seemingly homogeneous populations as composites ofmultiple
sub-populations, each with their own profile of clinicopathological features, responses to
therapy, and outcomes. A number of attempts to robustly define the true population level
distribution and existence of potential molecular subtypes took place over the course of the
early 21st century, though, like the IHC subtypes, theywere again challenged by discordance
iGeorge Beatson would demonstrate ovariectomy induced regression of the primary tumour in 1896, suggest-
ing the role of steroid signalling as a major factor in breast cancer24
iiIn fact two technologies for the total quantification of gene expression were published in the same 1995 edi-
tion of Science. Serial Analysis of Gene Expression (SAGE)30 and cDNA comparative hybridisation (i.e. mi-
croarray chemistry)31 were highly dissimilar in protocol and microarray-based approaches would prove
easier to accomplish, particularly for high-throughput studies.
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regarding their true existence and number. Themost widely cited ‘standard’ for breast can-
cer subtypes remains Perou et al.’s32 seminal class-discovery study. The group’s hypothesis
was simple, that the observable differences between tumours must relate to molecular dif-
ferences, and that this molecular heterogeneity could be harnessed to stratify patients.i
Most excitingly, these molecular differences, at the time understood to be driving the can-
cers, could potentially be determined in advance of any clinically observable features. Tak-
ing 65 unique invasive breast tumour samples, representing 42 individual patients, the
group used newly available microarray technology to analyse transcripts corresponding to
8,102 genes, a significant proportion of the entire transcriptome. Hierarchical clustering
grouped tumours and transcripts according to similarities in gene expression, illustrating
the heterogeneous nature of breast cancer in a previously unseen clarity. Notably these
differences were more often greater between patients of otherwise similar presentation
than between samples from the same tumour following treatment. That treatment is a pro-
cess fundamentally designed to disrupt a tumours normal state underlines the recurrent
theme and challenge imposed by tumour heterogeneity. Pursuing a supervised approach,
Perou and colleagues derived a subset of genes optimised for consistency between multi-
ple samplings of the same tumour and variation between different tumours. This ‘intrinsic’
gene set revealed five robust tumour subclasses — Luminal A (LumA), Luminal B (LumB),
HER2-positive (HER2), Basal-like and Normal-like. These would later be refined and shown
to correlate with prognosis and response to therapy34–36, as well as display distinct patterns
of metastasis, with individual subtypes showing preference for particular organs. These
were often shared, with bone metastases being common for all subtypes, but also distinct,
with HER2-positive tumours more commonlymetastasising to brain, liver, and lung tissues
compared with ER-positive disease. Similarly, and again compared to Luminal A tumours,
basal-like tumours displayed increased rates of brain, lung and distant nodal metastases,
though significantly lower rates for bone and liver37. Despite this seeming clinical rele-
vance, the ‘intrinsic’ subtypes would at first struggle to translate to clinical relevance38,
though HER2-positivity has since been incorporated clinically in both the PAMELA39 and
NOAH40 trials, selecting for patients suitable for blockade with the monoclonal antibody
trastuzumab. Interestingly, though the Normal-like subtype likely originated due to the in-
clusion of reduction mammoplasty in early subtyping studies, it continues to be observed
in ~7.8% of lymph-node negative cases, exhibits poor outcome despite a shared IHC pro-
file with Luminal A tumours41 and has been conjectured to overlap with a subsequently
defined subtype Claudlin-low42.
A decade later, redefinition of the breast cancer subtypes was attempted using gene
iAproof of concept for this approach came from theBroad Institute’s ToddGolub andEric Landerwhoderived
a gene signature whose expression could blindly classify acute myeloid and acute myeloid lymphoblastic
leukaemias, including distinguishing B- and T-cell acute lymphoblastic leukaemia.33
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copy-number alterations in ~2,000 patients, formalised as 10 ‘integrative clusters’, ICs 1-
1043. The integrative clusters exhibited distinct patterns of both survival and chemosensi-
tivities and may therefore represent both prognostic and predictive stratification. Equally,
they have been demonstrated to aid contextualisation of RNA sequencing-derived genomic
drivers, certainly more so than the intrinsic subtypes44. However, as-of-yet, the IC10 clas-
sification scheme has failed to progress to clinical adoption, perhaps even hampered by
its additional subtypes, where tumours are less confidently assigned to one subtype as a
result.
Figure 1.4.1: IC10 and intrinsic subtypes. IC10 subtyped patients are ordered left-to-right
for ICs 1-10. The corresponding PAM50 subtype is shown below. LumA, LumB, HER2, Basal
and Normal are coloured as dark blue, light blue, pink, red and green. Adapted from Ali et
al. 2014.
Though molecular characterisation revealed and described the degree of breast cancer
heterogeneity, to an extent molecular subtyping studies simply re-described the IHC
subtypes. Even the ten integrative clusters display a high degree of synonymity with ER
and HER2 statuses, with cluster 10 in particular overlapping with basal/triple-negative
subclasses44. This was perhaps expected but also somewhat unfortunate as basal and
triple-negative breast cancer (TNBC) subclasses remained defined by a lack of oestrogen
and HER2 signalling, rather than any driving molecular feature. This has resulted in the
lack of a TNBC-specific treatment, where patients continue to be offered chemotherapy
alone, with almost all of the improvement in breast cancer mortality stemming from ER-
and HER2-positive diseases. The potential of further unsupervised characterisation and
subclassification was therefore questionable, though the need for targetable drivers and
more reliable clinical stratification was clearly necessary. This would ultimately encour-
age a supervised approach, in an to attempt to define a direct molecular relationship with




Whilst molecular class discovery had proven to be feasible, and at the time hinted at being
mechanistically informative, theywere at heart purely descriptivemodels.i To achieve clin-
ically applicability, therewas a need for clinical andmolecular data to be considered in con-
cert rather than in isolation. Demonstrating a degree of foresight, The Nederlands Kancer
Instituut (NKI) had systematically collected frozen tumour samples with matched clinical
histories since the early 1980s. Twenty years later, the availability of whole-transcriptome
analysis offered the synthesis of these data to ask, not only which features define a tumour,
but which defined its relationship with survival. Of these biobanked samples, a cohort of
78 node-negative women, allowed a supervised approach to reduce the available ~25,000
microarray probes to a signature of 70 genes correlated with the occurrence of a distant
metastasis49. The team, led by Laura van’t Veer, validated their findings in an additional
collection of 295 breast tumour samples,ii where the 70-gene signature proved to outper-
form the then current clinically available predictors, including grade, nodal- and hormone
receptor statuses and represented a conceptual validation of high-throughput molecular
characterisation50. Further validation by the TRANSBIG consortium51 again outperformed
standard clinical assessment. The Amsterdam 70-gene signature would later be formalised
as MammaPrint, the first FDA-approvedmultigene test, allowing prospective validation, in
competition with AdjuvantOnline!iii, in the RASTER (n = 427)52 and MINDACT (n = 6,693)53
studies. Interestingly, of the 1,550MINDACT patients discordantly classified as high clinical
(AdjuvantOnline!) but low genomic (MammaPrint) risk and not receiving chemotherapy,
94.7% had at least 5-years distant metastasis-free survival (dmfs). These patients therefore
represented a subset who would otherwise have needlessly been offered chemotherapy.
Encouraged by the potential for accurate determination of prognosis the search for ad-
ditional prognostic gene signatures began in earnest. Despite the analytical and clinical
validity demonstrated by MammaPrint, it’s clinical utility was hampered by a reliance on
microarray technology and the associated practical and economic costs. Of the subsequent
generation of prognostic tests, Oncotype Dx, Prosigna, EndoPredict and the Genomic Grade
Index (GGI) would stand out in satisfying the need for clinical and analytical validity as
well as clinical feasibility.
Oncotype Dx measured a greatly reduced 21-gene signature by reverse transcription
polymerase chain reaction (RT-PCR), returning a recurrence score (RS). Of the 21 genes,
iSubsequent workwould later demonstrate that the unsupervised determination of the intrinsic subtypes did
indeed correlated with response to treatment and prognosis45–48
iiIn reality, 61 of the 295 patients included in the 70-gene signature validation were from the original training
set, complicating the independence of the validation
iiiAdjuvantOnline! allows online risk assessment based on clinical factors such as age, menopausal status,
ER-positivity and nodal involvement amongst others.
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16 were cancer-related non-housekeeping genes measuring ER- & HER2-signalling, prolif-
erative and invasive potential. Patients scoring below 18 would be classified as low risk;
above 30 as high risk. Oncotype DX would be retrospectively validated in 668 ER-positive
and node-negative women, demonstrating a significant difference in 10-year distant recur-
rence rates for each RS category (p < 0.001), independent of age and tumour size54. Similar
conclusions were demonstrated in 651 patients (including patients from the original train-
ing set) receiving adjuvant tamoxifen alone or in combination with chemotherapy, with a
RS of >30 indicative of chemotherapy benefit55. Prospective validation as part of the TAI-
LORx (Trial Assigning Individualised Options for treatment (Rx)) attempted to definitively
determine chemotherapy benefit for recurrence scores of <10 but also whether that ben-
efit was shared for intermediate scores of 11-25. The TAILORx study would demonstrate
in 2015 that low RS participants share a very low risk of 5-year recurrence with endocrine
therapy-alone56. More recently in 2018, 6,711 hormone-receptor positive, HER2-negative,
and axillary node-negative patients scoring between 11 and 25 inclusive were compared
by random assignment to either chemoendocrine therapy or endocrine therapy alone. En-
docrine therapy alone was found to be noninferior to chemoendocrine therapy for all end
points investigated, suggesting that chemotherapy in addition to endocrine therapy for in-
termediate recurrence scores and below could also be avoided, representing up to 85% of
women with early breast cancers57. Though originally intended for use in node-negative
disease, recurrence scores have also been demonstrated applicable in women with up to
three tumour-involved axillary lymph nodes58.
Refinement of the intrinsic subtypes as a 50-gene signature (PAM50)35 allowed for
FDA approval and commercialisation in post-menopausal and HR-positive tumours as the
Prosigna Breast Cancer Gene Signature Assay. Prosigna would use NanoString technology,
a microarray-like alternative, to accurately and efficiently measure signature transcript
abundance. Intrinsic subtype classification and calculation of a risk of recurrence (ROR)
score that, like to Oncotype DX, assigns low, intermediate and high distant recurrence
risk categories on a 0-100 scale. Validation in 786 ER-positive women of mixed nodal
status receiving adjuvant tamoxifen compared ROR score, IHC and clinical factors,
demonstrating Prosigna’s improved ability to predict disease-specific and recurrence-free
survivals59. Further validation comparing 1,478 post-menopausal ER-positive women
receiving endocrine therapy-alone again demonstrated accurate recurrence-free survival
and prognostic improvement over conventional methods60.
An eleven gene PCR based signature of endocrine treated ER+/HER2- 10-year recurrence
risk — EndoPredict — would show similar promise in training and validation studies61,62.
It would be integration with clinical factors, as EPclin, however, that would demonstrate
marked improvement over standard methodology, re-predicting a subset of high-risk pa-
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tients as having favourable prognosis63. Further validation in 555 chemotherapy treated
FFPE (formalin-fixed and parafin embedded) samples would establish EndoPredict and EP-
clin’s utility in independently predicting metastasis-free survival64.
Finally, an alternative approachwas taken by Sotiriou et al.65, to usemicroarray-derived
expression of 97-genes to directly infer grade, itself associated with prognosis, as the Ge-
nomicGrade Index (GGI). Comparing differentially expressed genes in 64 ER-positive breast
tumour samples, the GGI allowed partitioning of patients in to 1 of 2 categories — low or
high — which roughly corresponded to grades 1 and 3 respectively. Importantly, the GGI
does away with the intermediate IHC-derived grade 2 category, where patient tumours are
assigned as either of the GGI’s own 2 categories. The GGIwas validated in 597 breast cancer
samples, attempting to find an association between GGI and recurrence-free survival, and
indeed high GGI was associated with a higher risk of recurrence.
It was clear that clinically feasible and prognostic gene signatures were of relevance
in breast cancer treatment, albeit predominantly for ER-positive disease. To compare be-
tween signatureswould prove challenging however, and determination of a one-size-fits-all
modelwas proving unlikely. For any given signature, itwas likely that its usewould roughly
extend only to the context of its development, that is: the response measured (clinical, his-
tological, biological); the cohort studied (subtype specificity, pre- vs. post-treatment); and
the treatment used (chemo- and endocrine therapies). Despite these difficulties, Fan et al.66
would compared 5 signatures, including MammaPrint, Oncotype Dx and Prosigna, using
the 295 sample microarray-measured MammaPrint validation dataset. Whilst not identi-
cal, each individual signature largely demonstrated concordance in assignment. Perhaps
surprisinglyMammaPrint and Oncotype Dxwould show improved concordance when con-
sidering all samples (81%), opposed to ER-positive only tumours (77%), despite Oncotype
Dx’s development using strictly ER-positive datasets.
1.6 Lessons from high-throughput gene expression studies
A wealth of data was now available to researchers world wide. As the community called
for open-access to datasets, particularly those derived from patient-donated material, jour-
nals began necessitating that researchers deposit data in publicly-accessible databases, al-
lowing for further/re-analysis and study validation. The fulfilment of microarray-derived
data’s promise appeared inevitable. However, as more studies reported prognostic signa-
tures, it became clear that their ability to outperform currentmethodswas underwhelming,
that the overlap between signatures was small and, moreover, the total proportion of the
genome being reported was larger than anticipated. This represented a conundrum: how
could the diversity of prognostic signatures all be correlated with disease outcome and, by
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extension, with their underlying mechanisms?
Perhaps the most obvious (and troublesome) explanation was that microarrays were
simply non-reproducible and subject to non-specific hybridisation or, put another way,
were completely unreliable. To challenge this, a consortium effort by the Microarray Qual-
ity Control (MAQC) consortium assessed microarray reliability, performing a series of sys-
tematic reproductions across multiple different platforms and laboratories, demonstrat-
ing that not only was there high reproducibility but also confidence for clinical applica-
tioni67,68. Another possible explanation was hinted at by the unintended synonymous first-
generation signatures describing the ER-positive/ER-negative axis. In effect, because these
subtypes differed so consistently in their clinical outcomes, by comparing favourable and
poor outcome patients researchers were in essence comparing ER-positive to ER-negative
disease by proxy, and deriving genesets that re-described this relationship69. The diversity
of equally prognostic signatures could therefore be explained as a large pool of highly corre-
lated members of the same molecular pathways, as is the case for ER-target genes70. These
correlated genesets would be able to be substituted for one another with little effect on the
signature’s overall prognostic capacity71. Understanding of the interrelatedness of clinical,
molecular and prognostic features would make this result all but inevitable in retrospect,
and that many of the derived genesets were often only as effective as IHC ERmeasurement
was therefore unsurprising.ii
It was clear that assuming any given gene was unlikely to be associated with prognosis
was misguided. Venet et al., would go one step further demonstrating that most signatures
were no more prognostic than random subsets of genes, and that any single gene was rea-
sonably (5-17%) likely to be associated with prognosis72.iii The explanation proposed was
that a large proportion (>50%) of the genome correlated with proliferation and that, simi-
lar to ER target genes, any number of genes could be substituted for one another with little
effect on overall prognostic association. This was characterised as meta-PCNA of which
correction for could alleviate a seemingly spurious association with prognosis. However,
it would later be demonstrated that random signature association did not necessarily ex-
tend to all cancer types, despite their shared proliferative nature73. Again, as grade was
routinely measure by histological methods, it is no surprise that these signatures of prolif-
erative capacity failed to decidedly outperform existing methods.
iHowever, though reproducibility had been demonstrated, the use of high-quality RNA across the MAQC ex-
periments was nonetheless not wholly representative of early gene expression signatures derived from FFPE
material.
iiSalomon saith, There is no new thing upon the earth. So that as Plato had an imagination, that all knowledge
was but rememberance; so Salomon giveth his sentence, that all novelty is but oblivion (Francis Bacon:
Essays LVIII).
iiiThat this study was performed using the dataset originally used to derive 70-gene MammaPrint signature
was particularly worrying.
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It became clear that to avoid simply restating the ER+/- axis and/or measuring prolifera-
tion, more homogeneous patient sub-populationsmust be analysed. Iwamoto and Pusztai71
would comment
“Investigators who developed the first generation of supervised prognostic
and treatment response predictors started with the then prevailing notion
that breast cancer is a single disease, and all subtypes of breast cancer were
included in the analysis. This resulted in major limitations in the diagnostic
products that emerged from this research.”
However, stratifying cohorts would itself prove difficult, particularly for low-prevalence
subtypes. By grouping patients prior to an analysis, the sample size would inevitably de-
crease and, by extension, the statistical validity. By pooling data from several sources, how-
ever, researchers hoped to circumvent this pitfall, though, again, a naive assumption of
consistency would prove a stumbling block. Even data processed in the same laboratory as
part of sequential batches was liable to show systematic technical (i.e. non-biological) vari-
ation and would therefore require normalisation before comparison74. Correction meth-
ods would prove difficult to engineer, needing to remove technical batch differences alone,
leaving true biological variation unaffected. Ultimately, minimal correction of only suit-
ably similar datasets would be encouraged, though the definition of suitable similarity re-
mains ill-defined, as does the balance between improving sample size whilst respecting
dataset homogeneity. Complicating matters still further is the observation that even when
stratified by ER, some breast tumours remain inherently difficult to classify, being con-
sistently incorrectly classified by nearly all available signatures69. Moreover, analysis of
ER-positive cohorts simply tend to learn HER2 status and vice versa.
The challenges inherent in study design and cohort selection were also apparent in the
extent to which prognosis could be calculated. As almost all studies used in the design
of prognostic classifiers were developed using cohorts that had ~10-years follow-up, these
classifiers understandably have a 10-year cut-off forwhat they can predict. Whilst partially
reflecting the realities of cancer survivorship, it is equally true that recurrences do occur
well beyond this threshold and remain uncharacterised. Equally by considering patients as
a cohort, application remained relevant to this group and suffered limitations in predicting
the outcome of an individual. In fact, despite all the research that has gone into prognostic
andpredictive classifiers, clinically the only accepted predictivemeasures for breast cancer
remain ER and HER2 by IHC.
It could be argued that microarrays have failed to live up to their early promise in clini-
cally impacting cancer and, largely, the field hasmoved on to sequencing basedmethods of-
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fering the opportunity to explore novel as well as known transcripts and their isoforms, as
well as single-cell approaches75. It should, however, be stressed that themicroarray era has
been instrumental in furthering our understanding of the inherent heterogeneity of breast
cancer; the comparable relationship betweenmetastatic and primary tumours76,77; the fun-
damental role of proliferation, mitosis and chromosomal integrity in aggressiveness78,79;
and the interaction between tumour and stromal compartments80,81. Venet et al. them-
selves were cautious to note that the shared prognostic potential of derived and random
signatures did not invalidate that potential, further commenting that prognostic confound-
ing extended to pre-genomic era studies72.
Though progress towards predictive biomarkers has been piecemeal this understand-
ing has and continues to inform future studies. Furthermore, as the potential to combine
and interrogate pre-existing datasets improves, it remains to avoid throwing the baby out
with the bathwater. The wealth of microarray data available in the public domain remains
highly informative, if suitable questions are asked of it, and it remains a cost-effective assay
to maximise sample size. Ultimately, careful independent validation across multiple data
sources is critical to remain confident that the variation and heterogeneity measured is a
factor of the disease and not the dataset.
1.7 Tumour heterogeneity and evolution
The impact of heterogeneity is extensive, and in the context of cancer our consideration
of heterogeneity is twofold as (i) spatial heterogeneity at a distinct moment in time and (ii)
temporal heterogeneity, the evolution of a tumour over time. Importantly, both spatial and
temporal heterogeneity can themselves be subclassified as inter- and intra- tumour hetero-
geneity. Inter-tumoural heterogeneity is simply the variation between different individuals
tumours (or between multiple tumours from the same individual), and intra-tumour het-
erogeneity instead defines the variation inherent within a single tumour mass, either at
a single point in time or over time as multiple observations compared against themselves.
We can consider response (or lack of response) to treatment as a facet of temporal hetero-
geneity and, in many senses, temporal heterogeneity is the goal of treatment, to chemically
coerce a tumour towards a less aggressive and invasive phenotype over time. However,
heterogeneity more often than not complicates matters, both experimentally and clinically,
where any observation inevitably represents a cross-section in both time and space and is
at risk of not fully representing a dynamic tumour82–84. Given that treatment is prescribed
based on these snapshots reveals a diagnostic failing— that correct classification of a biopsy
does not guarantee correct classification of the tumour(s).
Key to the concept of temporal tumour heterogeneity is the well characterised sequen-
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Figure 1.7.1: Breast cancer heterogeneity. Heterogeneity can manifest in two ways, with
variation by either position or by time. For temporal heterogeneity, tumour subclones are
seen to vary in response to treatment.
tial acquisition of genomic lesions and alterations that additively destabilise cellular func-
tion and drive the cancer phenotype85,86. Classically this has been presented as a linear
developmenti but more recently it has become clear that, following a stochastic initiating
event,multiple subclonal populations are able to compete and evolve in tandem, expanding
or diminishing dependant on their environmental fitness88.ii This process of evolution is
consistent throughout the lifetime of the cancer, extending beyond its initial establishment
and allowing a dynamic response to any destabilising changes in its environment, most per-
tinently in resistance to therapy90,91. As fitter clones emerge, their potential to vary likely
increases, allowing the tumour to rapidly acquire fitness under changing circumstances,
highlighting the difficulty in addressing highly aggressive and resistant metastases and the
need to adequately profile and treat a tumour as thoroughly and early as possible. Even
the concept of “early” is challenging in this regard, and metastatic potential is likely to be
evident even at the clonal stage of the primary tumour76.
The implications of heterogeneity therefore include variation between ostensibly sim-
ilar separate tumours (inter-tumour) as well as within a single tumour housing subclonal
regions (intra-tumour), any of whichmay respond differently in the clinical setting. Whilst,
inter-tumour heterogeneity is likely a combination of germline and accrued somatic mu-
tations in addition to environmental factors, intra-tumour heterogeneity is understand-
ably fuelled by somatic alterations, as any present tumour subclones will share identical
iAnd is still representative of haematological malignancies.87
iiOne hypothesis reads that, in larger mammals, clonal diversity becomes a problem for the tumour itself. As
heterogeneity increases, the likelihood of an ultra-aggressive clone developing also increases. This hypertu-
mour effectively becomes ‘cancerous’ to the original tumour, destroying it.89
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germline and macro-environmental starting points. Though whole-genome single-cell se-
quencing has demonstrated that any given tumour cell is likely to be genetically unique92,
from a clinical perspective the role of tumour heterogeneity needs only to be as complex as
that which directly impacts upon patient survival and well-being.i Attempts to disentangle
non-specific from key driver alterations has proven difficult, particularly in breast cancer,
with no single genetic mutation proving integral to tumour function; thereby limiting the
ability to selectively target an ‘Achilles heel’. Instead many cancers are diverse in their
driver mutations, with no one mutation being consistently found in more than even 20%
of 1,013 prostate tumours94.
Clonal evolution in response to therapy, including targeted agents, is dynamic, unpre-
dictable and largely synonymous with resistance95–97. Selection is able to occur during the
course of treatment, with the EGFR tyrosine kinase inhibitor erlotinib inducing expansion
of resistant EGFRT790M mutant clones in a lung cancer patient, but also in its absence, with
these same resistant clones diminishing and becoming undetectable following a 10-month
treatment-free period95. This highlights that the most resistant clone may not necessarily
represent the broadest fitness, potentially only able to flourish under the extreme selec-
tive pressure of a targeted therapy. It has therefore proven beneficial to perform longi-
tudinal tumour sampling, with a focus on observing a response to treatment, rather than
predicting from a static pre-treatment or surgical biopsy alone. Routinely, where multiple
tumour biopsies have been collected, diagnostic core-needle biopsies (CB) and surgical exci-
sion biopsies (EB) have been used to compare pre- and post-treatment effects. To an extent
this has been limited to a small number of pre-defined molecular markers, including the
routinely measured ER, PR, HER2 and Ki67, though whole-omic investigations have also
been performed, investigating the effects of anthracycline-based chemotherapy; celecoxib;
RAD001; anastrozole; letrozole; exemestane; and fulvesterant98–107.
Ultimately, heterogeneity increases treatment complexity and the tumour represents a
moving target. Even for ER-positive disease, initial or eventual resistance to endocrine ther-
apy is commonplace and it is in characterising and predicting these patients that chapter 4
of thesis will focus.
1.8 Endocrine therapy
For a patient presenting with ER-positive disease, several systemic treatment options (sum-
marised Table 1.1) are available, including chemo- and endocrine therapies. Endocrine
therapy specifically targets susceptibilities in oestrogen dependent tumours at the expense
of much of the toxicity associated with chemotherapy108. Moreover, this decreased toxi-
iAnd in fact heterogeneity in of itself is a prognostic marker.93
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city has little bearing on their efficacy, with several studies reporting greater benefit in
the adjuvant setting for post-menopausal women109. By disrupting oestrogen biosynthe-
sis or signalling, endocrine therapies achieve cell cycle arrest in G1/S, and are therefore
non-cytotoxic110. Selective oestrogen receptor modulators (SERMs, including the widely
pre-menopausally prescribed Tamoxifen) antagonisticallyi compete for intra-nuclear ER,
inducing a conformational change and destabilising its ability to bind oestrogen response
elements (EREs). However, this inhibitory effect on oestrogen signalling is incomplete, with
a partial response still evident113. Selective oestrogen receptor downregulators (SERDs)
also bind competitively to dimerised ER but instead facilitate downregulation by degrada-
tion, avoiding any residual partial oestrogen agonism113,114. In the post-menopausal setting,
aromatase inhibitors (AIs) act to destabilise the aromatase enzyme (CYP19), downregulat-
ing oestrogen biosynthesis occurring in subcutaneous fat stores prevalent in peripheral
and breast tissue115. Aromatase catalyses androgens as part of the final step in producing
oestrogens, where it can be irreversibly and inactivatingly (Type I AIs), or reversibly and
competitively (Type II AIs), inhibited116,117. Results from the ATAC (Arimidex, Tamoxifen
alone or combined) trial118 have shown anastrozole to outperform tamoxifen in the post-
menopausal setting and improve disease-free but not overall survivals in the adjuvant set-
ting.
Endocrine treatment selection is based on toxicity, tolerability, the potential for partial
ER agonism, and menopausal status119. In the post-menopausal setting, results from the
FIRST (fulvestrant first-line study comparing endocrine treatments) trial have suggested
fulvestrant to be equally as effective as anastrozole as a first-line therapy but with an in-
creased time-to-progression and overall survival, as well as increased progression-free sur-
vival as a second-line therapy120,121.
SERMs SERDs SERM/SERD Hybrids AIs
Tamoxifen (1977) Fulvestrant (2002) Elacestrant (Phase II) Anastrozole (Type II, 1995)
Toremifene (1997) Letrozole (Type II, 2005)
Raloxifene (2007) Exemestane (Type I, 2011)
Table 1.1: Endocrine therapies and FDA approval dates.
The degree of choice and specificity of application highlights the difficulties in prescrib-
ing treatment, even within the seemingly homogeneous collection of patients exhibiting
ER-positivity. Further complicating matters is that correct prediction of a response to en-
docrine therapy is only half the battle, and histologically confirmed ER-positive tumours
are observed to display a lack of response to endocrine therapies in 50-70% of cases104,122.
It should be noted that this number ignores the fraction of initially responding patientswho
iTamoxifen conversely agonises ER in the uterus and liver, as well as demonstrating species-specific effects111.
Agonistic action is thought to explain small increases in the rate of endometrial cancers.112
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eventually become desensitised to treatment, an inherently difficult dynamic to study ex-
perimentally. Taken together, these highlight the clear benefit that could be derived from
improved models of endocrine resistance, not least in producing predictive biomarkers of
response to endocrine therapy.
1.9 Endocrine therapy resistance
Resistance to endocrine therapy is pervasive in ER-positive disease though, broadly, re-
sistance mechanisms are common for both targeted and chemotherapies. Superficially,
these can be defined by drug target alterations, activation of pro-survival compensatory
mechanisms, and avoidance of programmed cell death.i Underpinning these escapes are
both specific alterations, including mutations in — or overexpression of — the drug target
and/or regulatory elements and post-transcriptional modifications; as well as more gen-
eral changes at the level of the cell, including DNA damage repair pathways, alternative
signalling activation and non-specific drug efflux. Within the context of ER-positive dis-
ease, multiple mechanisms of resistance to endocrine therapy have been proposed, though
a definitive explanation remains inconclusive. Perhaps surprisingly, loss of ER expression
is not common amongst these, with only ~10% of initially ER-positive tumours later pre-
senting as ER-negative123. ERmutants often remain sensitive to second and third line antie-
strogenics, targeting varying facets of oestrogen signalling, though at iteratively reduced
rates124. Further complicating the role of mutant ER in endocrine resistance is evidence
of heterodimerisation with wildtype ER. Nonetheless ER mutants have been functionally
characterised in vitro125–127 and shown to be enriched in the metastatic lesion compared to
the primary tumour128–132.
More commonly, dysregulation downstream of ER is observed, including interactions
between ER coactivators and corepressors, and alternative signallingmolecules. Ligand in-
dependent ER phosphorylation and activation via growth factor signalling pathways, such
as insulin/IGF (insulin-like growth factor) and epidermal growth factor receptor (EGFR)
superfamilies133,134 converge on mitogen-activated protein kinase (MAPK) family kinases
able to activate ER by phosphorylation. Ligand independence represents a possible es-
cape from aromatase inhibition, as well as in activating parallel programs of growth and
survival135. Though cross-talk between ER signalling and growth-factor receptors has been
described, there is little evidence that combination therapies can counteract the resistant
phenotype101,136–138, potentially reflecting the relative deficiency of cell linemodels in inves-
tigating the vastly complex nature of cancer and resistance. A notable potential exception
iHere we will only discuss pharmacodynamic mechanisms of resistance, though pharmacokinetic mecha-
nisms (variation in drug absorption, distribution,metabolismand elimination) are also factors liable to effect
drug responsiveness.
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to this is the PI3K/AKT/mTOR signalling pathway, for which a number of targeted therapies
are currently in clinical trials. PI3K/AKT/mTOR is frequently mutated in breast cancer139,
and has been demonstrated to impart AI resistance in cell line models140. FDA approved
everolimus, a TORC1 inhibitor has shown some promise in combination with chemother-
apy (exemestane) or tamoxifen for patientswith advanced ER-positive disease141. However,
inhibition of PI3K/AKT/mTOR pathway members has alternatively been demonstrated to
remove the pathway’s own inhibitory checks as well as activate pro-survival factors142–145.
Resistance mechanisms independent of oestrogen signalling include alterations to ta-
moxifenmetabolismbyCYP2D6, which converts tamoxifen to antiestrogenic endoxifen and
4-hydroxytamoxifen146. Allelic variation in CYP2D6 impacts upon its ability to adequately
metabolise tamoxifen and, therefore, poor metabolism presents both a mechanism of re-
sistance as well as a potential predictive genotype115.
Resistance can be realised in twoways: de novo/intrinsic (existing prior to treatment) or
acquired resistance. Intrinsic resistance implies that a pre-existing resistance mechanism
is apparent in the tumour at diagnosis and that tumour is immediately insensitive to treat-
ment. Acquired resistance occurs in response to treatment, where a previously responsive
tumour eventually fails to respond. For ER-positive disease desensitisation to first-line ther-
apy and acquisition of resistance is evident in up to 30% of cases148,149. Second- and third-
line therapies remain effective, though again at gradually reduced rates decreasing from a
response in 70% of patients to only 30%121,150. Mechanistically, intrinsic and acquired resis-
tances differ, and acquired resistance is associated with a wider mechanistic diversity148,
and this diversity is both patient as well as treatment specific151. It is worth noting that,
though they develop over the course of treatment, the mechanisms of acquired resistance
may be presentwithin the tumour at diagnosis. For instance, a subclone of a heterogeneous
tumour may be intrinsically resistant to therapy but it is only after the selective pressure
of treatment that it is able to progress.i Whether intrinsic and acquired resistance are inde-
pendent of one another remains debated and it is possible that the immediacy of resistance
is simply a factor of the subclonal population of the tumour at diagnosis. The actual mech-
anisms of resistance may be shared between de novo and acquired instances and simply
differ in the time of their presentation152.
Together, this portrays a rather jumbled picture ofmultiple competingmechanisms and
a paucity of patient-derived models. Acquired resistance in particular presents a research
challenge due to its latent presentation, with ER-positive tumours displaying a steady rate
of recurrence even decades post-surgery153. Key to this difficulty is in procuring research
material— for any latently presenting phenotype, inevitably the tumourmaterial has been
iHis arrows they are only claws, his wings a pair of lies, his horns are hidden by the wreath, he is, we must
surmise, like all the Gods of ancient Greece, a devil in disguise.
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removed at the point of surgery and treatment. Acquired resistance has instead been
characterised by cell line and animal models, typified by epithelial to mesenchymal tran-
sition (EMT) and an increased invasive and migratory phenotype within this context154–157.
Equally, enrichment for stem-like progenitor cells in tamoxifen-resistant breast cancers
has been linked with a mechanism for acquired resistance158. Specifically, Sansone et
al. demonstrated subclonal upregulation of IL6 in CD133hi cells, in response to chronic
ER downregulation in a patient-derived xenograft (PDX) model159. Though compensatory
growth factor signalling has been proposed as amechanism of sustained growth in the face
of endocrine therapy160, attempts to target these pathways have so far been unsuccessful
and short-lived161,162. Furthermore, of the targeted therapies demonstrating most promise
(CDK4/6 and mTOR inhibitors), there are associated toxicities that complicate administra-
tion and require accurate predictive biomarkers to be developed163.
Key to acquired resistance is the long-term survival of residual disease, able to perpet-
uate in a true quiescent or balanced-turnover dormant state. This may manifest as only
a single disseminated cell but importantly, time until clinical presentation is independent
of cell doubling rates164. Instead cells can remain dormant for extended periods of time,
upwards of 5-years, before they reawaken and begin to propagate. Characterising and pre-
dictingwhen this reawakeningmay occurs has been understandably challenging and again
cell and animal models have made up the bulk of the literature on breast cancer dormancy.
Current theories implicate escape from immune surveillance and/or microenvironmental
effects or increased angiogenesis165,166, though again these results are based on cell and an-
imal models that may not translate and the need for patient-derived models of acquired
resistance and dormancy are needed.
1.10 The adjuvant and neoadjuvant settings
Currently, five major treatment practices are used in managing breast cancers: surgery, ra-
diotherapy, chemotherapy, hormone therapy and immunotherapy. Of these five, for the
majority of patients surgery is associated with the largest single benefit167, with the re-
maining four being employed as secondary, adjuvant measures. By considering clinical
presentation of the disease and patient, breast cancer management has traditionally pro-
gressed as surgery followed by one or more adjuvant treatment — most commonly radio-
and chemotherapies— to eradicate residual primary disease ormicrometastases. Systemic
therapies, such as chemo-, hormone and immunotherapies are now regularly given in an
attempt to remove residual disease burden that remains post-surgery, either at the surgical
site or as a metastasis. The success of this strategy is unequivocal and, for radiotherapy, ad-
juvant use following breast-conserving surgery has been shown to be as effective as total
18
1.10 The adjuvant and neoadjuvant settings
mastectomy combined with axillary lymph node dissection167. However, due to the nature
of the adjuvant setting, determining drug effectiveness as part of a clinical trial is likely
to exceed 10 years. This is due to the fact that the most immediate read-out of response
(i.e. whether tumour cells are being killed) has been removed by the act of surgery. This
effectively leaves late stage events, such as relapse and/or metastasis, as the only viable
surrogate measures, each of which can take decades to present clinically.i Beyond the ob-
vious time limiting nature of this approach, patient monitoring and drop-out also present
serious hurdles, affecting the statistical validity of any given study. Combined with the
well-described attrition rates and long development time-scales for novel targeted thera-
pies, this delay represents a significant obstacle to drug availability.
In response to these difficulties, and in an attempt to expedite clinical research, it was
proposed that the pre-operative setting could instead be used to directly correlate treat-
ment with a measurable affect on the in situ tumour. This neoadjuvant setting opened up
a number of possibilities in improving a patient’s clinical management. Ultrasound sonog-
raphy (USS), mammography and/or physical calliper measurement were able to measure
dynamic changes in tumour volume over time in response to treatment, revealing the suc-
cess or failure of a prescribed treatment.ii If a treatment was observed to be ineffective, a
second regimen could then be employed. As this treatment would be continued into the
post-surgical adjuvant setting, treatment could be effectively tested on a patient-by-patient
basis and, furthermore, any reduction in tumour volume would allow for less invasive
surgery and increased the likelihood of breast conserving surgeries, potentially removing
the need for surgery entirely169.
It should be noted that neoadjuvant interrogation is dependent on accurate characteri-
sation at the phenotypic level, most commonly in themeasurement of tumour volume, used
as a surrogate for response to therapy, and performed by the methods listed above. Like
any method performed physically by a clinician, and relying on subjective assessment of
the data in real time, technical variability is guaranteed. Moreover the technologies them-
selves are known to performonlywithin a tolerance of error, thoughUSSmeasurement has
been shown to outperform callipermeasurement as well as demonstrate high re-test agree-
ment as well as inter-observer agreement170–172. The practice has been used to successfully
guide patient classification in a number of studies, including in a successful blind validation
of endocrine therapy response prediction102. Conversely it has been demonstrated that al-
ternative — though more involved — techniques such as CT (computed tomography) scans
iIt would take 15 years (1974-1989) following the early adoption of the adjuvant setting to reliably prove that
tamoxifen reduced breast cancer incidence.168
iiIn fact a side-effect of improvement in breast cancer management is that long-term events, such as recur-
rence or metastasis, become less prevalent and statistical comparison become underpowered. The neoad-




offer greater sensitivity and positive predictive value, at a cost of efficiency173. Furthre-
more, the determination of tumour size is potentially overestimated byUSS, comparedwith
CT174.
Phenotypic classification often problematically involves hard divisions to be drawn, for
instance defining responsive vs. non-responsive patients, where in truth a spectrum of re-
sponse may exist. Here, again, Turnbull et al.102 would demonstrate that a quick response
to therapy, defined via rapid tumour volume reduction, and a slower response were tran-
scriptomically comparable, encouraging classification despite the likelihood of shades of
grey. It also remains that volume reduction of a tumour may liberate resistant clones that
were otherwise kept in check, as discussed in Section 1.7, implying that tumour shrinkage
may not always necessarily correlate with better prognosis in the long-term. It is critical
to remember, however, that these methods are understood to be imperfect, and it is this
imperfection that necessitates their use in clinical and molecular studies, in an attempt to
derive more accurate and sensitive methods.
Figure 1.10.1: The adjuvant (top) and neoadjuvant (bottom) settings. Study times are often
more than 5 years in length and adjuvant therapies can only be validated after this time has
elapsed. By tracking the tumour prior to surgical excision, a dynamic response to therapy
can be evaluated within a greatly reduced time frame and multiple biopsies can be taken
from the in situ tumour.
From a research perspective, the neoadjuvant window offers the ability to collect tu-
mour samples over time from the same patient. Multiple biopsies from the same patient
allow an additional dimension to be considered in the dynamicmolecular response to treat-
ment — i.e. it’s no longer just that the expression of gene X was high at diagnosis, rather
that it has shown a significant reduction following treatment. By focussing on changes in
the molecular profile of a tumour, researchers are able to add patient-specific context to
their response or progression and effectively model temporal heterogeneity102.
It should be noted that neoajduvant interrogation was dependent on accurate charac-
terisation at the phenotypic level, most notably in the measurement of tumour volume,
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used as a surrogate for response to therapy, performed by the methods listed above. Like
any method performed physically by a physician or clinician, and relying on subjective as-
sessment of the data in real time, variability is guaranteed to be apparent. Moreover the
technologies themselves are known to perform within a tolerance of error [ref]. However,
the practice has beenused to successfully guide patient classification in a number of studies,
including in a successful blind validation of endocrine response prediction102. Phenotypic
classification, by USS for instance, somewhat problematically involves hard classifications
to be drawn, often defining responsive vs. non-responsive patients, where in truth a spec-
trum of response may exist. Here, again, Turnbull et al.102 would demonstrate that quick
response, defined via rapid tumour volume reduction, and slower responsewere transcrip-
tomically comparable, encouraging classification despite the likelihood of shades of grey.
It also remains that volume reduction of a tumour may liberate resistant clones that were
otherwise kept in check, as discussed in the previous chapters, implying that tumour shrink-
age may not always necessarily correlate with better prognosis. It is critical to remember,
however, that these methods are understood to be imperfect, and it is this imperfection
that necessitates their use in clinical and molecular studies, in an attempt to derive more
accurate and sensitive methods.
This has most notably been demonstrated as part of the IMPACT (immediate preoper-
ative anastrozole, tamoxifen, or combined with tamoxifen), P024 (letrozole vs. tamoxifen)
and POETIC (peri-operative endocrine therapy for individualising care) trials. IMPACT and
P024 both independently demonstrated that Ki67 reduction between study arms was anal-
ogous to rates of recurrence observed in the ATAC trial175,176. However, key to utilising
molecular features as surrogates for pathological outcomes, and symptomatic of a gradual
growing scepticism for seemingly inconsistent high-throughput technologies, was a need
to robustly and reliably determine biomarker consistency over time. A host of studies un-
dertook this challenge, measuring hormone and growth receptors and Ki67 expression con-
sistency by IHC, both in lieu of treatment177 and under conditions of treatment177–179. One
meta-analysis summarising these consistencies reported reliably accurate and concordant
determination of ER, PR and HER2 statuses for both core and excision biopsies180, though
another described a meaningful difference in the determination of PR in particular181.
That discordancy between core and excision biopsies existed was expected and the
characteristics of change were intuitive. That large, aggressive and node-positive tumours
are liable to show the greatest discordancy in Ki67, a marker of proliferation, following
chemotherapy was self-evident but raised the question: does treatment-induced hetero-
geneity causing a loss of ER/Ki67 imply that treatment should be altered? Kim et al.182
demonstrated that extreme Ki67 discordance between CB and EBmeasurements are corre-
latedwith poor prognostic factors, including size, PR-negativity, grade III, and early disease
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onset. It has additionally been demonstrated that 12-21% of luminal A tumours defined by
IHC at diagnosis would otherwise have been classified as luminal B if alternatively defined
at surgery183,184.
The spectre of a tumour changing subtype over time is a troubling one. Though treat-
ment is routinely altered and fine-tuned throughout a patient’s therapy, for instance in the
case of resistance to anti-estrogenics, as discussed in “Endocrine therapy resistance” (Sec-
tion 1.9), little has been written on how to deal with tumours losing a marker that was
previously apparent. Indeed, simply monitoring changes in the primary tumour’s subtype
have only recently been possible within the framework of the neoadjuvant window. If
we consider the situation where tumour subtype alters from ER-positive to ER-negative be-
tween treatment initiation and surgery, two contrasting possibilities are apparent — that
treatment has effectively eradicated its particular target and should be continued, or that
a once successful treatment no longer has a population that is sensitive to its effects. From
a patient’s perspective, the latter is particularly troubling, where the potential for useless
overtreatment becomes increasingly possible. Effectively, as subtype changes the amount
of data that can be used to assign treatment increases, where one, be it the original or the
revised assignment, may better reflect the post-surgical prognosis. This is further compli-
cated in that it is not necessarily routine practice to biopsy even recurrent disease when it
presents. To date, most studies have only gone as far as characterising the potential for sub-
type discordance, without making any recomendation on how to manage this occurence.
Where centres have altered their treatment in response to changing subtype, no survival
analysis has yet been calculated185. However, there is evidence that discordancy is associ-
ated with a decrease in overall and post-recurrent survivals186, and in the case of ER, dif-
ferential loss following neoadjuvant chemotherapy has been linked to worse disease-free
and overall survivals in a multivariate analysis187, whilst the opposite appeared true for
Ki67188. Despite these varying effects, results from the IMPACT trial confirmed Ki67 reduc-
tion as predictive of long-term survival in hormone receptor positive tumours, additionally
suggesting that longer-term changes in expression may be observable at as few as 2-weeks
on treatment, offering the potential for clinically feasible testing within the context of the
neoadjuvant window189,190.
Whilst treatmentwas evident tomolecularly alter tumours and that these changeswere
associated with survival, several groups additionally suggested that the act of the tumour
biopsy may directly impact upon both the data generated but also, more worryingly, the
disease trajectory191,192. Surgical excision — and induction of a wound-healing state — of
HER2-positive cancers has been implicated in promoting malignancy via systemic growth
factor release and immune suppression193,194. Tagliabue et al. would further demonstrate
that residual disease removal, effectively a second surgery, for HER2-positive tumours re-
22
1.10 The adjuvant and neoadjuvant settings
sulted in a significant increase in proliferation195. Similarly, Chen et al. demonstrated a
correlation between molecular subtype, surgical biopsy interval and Ki67, implying that
the structure of the study was able to effect the data observed, specifically implicating the
CB in upregulating Ki67196.
Fundamentally confounding these studies was that the act of sample biopsywas concur-
rent with treatment — the effects of one were difficult to disentangle from the other, and it
was therefore necessary to molecularly define changes occurring in lieu of treatment, par-
ticularly in instances where, as suggested by the IMPACT trial, molecular markers such as
Ki67 were seemingly able to be used as surrogate endpoints. Whilst this had been accom-
plished for a small set of classical IHC markers, these were susceptible to technical and in-
terpretive biases and represented only a tiny proportion of potential molecular alterations.
Jeselsohn et al.197 sought to test for procedural bias in routine neoadjuvant comparisons
by analysing an extended set of 147 breast cancer-related genes, including the oncotypeDx
andPAM50 signatures, in 23matched anduntreated core and excision biopsies. The group’s
primary focus was on validating Ki67 as a tangible end point for neoadjuvant trials, test-
ing for variation in expression independent of treatment, as well as comparing prognostic
signature genes to determine any relative benefit of CB or EB in pre-treatment prognos-
tic assignment. Minimal variation was observed between biopsy time points, with samples
routinely clustering with their biopsy pairs for both the oncotypeDx and PAM50 signatures,
demonstrating that, whatever variation did occur in lieu of treatment it was less than the
variation between non-paired samples. Similar results were obtained for Ki67, with the
group commenting that
“The majority of the genes, including MKI67 (Ki67) did not differ significantly
between the core and excisional biopsies without therapeutic intervention,
[…] changes seen in Ki67 levels after a brief exposure to a treatment, are likely
due to the exposure and not because of differences in sampling”
Whilst genes previously linked with therapeutic response were unaffected by sampling
method, Jeselsohn and colleagues also highlighted a set of 14 immune-related transcripts
that were significantly altered between core and excision biopsies. Of particular note was
CD68, a tumour-associated macrophage (TAM) marker. TAMs have previously been asso-
ciated with poor prognosis, increased grade and decreased disease free survival198,199, and
TAM recruitment in response to CB was highlighted as a real risk, both in confounding the
assessment of immune modulating drugs and, perhaps more worryingly, in potentially en-
couraging factors associated with poor survival.i
iFaithless lyrists I have read, they’d amputate the rose to know the rose (Gregory Corso)
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With one eye on the hype once associated with microarrays, the known and highly con-
voluted impact of heterogeneity and the huge potential of the neoadjuvant window as a
research tool, it remained pertinent to fully explore its dynamics, particularly in the ab-
sence of treatment, where a rigorous control study was lacking.
1.11 Hypothesis and aims
Cancers, in particular breast cancers, are not all equal. Classification, as well as prediction
of a likely disease course, at the time of diagnosis has allowed more appropriate treatment
on a patient-by-patient basis. However, though sub-categorisation has proven useful, it has
as yet failed to capture all clinically relevant phenotypes, and patients routinely fall into a
category that they do not belong to. This translates to under- and over-treatment. Recent ap-
preciation of just how heterogeneous breast cancers are, as well as improved technologies
and approaches have fuelled ever finer characterisation. Two of these — high-throughput
molecular assays and neoadjuvant investigation — promise to achieve this characterisa-
tion both more reliably and more rapidly. The application of these methods are wide, in
particular they allow researchers to integrate clinical and molecular features over time, in
particular in addressing the effects (or lack of effect) of treatment. To an extent, the limit to
which questions can be asked is the data available and, if the right patient cohort are avail-
able, it’s possible to investigate many difficult to model problems, not least the acquired
resistance to a previously successful treatment.
Therefore the aims of this thesis are three-fold:
1. To model breast cancer temporal heterogeneity, with an emphasis on its relevance
to previous and future studies of drug response and biomarker study.
2. To demonstrate the neoadjuvant window’s potential in modelling hard to study phe-
notypes, with a specific focus on acquired endocrine therapy resistance and breast
cancer dormancy.
3. To characterise these phenotypes at the molecular level with the intent to derive
therapeutic targets as well as predictive and prognostic biomarkers.
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The methods detailed here relate only to work directly performed by myself or in direct
collaboration with others. Some work pertinent to the results, though not performed by
myself, is therefore not included unless strictly necessary. The thesis as a whole makes
use of both novel and previously published datasets, and only those datasets produced
de novo for the purposes of this thesis are described in detail. All data originates from
microarray technologies and quantifies global gene expression, though a number of dif-
ferent platforms were used. All analysis was conducted in R http://www.r-project.org us-
ing software packages available via CRAN http://cran.r-project.org/ and Bioconductor http:
//www.bioconductor.org/.
2.1 General methods and concepts
2.1.1 Microarrays
At the basic level, microarrays are a bed of messenger RNA (mRNA) capture probes. For
each expressed protein-coding mRNA, a sequence-specific complimentary oligonucleotide
probe is present. As a specific mRNA is introduced, it is able to bind to its complimentary
probe and hybridise. Conversely, if a gene is not present (i.e. it is unexpressed) its capture
probe remains empty. By fluorescent labelling of mRNA prior to hybridisation, mRNAs can
be quantified in response to laser excitation, where individual mRNA quantity is propor-
tional to fluorescent emission.
Whilst microarrays offer the opportunity to greatly increase the number of parallel as-
says performed, their bulk nature are liable to introduce a number of systematic technical
biases and artefacts, collectively referred to as noise. Key to the concept of technical noise
reduction is the preservation of true biological signal. Quality control is implemented as
several steps, beginning at the point of scanning. A microarray chip typically consists of
6 spots, each composed of the capture probe library and able to perform sample hybridis-
ation in parallel. By comparing spot signal intensity and consistency to background level,
proprietary scanning software is able to minimise intra-chip noise. Affymetrix microar-
ray chips in particular include a mismatch probe pairing for each capture probe, designed
25
2 Methods
to quantify background hybridisation. By varying the capture probe sequence by a single
nucleotide, mismatch probes are able to effective represent non-specific mRNA binding,
relative to the capture probe.
2.1.2 Fresh-frozen vs. formalin fixed and paraffin embedded material
A key facet of sample collection is storage. Historically, clinical tumour samples have been
fixed with formalin before being embedded in paraffin wax, whilst more recently snap
freezing in liquid nitrogen has become increasingly common200. Fuelling this transition is
themolecular degradation observed in FFPE stored samples, particularly in the case of a no-
toriously delicate molecule such as RNA200. This is clearly evident in Figures 2.1.3 and 2.1.4,
wherein FF and FFPE samples are integrated via batch correction. Whilst intra-material
correlations are high, the correlation betweenmaterials are significantly lower, most prob-
lematically in the case of replicate samples biopsied from the same tumour at the same
point in time. The process of batch correction for these samples therefore becomes a bal-
ance between maximising the number of samples at our disposal and minimising the in-
fluence on artificial correction techniques liable to introduce unwanted and unexpected
noise. A further consideration is that to combine FF and FFPE batches a researcher must
take the intersection of those probes called with sufficient certainty following microarray
hybridisation. As probe detection is known to be particularly poor in FFPE material, FFPE
samples can drive a reduction in the available features that could otherwise be preserved
if FF samples alone were used in the downstream analysis. Finally, at a practical level, it’s
increasingly likely that FFPE samples would have been collected significantly earlier than
FF samples, and that the corresponding differences in clinical practice and patient lifestyle
for FFPE and FF samples may be sizeable and represent a massive confounding factor. Ul-
timately, the importance of maximising dataset size has been chosen to be of greater value
for the analysis performed in the subsequent chapters and FF and FFPE samples were in-
tegrated where possible.
2.1.3 Batch correction
Technical artefacts result from variability in all stages of sample extraction, preparation
and hybridisation. These artefacts, or “noise”, lack any biological meaning, are spurious,
cloud interpretation, and perpetuate throughout all stages of downstream analysis if left
uncorrected. Key to ensuring a robust analysis is maximising the signal-to-noise ratio,
wherein true biological effects are accentuated and technical noise is reduced. Correction
for batch effects differ from standard normalisation procedures, described in section 2.1.1,
in their per-feature approach, eschewing the notion that all featureswill be affected equally.
ComBat, used throughout this thesis, is an empirical Bayes-basedmethod and, as such, deals
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well with small sample sizes201 and has been demonstrated to outperform other methods
including batch mean centring and distance weighted discrimination74.
2.1.4 Dimensionality reduction
Whilst visualisation of two or three variables can be achieved in as many geometric di-
mensions, representing hundreds or thousands (e.g. an entire transcriptome) presents a
challenge to interpretability. Dimensionality reduction techniques, such as principle com-
ponent analysis (PCA), allow simplification of high-dimensionalmultivariate data to greatly
reduced linear combinations of variables explaining the greatest degree of variation— the
eponymous principle components— often depicted in a human-friendly 2-dimensions that
capture the inherent structure of the data. Whilst depiction of rawhigh-dimensional data is
problematic, mathematically solving which linear combination of features are responsible
for the greatest amount of variation is trivial. Assuming that these principle components
explain a sufficient amount of the total variation within the data, plotting using the 1st and
2nd allows a 2D representation where, in the case of transcriptomic data, samples sharing
similar expression profiles will cluster.
Capturing high-dimensional structure for 2D visualisation by PCA therefore allows
visual appreciation of global cluster relationships but its linear nature can perform poorly
in representing local relationships in the raw data. Alternatively, t-SNE (t-distributed
stochastic neighbor embedding) attempts to maintain these local relationships by min-
imising the divergence between pairwise similarity scores of the raw input and their
corresponding low-dimensionality counterparts. In essence, t-SNE iteratively rearranges
a random low-dimensional data representation until it’s pairwise similarities most closely
corresponds to those of the original input’s. t-SNE is particularly useful in preserving local
high-dimensional structure when displayed in a low-dimensional space, though it may
fail to accurately — and quantitatively — represent global differences, with the distance
between sample clusters not necessarily depicting their quantitative (dis)similarities.
2.1.5 Clustering methods
Hierarchical clustering reorders variables (e.g. genes, samples) into clusters based on sim-
ilarities, to reveal shared patterns of expression. By calculating all pairwise similarities
the two most correlated features/variables are aggregated as a single cluster and the pro-
cess repeated using this cluster as a novel pseudofeature in the next round of calculations.
Throughout this thesis, “similarity” is calculated as the Pearson correlation coefficient and
pseudofeatures are compared using each cluster’s least correlated member (complete link-
age). Clustering can be represented as a dendrogram, a diverging tree diagram that places
variables from the same cluster adjacently. Similarity between individual variables or ag-
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gregated clusters are encoded by dendrogram height, with more similar variables being
connected by lower horizontal connections. By combining hierarchically clustered sample
dendrogramswith an expressionheatmap, a 2D expressionmatrix representation, patterns
of gene expression can be visually determined and compared.
2.1.6 Differential gene expression analysis (DGEA)
Differential gene expression analysis allows class-specific differences in gene expression
to be quantified, generating ameasure of statistical significance in conjunction with amag-
nitude of fold change. Within this thesis, significance analysis of microarrays (SAM) was
utilised. SAM non-parametrically computes the strength of association between gene ex-
pression and a response variable, such as treatment class or time point, implementing
permutation based re-sampling strategies whereby test statistics are compared to a null
distribution for random class shuffling.
2.1.7 Pathway analysis
Analysing gene expression patterns at the pathway level allows changes in individual genes
to be summarised as a collective effect. This allows the functional significance of multi-
ple genes contributing to a given biological pathway/effect to be combined, simplifies long
genelists to smaller and more manageable collections of pathways, and helps explain the
most likely biological context in the case of pleiotropy. In essence, for a given genelist,
related pathways are summarised and compared as an expected likelihood of being asso-
ciated with a given pathway by random chance, dependent on the size of the genelist, the
pathway and background universe being compared. Within this thesis, statistical enrich-
ment was performed by hypergeometric testing, applied in identifying Reactome pathways
in which a gene list of differentially expressed genes were over-represented202.
2.1.8 Survival analysis
Modelling an association between gene expression and time to a given outcome/event re-
quires a collection of functions able to cope with the realities of clinical trials, that is —
patient drop-out and the non-normality of time-to-event data. Survival analysis can be bro-
ken up into a collection of inter-related non-parametric, semi-parametric and parametric
functions that build upon the survival and hazard functions to determine the association
of a variable, such as the expression of a gene of gene signature, and time to outcome203.
The survival function
S(t) = P (T > t) (2.1)
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where T = case-specific survival, t = time, focusses on the probability of failure for a given




Pr(t ≤ T < t + ∆t|T ≥ t)
/
∆t (2.2)
determines the instantaneous potential (numerator) per unit time (denominator) for event
occurrence, given a survival up until at least t. A common analogy for the hazard function
is a speedometer: at a given instant, a speed of 60mph is simply the potential of travelling
60 miles within a single hour — the true distance covered will vary as the speed increases
or decreases around 60mph. The survival and hazard functions are related in that we can
reciprocally calculate one from the other. Put simply, as the hazard function increases, the
survivor function decreases.
The Kaplan-Meier formula — alternative known as the product-limit formula — esti-
mates the survival function by calculating the product of all probabilities of surviving past
a specified time204. Whilst the survival function is defined by a smooth continually declin-
ing curve, the Kaplan-Meier estimator is represented by a series of decreasing steps, effec-
tively comparing survival time against the proportion of samples (e.g. patients) yet to suffer
an event. Critically, the method is able to deal with right censored data, where current out-
come information is unavailable and only a record of survival up until a given past time
with no indication of current outcome status.
By plotting the Kaplan-Meier estimate, it is possible to represent a cohort’s declining sur-
vival as a whole or in competition between sub-populations, such as treatment and placebo
trial arms. The hazard ratio allows the relative survival of these groups to be compared, in
effect deriving a single value for the difference between the two arms.i Complimentary to
the hazard ratio, survival differences can equally be compared by logrank test calculation,
whose formulation is based on the null hypothesis that two groups share identical survival
functions205. Any differences in survival functions are thereby calculated as measure of
significance, implicating the stratifying factor as being associated with outcome
2.2 Data generation and chapter-specific analyses
2.2.1 Chapter 3 : No-intervening treatment
The no-intervening treatment dataset was composed of 74 sequential paired diagnostic
core-needle biopsies (CB) and surgical excision biopsies (EB). Thirty-seven patients were
originally identified at the Western General Hospital, Edinburgh, between 2003 and 2011,
ii.e. group b suffer an event at twice the rate of group a.
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with a histologically confirmed primary invasive breast cancer who had received no pre-
operative/neoadjuvant treatment at any time for medical or personal reasons and were
entirely treatment-naïve. All patients gave informed consent to be included in the study,
which was approved by the Lothian Regional Ethics Committee (2001/8/80 and 2001/8/81)
and all experiments were performed in accordance with relevant guidelines and regula-
tions. A summary and complete clinicopathological characteristics of the patients diagnos-
tic core biopsies are given in Appendix 1: Tables.
Core-needle biopsies were taken at diagnosis in all patients using a 14-gauge automated
needle device. For each biopsy, multiple cores were taken per tumour and combined as in-
dividual samples. Surgical excision biopsies, also physically taken as core-needle biopsies,
were collected between 13 and 53 days later (mean interval = 27.5 days). Sampleswere snap
frozen in liquid nitrogen and stored at −80 °C before homogenisation and RNA extraction
using the RNeasy Mini Kit with RNAse Free DNAse treatment (Qiagen). Only samples with
≥50% cellularity and ≥60% tumour tissue, determined by haematoxylin and eosin (H&E)
staining were included in the study. RNA quantity and quality was assured using a Nan-
odrop 2000c spectrophotometer (Thermo Scientific). RNA was reverse transcribed and am-
plified using the WT-Ovation FFPE System Version 2 (NuGEN), purified using the Qiaquick
PCR purification Kit (NuGEN), biotinylated using the IL Encore BiotinModule (NuGEN), and
purified using the minElute Reaction Cleanup Kit (Qiagen). At each step RNA/cDNA quan-
tity and qualitywas assured by repeat assessmentwith theNanodrop 2000c. Labelled cDNA
was hybridized to Illumina Human HT-12 version 3 and version 4 whole-genome expres-
sion bead arrays according to the standard protocol for NuGEN labelled samples. Data
was extracted using Illumina GenomeStudio software. Illumina probe profiles were pre-
processed using the lumi package, consisting of log2 transformation, quantile normalisa-
tion. Probes mapping to multiple official gene symbols were summarised by mean expres-
sion. Probe expression information was extracted and detected probes were standardised,
by passing a detection threshold (p ≤ 0.05) in ≥3 samples.
The NIT dataset was originally hybridised as 3 distinct processing batches and it was
therefore necessary to determine the presence of any technical batch effects and, if present,
to correct. Due to the presence of replicate and universal human reference RNA (UHRR)i
samples between batches, it was possible to accurately infer batch effects by t-SNE visualisa-
tion, where it would be anticipated that replicate and UHRR samples should cluster tightly
if batch effects were absent. Visualisation using the 500 highest-variance genes within the
3 batches, revealed batches A and B to be highly similar to one another, whilst batch C was
noticeably distinct (Figure 2.2.1A). UHRR and replicate samples shared between batches A
iUHRR was developed by the MAQC project as a highly reliable, consistent and commercially available refer-
ence sample68.
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or B were effectively identical. Though batch C didn’t contain UHRR samples, it was clear
that replicate NIT samples were distinct from their batch A/B counterparts. In considering
overcorrection as necessary to avoid as under-correction, it was determined to consider
the 3 processing batches as only 2 batches for correction. Following correction, the three
batches formed a single NIT sample cluster (Figure 2.2.1B). Importantly, the biologically
distinct UHRR samples are found separated as a second small cluster.
Figure 2.2.1: NIT batch effect removal. Pre-corrected raw data (A) reveals two major clus-
ters, batches A+B (blue, green) and batch C (orange). Replicate samples shared between
batches A and B demonstrate high similarity with near perfect t-SNE overlap. In contrast,
batch C remains more distal, particularly for replicate samples, where dashed lines display
replicate connections. Post-ComBat correction (B) effectively reduces inter-batch differences,
noticeably minimising replicate sample distance and maximising NIT and UHRR cluster inde-
pendence.
Sophisticated batch correction methods, such as ComBat, promise to retain biological
signal at the expense of technical noise201. Therefore, it is possible to quantify the impact
of batch correction as the removal of signal noise and the protection of biological differ-
ences. These two metrics were considered as overall correlation, and the combination of
intra-batch paired and unpaired correlations respectively. In essence, a ‘good’ correction
would increase the overall correlation (representing removal of technical noise) but not
affect intra-batch correlations (representing the preservation of biological signal). Con-
scious of the distorting impact of replicate samples in batch correction, they were neces-
sary to be removed prior to ComBat correction, accomplished using a hierarchical selection
scheme. Given the obvious batch differences, wherever possible batch C samples would be
discarded and only selected if they were unique, to minimise the need for correction. For
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selection between batches A andB, biopsy correlationswould be calculated on a per-patient
basis. The replicate demonstrating the highest mean correlation would be retained.
Following replicate sample removal and ComBat correction, it was evident that over-
all sample correlations significantly improved (p = 1.1x10-6), though not at the expense of
intra-batch correlations, indicating the removal of technical noise but not biological signal
(Figure 2.2.2).
Figure 2.2.2 Batch effect
removal quality. Follow-
ing batch correction by Com-
Bat, overall sample cor-
relation (Overall, represen-
tative of technical batch
differences) significantly in-
creased (p = 1.1x10−6),
though intra-batch paired
and unpaired sample corre-
lations (A-C, representative
of biological differences) re-
mained unaffected. White
= uncorrected, grey = Com-
Bat corrected
All significances were calculated by a two-tailed Wilcoxon rank sum test and corrected
formultiple testing (Benjamini-Hochberg correction), unless otherwise stated. Pairwise dif-
ferential gene expression (DGE) was calculated using significance analysis of microarrays
(SAM). Hierarchical clustering was performed on pairwise fold change expression values
using a complete linkagemethod. SAM analysis of treated data was performed using a hun-
dred 18-sample permutations, to fairly match sample size between subsets, with the inter-
secting significant genes being taken as a mean average. The raw and processed data from
this study can be accessed from NCBI GEO under the accession GSE76728. For the letrozole
treated comparison dataset, as well as all other datasets used in the meta-analysis, details
and sources can be found in Table 3.1.
2.2.2 Chapter 4 : Extended endocrine therapy
The extended endocrine therapy dataset was composed of two independent cohorts com-
posed of multiple sequential biopsies: discovery (n = 177) and validation (n = 53). All pa-
tients gave informed consent to be included in the study, which was approved by the local
regional ethics committee (07/S1103/26, August 2007). The patients included in the study
forwent surgery due to either medical or personal reasons, though all were treated for
at least 4-months with letrozole (Femara, 2.5mg; Novartis Pharma AG, Basel, Switzerland).
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Over this period, sequential tumour biopsies were taken using a 14-gauge core-needle prior
to a final surgical biopsy of the excised tumour. Following biopsying, samples were snap-
frozen in liquid nitrogen (discovery and validation cohorts) or formalin fixed and paraffin
embedded (validation cohort). Only tumours histologically confirmed to contain≥ 50% cel-
lularity and ≥ 60% tumour tissue were included for microarray hybridisation. In parallel,
multiple sequential tumour volume measurements were performed by ultrasound sonog-
raphy (USS). Tumour tissue was homogenised using amembrane disruptor and phase sepa-
rated. RNA extractionwas performed using a column-based purification allowing labelling
and microarray hybridisation.
Though sample collection and RNA extraction were performed in Edinburgh, the ex-
tended endocrine dataset was profiled as two major batches, one each in Edinburgh and
Georgetown,WashingtonDC. The Edinburgh discovery datasetwas labelled and hybridised
using Illumina protocols for HumanHT-12 v4 BeadChips and normalisation performed sim-
ilarly to the no-intervening treatment dataset, consisting of quantile normalisation, log2
transformation, summarisation and probe filtering (p ≤ 0.05 in ≥ 3 samples). The final
discovery cohort was produced in combination with data from two previous studies also
generated at Edinburgh: GSE59515102 (14 patients) and GSE55374103 (9 patients).
The Georgetown validation dataset, was hybridised using Affymetrix HG-U133Plus 2.0
microarrays. Probes were filtered using MAS5 presence/absence calls before fRMA and
loess normalisation.
As each batch was hybridised using different microarray platforms, the Edinburgh and
Georgetown datasets would be analysed separately, for discovery and validation purposes,
thereby avoiding the complications of inter-platform batch correction. However, each
dataset alone remained likely to contain technical batch effects requiring correction,
and batch correction would therefore be performed on a per-dataset basis. For the
Edinburgh, dataset correction was required to offset technical bias introduced by simple
processing batch differences, being a composite of three highly similar small cohorts. The
Georgetown dataset was composed of a mixture of fresh frozen (FF) and formalin-fixed
paraffin-embedded (FFPE) sample preservations and would require correction on this
basis (Figure 2.2.3A). Both for brevity, and that the Edinburgh data was originally pre-
processed and corrected by Dr. Cigdem Selli, correction is only detailed for the Georgetown
dataset here.
As in Chapter 3, post-correction increases in sample size would be balanced against bi-
ological integrity, with care shown to preserve the original intra-batch relationships. Once
again, correction quality would be assessed as maximising overall inter-batch correlation
(indicating the removal of technical noise) andminimising changes in pairwise correlations




Following ComBat correction for sample material type, the noticeable FF-FFPE batch ef-
fect was removed, with samples aggregating by patient post-correction (Figure 2.2.3B). This
effect was most noticeable among replicate samples shared between FF and FFPE batches
(in all but 2 cases), demonstrating overwhelming preservation of biological signal post-
correction. Of the two failures to aggregate by patient following correction (samples 416-1
and 188-1), replicate samples were available that did cluster effectively by patient, cluster-
ing with their corresponding paired samples (Figure 2.2.3C). Therefore these outliers were
chosen to be excluded in preference of their well-clustered replicates.
Figure 2.2.3: Validation dataset batch correction. (A) t-SNE dimensionality reduction and
visualisation reveals a clear batch effect between fresh frozen (FF, circles) and formalin-fixed
paraffin-embedded (FFPE, squares) sample preservations, most notably for replicate sam-
ples (black outlines, grey connections). (B) Following ComBat correction, samples cluster
irrespective of preservation type, and replicate and paired samples form local clusters of
similarity. (C) When replicate samples alone are visualised samples overwhelming cluster
by replicate and patient. Only a single replicate pair (416-1 & 188-1, emphasised) exhibit
distinct dissimilarity and were removed from subsequent analysis.
ComBat correction was quantified by considering overall and replicate inter-batch
correlations as well as intra-batch correlations (Figure 2.2.4). It was clearly evident that
as inter-batch correlation improved, intra-batch correlations remained largely unaffected,
with post-correction correlations displaying no significant difference (p = .8, one-way
ANOVA). Together these results supported increasing sample size by integrating FF and
FFPE materials. Aside from the 2 outliers described above, study samples were then
selected by removing FFPE replicates where FF equivalents were available, with long-term
FFPE storage associated with greater RNA degradation, before re-correction using only
those samples included in the downstream analysis.
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Figure 2.2.4 Batch correction
quantification. ComBat seeks
to remove technical batch effects
whilst maintaining biological sig-
nal. To validate its effective-
ness, overall and replicate corre-
lations (i.e. samples shared be-
tween batches) are used to mea-
sure the effects of technical noise;
intra-FF and intra-FFPE correla-
tions (i.e. samples from each
batch individually) are used to
measure the preservation of bio-
logical signal. Overall and repli-
cate correlations dramatically in-
crease following ComBat correc-
tion (right panel), whilst FF and
FFPE correlations remain stable.
No significant difference in corre-
lations are evident following Com-
Bat correction (p = .81 one-way
ANOVA).
Following batch correction, discovery (Edinburgh) and validation (Georgetown)
datasets were composed of 177 and 53 samples, detailing multiple biopsies from 62 and
20 unique patients, respectively. A proportion of these samples were shared between
datasets and would eventually be partitioned for predictive modelling, though all possible
Edinburgh samples were utilised for the initial exploratory analysis.
2.2.3 Chapter 5 : survivALL
Chapter 5 used only publicly available microarray data to describe and benchmark the sur-
vivALLmethodology and approach. Relevant information can be found under the GEO ac-
cessions: GSE9195206, GSE6532207, GSE12093208, GSE299065 &GSE17705209, or at cBioPortal43.
The five GEO datasets were identified as part of a systematic literature review in which 44
Affymetrix hybridised breast cancer datasetswere found and their phenotypic information
harmonised. Importantly, each of ER status, treatment, grade and survival information —
amongst other factors —were available following harmonisation. This allowed the totality
of all data collected to be queried by these factors, revealing the 5 datasets suitable for the
survivALL study, defined by 100% ER-positivity, 100% tamoxifen treatment and available
survival and grade information. All GEO datasets were downloaded as normalised matri-
ces, though each were then scaled by subtraction of the feature-wise mean and division
by the feature-wise standard deviation, to better allow inter-dataset comparison. More so-
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phisticated batch correction was purposefully not implemented to impart an additional
‘noisiness’ handicap to the comparisons.
TheMETABRIC datasetwas selected as it represents the largest single breast cancer gene
expression dataset, totalling 1,971 samples with complete disease-specific survival infor-
mation. It was originally assembled as part of the IC10 subtypinging study43, as described
in section 1.4. Importantly and unusually, METABRIC is split into two equally sized and
composition-matched subsets, allowing for independent discovery (n = 980) and validation
(n = 991). METABRIC data was downloaded as normalised gene expression data, before
scaling as described for the GEO datasets above.
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3 | Tumour sampling method can
significantly influence gene ex-
pression profiles derived from
neoadjuvant window studies, or
No-intervening treatment (NIT)
3.1 Context
Breast cancer clinical studies within the adjuvant setting are subject to limitations in speed,
patient drop-out, and in situ characterisation of response. Alternative treatment prior to
surgery, within the neoadjuvant setting, can avoid these limitations, allowing fast determi-
nation of preliminary treatment response within a ~2-week to 3-month window. Due to the
neoadjuvant window’s pre-surgical nature, the in situ tumour can be interrogated during
the course of treatment, and these clinical measurements related to clinical response. At a
simple level, these may include measurements of tumour volume, but the opportunity for
multi-sample in-depth molecular characterisation is equally possible210. In acquiring mul-
tiple biopsies per patient over the course of a study, and in determining those genes most
indicative of a response to therapy, the potential exists to develop predictive and prognos-
tic signatures, to better aid patient stratification and, by extension, correct assignment of
treatment and the avoidance of over treatment102. However, derived signatures are subject
to biological as well as practical heterogeneity, that is — the particular cohort assembled
and the design, including length, of the study.
Due to the short course of the neoadjuvant window, robust endpoints such as recur-
rent, metastatic, and disease-specific death incidences remain unknown and alternative
measures of efficacy are required. Whilst physical measurements such as tumour volume
allow for determination of a pathological complete response (pCR),i these still may fail to
i“pCR is defined as the absence of residual invasive and in situ cancer on haematoxylin and eosin evaluation
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occur within the short neoadjuvant ‘window-of-opportunity’ study time frame. Therefore,
proposals to use reduction in tumour proliferation asmeasured by Ki67 expression,i sought
to formalise molecular changes in response to treatment as viable primary endpoints175.
Ki67 reduction as primary endpoint has been used in a number of neoadjuvant win-
dow studies213,214, comparing pre-treatment diagnostic core-needle biopsies (CB) and peri-
treatment surgical excision biopsies (EB), and demonstrated to be associated with both
recurrence-free and overall survivals175,176. In essence, the studies discussed here perform
an initial diagnostic biopsy, administer treatment, and perform a subsequent biopsy at the
time of surgery. Though biopsying of the post-operative tumour can take place by a number
of methods, for the purposes of this study an excision biopsy was performed by a taking
core-needle biopsy of the surgically excised tumour specimen. Within thismodel, variation
occurring between biopsies is attributed to the treatment given, under an assumption of
no change in the absence of treatment. Concordance between IHC measured biomarkers
(e.g. ER, PR, HER2) has been studied extensively180, and found to be comparable between
biopsies, but these studies routinely lack in scope, either in terms of the markers assayed
or the number of samples included. The largest study prior to the publication of Tumour
sampling method can significantly influence gene expression profiles derived from neoadju-
vant window studies1, analysed 147 breast cancer-related genes, derived from ER-related,
PAM50 and oncotype Dx genesets, determining concordance between sample pairs from 21
individual patients197. High overall concordance was demonstrated, notably for the PAM50
and oncotype Dx prognostic signatures, however at the same time significant differential
expression was demonstrated for a subset of “immune-related” genes. Worryingly, this im-
plicated the core-needle biopsy in activating this immune response, itself associated with
poor prognostic factors in breast cancer.
The utility of the neoadjuvant window was therefore threatened by, at best, potential
unreliability and at worst detrimental effects to patient well-being. It was therefore neces-
sary to performa large-scale andhigh-throughput study to robustly determineneoadjuvant
window study paired biopsy sample variation in the absence of treatment. To this end a
cohort of 37 patient-derived core-needle and excision biopsy pairs were profiled using Il-
lumina BeadChip microarray technology. Beyond simple characterisation of sample pair
variation, it remained critical to determine whether diagnostic prediction by notable prog-
nostic and predictive signatures and biomarkers were liable to differ depending on when
during the course of clinical management a biopsy was taken.
of the complete resected breast specimen and all sampled regional lymph nodes following the completion of
neoadjuvant systemic therapy”.211
iExpressed at all stages of the cell cycle (excluding G0), Ki67 has been robustly correlated with breast cancer
prognosis as an alternative clinical end-point.212
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Figure 3.1.1: No-intervening treatment study design. Forty-six sequential tumour pairs
(red) were biopsied at both diagnosis (squares) and immediately following surgery (circles).
No treatment was given before or during this time frame, covering a span of 13-54 days.
Successful biopsying and microarray hybridisation (blue) was apparent for 38 diagnostic and
42 post-surgical samples, of which 37 overlapped and were included in the study.
3.2 Results
3.2.1 Consistent treatment-independent transcriptomic variation within the neoadju-
vant window
A perhaps clumsy yet useful null hypothesisi was the assumption that under conditions of
no-intervening treatment, sequential paired tumour biopsies would display a minimum of
transcriptomic variation. Indeed, unsupervised hierarchical clustering revealed a reason-
able degree of sample pair co-clustering at the first level of the dendrogram (25/37 pairs, Fig-
ure 3.2.1A upper) and pairwise, intra-tumour, correlations were significantly higher than
inter-tumour unpaired correlations (p = 7x10−11, Figure 3.2.1B). It was therefore readily
apparent that, though samples derived from the same patient were highly similar, they
remained non-identical and below the expected dissimilarity as a result of technical inter-
ference and sample processing, with microarray-derived correlations below r≈ 0.97 likely
due to underlying tumour heterogeneity216.
Perhaps more substantive, a 50-gene differentially expressed geneset (DEGs) was de-
rived comparing paired diagnostic core and surgical excision biopsies (SAM, fdr = 5%). This
geneset was enriched for MAPK signalling (DUSP1, JUN, NR4A1, and FOS), cancer-specific
(COX-2, PGE2, JUN, and FOS), apoptotic-induction (FOS and JUN), and genomic reformatting
(brain) ischaemic (EGR1 and JUN) pathways. As expected, based on these genes, samples
clustered irrespective of their patient and represented a consistent biological alteration
iThough an assumption that was nonetheless implicit in numerous neoadjuvant window studies.
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Figure 3.2.1: Treatment-independent and pairwise variation. (a) Hierarchical clustering of
37 patient-matched diagnostic core and excision biopsy samples using the 500 highest vari-
ance genes (upper) and a 50-gene DGE signature between core and excision biopsies (lower).
Bars represent IHC status (ER+/HER2− = Blue; ER+/HER2+ = Pink; ER-/HER2− = Red)
or biopsy method. Lower-most bar indicates where sample pairs co-aggregation. Two-thirds
(25/37) of the pairs cluster at the first level of the upper dendrogram, whereas pairwise asso-
ciation is lost in 31/37 cases for the lower. (b) There remains significantly stronger correla-
tion between biopsy pairs (intra-tumour) than between different tumours (mean inter-tumour).
***p < 0.001. (c) Discordance in molecular subtype assignment between core and excision
biopsies. Patients are ranked left to right by pairwise correlation. Colours represent single
sample predictor (SSP) subtypes (Luminal A = Dark blue; Luminal B = Light Blue; Her2 =
Pink; Basal = Red; Normal = Green). (d) Sample pairs were called discordant when Biopsy
A ≠ Biopsy B for at least 4/5 classifiers. Comparison of concordant vs. discordant pairwise
correlations then revealed an inverse relationship between correlation and discordancy.
over the period of no-intervening treatment (Figure 3.2.1A lower). Variation in lieu of treat-
mentwas substantial enough to cause discordance in subtype assignment betweenbiopsies.
Application of 5 subtyping schemes (PAM50, Sorlie217, Hu34, Desmedt218, and Wirapati79)
classified patients as either concordant (pairwise subtype agreement for >3 classifiers) or
discordant (≤3 agreements, Figure 3.2.1C, PAM50 shown). Per-class pairwise correlations




3.2.2 Pairwise variation in lieu of treatment may be associated with either time or
biopsy methodology
Having determined that significant and consistent pairwise variation was occurring in lieu
of treatment, it was pertinent to determine the contributing factors. A number of hypothe-
ses appeared likely, that (i) greater variation would be apparent at shorter time intervals if
variation was induced in response to diagnostic biopsying; (ii) longer time intervals would
display greater divergence if it reflected tumour evolution; (iii) variation was independent
of tumour biology. Modelling pairwise correlations as a function of both time interval
and IHC subtype displayed no significant association however, largely ruling out a molec-
ular response to diagnostic biopsying as well as tumour evolution (Figure 3.2.2A). Here
we would expect an association with time in the case of the former and associations with
both time and subtype for the latter, with ER-/HER2- subtypes known to be more muta-
tionally active219. Together, these results suggested that the root of the observed variation
may not be explained simply as a result of unchecked tumour biology and, following this
logic through, it stood to reason that the variation observedwithout treatment would likely
be equally apparent in a similarly processed treated dataset. By applying the 50-gene NIT
signature to a letrozole treated dataset, analogous in all of laboratory, microarray platform
and structure (multiple paired biopsies over time) it was obvious that a subset of the treated
samples displayed a similar pattern of expression to those of the NIT dataset (Figure 3.2.2B).
The treated samples that most exhibited the NIT expression pattern were those with the
longest treatment, implicating time between biopsies as the causative factor. However, as
in the NIT dataset, these longer-term treated biopsies understandably happened to be those
that were collected at the time of surgery, a fundamentally different biopsy method.
The definitive root cause of NIT signature expression — either time or biopsy method
—was difficult to dissect. For the letrozole treated dataset, upregulation of the NIT geneset
was apparent only after 3-months, for both on-treatment core-needle biopsies as well as
surgical excision biopsies, albeit to a lesser degree for CB samples (Figure 3.2.2D). How-
ever, global geneset enrichment analysis (GSEA) analysis was able to demonstrate that
the NIT signature could significantly define the differences between untreated and treated
data only when sampling method differed (NIT vs. 2wCB, p = 0; NIT vs. 3mCB, p = .02; NIT
vs. 3mEB, p = .25). Similarly, only in the instance of excision biopsy was DGEA able to
reproduce ≥30% of the NIT geneset. More so, out of 3,955 differentially expressed treated-
EB genes, seven of those common to NIT differential expression were amongst the top 15
in terms of fold-change magnitude. It therefore remained difficult to disentangle whether
time between biopsies or biopsymethodwas the causative factor in NIT geneset expression
and in all likelihood a combination of both may have been apparent.
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Figure 3.2.2: Causative factors influencing treatment-independent variation. (a) Pairwise
correlations between biopsy pairs are not explained as a function of either time between
biopsies (p = .32) or IHC status (p = .43). ER+/HER2− = Blue; ER+/HER2+ = Pink;
ER-/HER2− = Red. (b) NIT signature fold-change between CB and subsequent patient-
matched EB biopsies for both NIT and letrozole treated cohorts (upregulation = yellow;
downregulation = blue). Samples are ordered by increasing time between biopsies and
reveal a pattern associated with either extraction method - CB (grey) or EB (dark grey) -
or time. (c) Frequency distribution of biopsy time intervals. (d) To investigate the effects of
biopsy method and/or time on gene expression, the letrozole treated data was split into three
subsets – 2-week CB (2wCB), 3-month CB (3mCB) and 3-month EB (3mEB) and mean fold
changes calculated. Both 3-month subsets closely resemble NIT differential expression.
3.2.3 Multiple patient-matched datasets also demonstrate changes in NIT early
growth response genes
Irrespective of the underlying reason for pairwise variation in the NIT geneset, it remained
that changes occurring in lieu of treatment were apparent in treated datasets. To further
validate the NIT signature, a panel of four genes most representative of pairwise NIT gene-
set variation (DUSP1, EGR1, FOS, FOSB) were selected based on differential expression
fold-changemagnitude and significance, for comparison in six external validation datasets
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(Figure 3.2.3 & Table 3.1). Importantly, as well as being highlighted in the NIT geneset,
these genes were both well characterised in the literature as early growth response genes
and notable for their potentially spurious inclusion in previously published neoadjuvant
studies220–222. For these genes, significant differential gene expression was consistently ob-
served to a greater degree only when an excision biopsy followed a previous core-needle
biopsy in all datasets.
Figure 3.2.3: Pairwise variation for four early growth response NIT signature genes in six
validation datasets. These genes potentially represent an association between gene expres-
sion and sampling method, with surgically excised samples (EB) showing greater expression
fold-change than their core-needle biopsied (CB) counterparts. *p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001; − = not significant.
Biopsy Time Interval/days Biopsy Type
Treatment n median range 1st On- Final Dataset/Reference
None 37 27 13–53 CB - EB Pearce 2016
Letrozole 122 107 13–884 CB CB CB/EB Turnbull 2015
Celecoxib/none 22/15 NA 14–21 CB - EB Brandão 2013
Anastrozole 99 14 14–112 CB CB CB Smith 2007
RAD001 21 14 14 CB - EB Sabine 2010
Chemotherapy 69 NA NA CB CB EB Magbanua 2015
None 56 14 14 CB - EB Lopez-Knowles 2016




3.2.4 Markers of proliferation as surrogates for clinical response to treatment
Given the International Ki67 in Breast Cancer working group’s recommendation of on-
treatment changes in Ki67 expression as an alternative to pCR as well as longer term out-
come measures212, it was necessary to determine whether MKI67 gene expression was li-
able to change in lieu of treatment. However, unfortunately, probe quality control deemed
MKI67 to have not been reliably measured in the NIT dataset. Despite this, it remained pos-
sible to compare core-needle and excision biopsies using alternative proliferationmarkers,
such as PCNA223, MCM2224 and CCNB1225 (Figure 3.2.4). Expression of these three markers
clearly varied, demonstrating a general decreasing trend between biopsies, though not sig-
nificantly so (Figure 3.2.4A, Wilcoxon signed rank test p-value range = 0.07-0.35). This ten-
dency for proliferation to decrease was significantly more pronounced (PCNA p = 1.1x10-10;
MCM2 p = 4.0x10-16; CCNB1 p = 1.9x10-23, one-way ANOVA) in the letrozole treated neoad-
juvant dataset of similar experimental design. As a positive control, 2 NIT signature genes
(HBB and EGR1) were also compared, with the degree of differential expression remaining
similar between datasets (Figure 3.2.4B).
Figure 3.2.4: Reduction in proliferation in lieu of treatment. Three markers of proliferation
(PCNA, MCM2 and CCNB1) demonstrated non-significantly decreased expression between
core-needle and excision biopsies in the NIT dataset (A) (Wilcoxon signed rank test). These
relative differences were more pronounced, and independent of biopsy type, in a second
treated dataset (B) (PCNA p = 1.1 x 10−10; MCM2 p = 4.0 x 10−16; CCNB1 p = 1.9 x
10−23, one-way ANOVA). For comparison, two NIT signature genes (HBB and EGR1) were
similarly significantly differentially expressed in both datasets. Lines denote pairwise changes.
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Figure 3.2.5: Prosigna risk of recurrence variation between biopsies. (A) Categorical clas-
sification is largely robust between biopsies, with a minority of classifications varying. Where
risk group classification does alter, it is almost exclusively interchange between one of either
low or high risks and intermediate risk. (B) Changes in risk classification are mediated by
variation in risk scores between biopsies.
3.2.5 Prognostic assignment by commercial gene tests is partially affected by biopsy
type
From a clinical perspective it was important to determine whether biopsy time and/or type
could affect prognostic assignment by clinically available gene signatures and, by exten-
sion, whether either biopsy could be considered more suitable in determining prognosis.
Prosigna ROR classification displayed discordance, though only in a minority of patients
(29%) and — for all but a single patient — only to or from the intermediate classification
(Figure 3.2.5A). Core-needle and excision biopsy risk score correlation revealed a moder-
ate correlation (Figure 3.2.5B, R2 = .46, p = 4.2x10−6), explaining the variation observed in
Figure 3.2.5A.
3.2.6 Immune-related response to core-needle biopsy
Finally, immune activation, specifically recruitment of the poor prognosis-associated CD68,
as a result of a core-needle biopsy had been previously highlighted197. However, the NIT
dataset failed to significantly demonstrate this effect for any of the available (7/9) high-
lighted genes (Figure 3.2.6, pairwise Wilcoxon signed rank test = 0.16-0.83). Furthermore,
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Figure 3.2.6: Lack of immune activation in response to core-needle biopsy. All available
immune signature genes (CD68, CD14, CD52, CD44, PPARG, ADM, VEGFA) were com-
pared between core-needle and excision biopsies, though none demonstrated a significant
change in expression. For comparison, EGR1, a NIT signature gene, and ELOVL5, a nega-
tive control highly expressed in testis, were included. Lines denote pairwise changes.
pathway enrichment analysis demonstrated a lack of any significantly (p < .05) enriched
pathways, immune or otherwise, for the proposed immune gene set.
3.3 Perspectives
The no-intervening treatment study was an important as well as necessary control analy-
sis to reinforce the applicability of the neoadjuvant window as a tool for expedited clinical
studies in breast cancer. The results presented here detail that changes in gene expression
do indeed occur between untreated tumour biopsies, within the time frame of the neoadju-
vantwindow, and canpotentially introduce a confounding factor into downstreamanalysis.
However, this variation is superseded or “drowned-out” by changes occurring in response
to therapy. This informs the validity of previous neoadjuvant studies conducted to date but
still cautions against over-interest in novel biomarkers overlapping with the NIT signature
geneset, many ofwhichhave indeedbeenhighlighted in previous treated studies220,221,226,227.
It should, however, equally be noted that it remains plausible for the NIT signature genes
to have a legitimate role in treatment response in addition to their response to surgical
excision.
The proposed causative hypothesis for NIT variation is up-regulation of an early growth
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response in response to surgical trauma and warm ischaemia before newly biopsied sam-
ples are processed, where the cellular metabolic machinery attempts to mount a survival
or apoptotic response before all metabolic activity ceases. Tissue ischaemia may result
from exclusion of the vascular supply or simply from handling by the surgeon, scrub nurse,
pathologist and tumour bank personnel before the sample is snap-frozen in liquid nitro-
gen. This time delay is likely (on average) to be significantly longer for surgical excision
specimens than core biopsy samples. The effect of ischaemia on gene expression has been
described previously and warm ischaemia associated with the surgical extirpation of hu-
man tissues has significant effects on gene expression228. Morrogh et al.227 similarly con-
cluded that window trials are influenced by a wound-healing process, comparing a 502
cancer-related gene panel in 8 untreated controls and Dash et al.229 demonstrated signifi-
cant changes in the expression of FOS, JUN, ATF3 whilst investigating the effect of sample
processing time in prostate cancer. Two further studies also highlighted ischaemia as a
potential source of molecular variation and, again, key molecules including FOSB were
highlighted230,231. Importantly, the investigators compared excision biopsies placed into
RNAlater either immediately post-surgery or following an interval, and again observed
early growth and stress response associated genetic expression to increase.
Ideally this ischaemic effectwould be confirmedby comparing paired biopsies taken im-
mediately before and after surgery. However, ethical considerations, specifically the previ-
ously proposed induction of a poor outcome-associated immune response following a core-
needle biopsy, prohibit superfluous biopsies being performed. However, transcriptome-
wide DGEA of paired biopsies taken at increasing post-surgical time intervals has subse-
quently been performed, revealing that post-surgical biopsy processing time does indeed
significantly effect gene expression. Importantly, significant differences inmany of the NIT
signature genes (34%), including DUSP1, FOS, FOSB, JUN, ZFP36232 conclusively implicate
surgery, surgically-associated sample fixation and X-ray processing times with NIT signa-
ture gene induction. Taken together these data support the carefulmonitoring of ischaemic
time for tissues harvested for the purpose of gene profiling.
The clinical impact of neoadjuvant changes in gene expression in lieu of treatment re-
main somewhat unresolved. The results here suggest that, if excision biopsying induces
the NIT response, then core-needle biopsies remain the optimal point at which to consider
prognosis by gene signatures and biomarkers. Perhaps the only argument counter to this
logic is that intermediate ROR risk classification appears to be depleted for surgical exci-
sion biopsies, with classifications being more clinically relevant/actionable as either ‘high’
or ‘low’.
It remains that a major limitation of the study was the necessary exclusion of MKI67,
among other potentially informative genes, due to probe quality control measures. Reli-
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ably demonstrating MKI67 expression consistency between biopsies would have allowed
greater confidence in the use of Ki67 as a surrogate outcome marker. Instead, it was only
possible to demonstrate the consistency of three alternative proliferationmarkers— PCNA,
MCM2 and CCNB1—none of which were evidenced to significantly alter in a paired analy-
sis, though a trend of decreased expression was apparent. However, when compared with
the analogous proliferative decreases expected in a treated study, these changes proved
negligible. It has recently been demonstrated that IHC measured Ki67 significantly in-
creases between untreated core-needle and excision biopsied samples, in contrast to sharp
decreases in chemotherapy treated patients233. It could be argued that this does not invali-
date treated studies use of Ki67 as a surrogate outcome measure, as similarly to the results
presented here, the no-treatment effects are again clearly superseded by their treated coun-
terparts.
Further methodological considerations include the determination of intra-patient
discordancy at the unsupervised level. Here, discordancy was calculated using the
combined results of 5 gene expression signatures, each applied in assigning subtype to
highlight changes between core and excision biopsies from the same patient. Importantly,
the assignments for any given sample were themselves subject to variation between
signatures, where one signature may call a sample Luminal A and another call that same
sample as HER2-enriched, potentially inflating the perceived differences resulting from
samplingmethodology (Figure 3.3.1). Of the subtypingmodels applied, 3 classified samples
as 1 of 5 subtypes and the remaining 2 as 1 of 3 subtypes. Understandably the 3-subtype
models demonstrated a greater degree of consistency in assigning the same subtype to the
same sample, with a large proportion of 5-subtype variation being between Luminal A and
Luminal B subtypes that may only differ subtly at the molecular level. For the purposes
of the NIT study it may have been more robust to apply only the 3-subtype models in
assigning discordancy. Furthermore, though subtype assignment results in a discrete
classification it additionally computes the confidence of that same assignment. These
confidence values could additionally have been utilised to control for superfluous subtype
disagreement.
Beyond the methodology of the study, it remains that, whilst full transcriptome mea-
surement allowed previously unseen characterisation under conditions of no treatment
for breast cancer within the neoadjuvant window, clinically it’s unlikely for biomarkers
to be measured by microarray, with cheaper and quicker alternatives such as qPCR being
more practical. It would therefore be prudent to validate the NIT signature in terms of
these simpler methods. Furthermore, experimental design mimicking that used by Lopez-
Knowles et al.232, comparing variable post-surgical tissue processing times, could allow a
quantitative assay of surgical impact to be devised, measuring changes in NIT signature
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Figure 3.3.1: Aggrement in subtype assignment. Samples, ordered from left to right were
subtyped by 5 different methods. Consistency/variation in assignment for the same sample
is displayed in the vertical axis. Subtype assignment is observed to vary depending on the
method used. Understandably the majority of variation in subtype assignment for the 5
subtype models (upper) occurs between Luminal A and Luminal B classes. This is reinforced
by the more stable assignment demonstrated by the 2 subtype models (lower).
genes most representative of inter-biopsy changes independent of treatment. In this way,
treated studies could determine the study-specific impact posed by surgical excision.
Ultimately, with the potential for pairwise variation irrespective of treatment, our study
raises potential concerns of the suitability of the neoadjuvant window in gene expression
profiling studies. Recent results of the ALTTO (adjuvant lapatinib and/or trastuzumab treat-
ment optimisation) clinical trial were, however, found to be consistent with the predicted
benefits from the neoALTTO trial234. This supported the utility of the neoadjuvant set-
ting as a suitable and important window for evaluating promising new targeted agents,
as well as the continued use of patient-matched samples to assess intervention studies for
translational research235. Nonetheless it remains critical to understand that whilst patient-
matched samples reduce variation due to individuals, all possible sources of variationmust
be considered for an optimal experimental design. For example, in an intervention study
to assess dietary changes on normal breast tissue from pre-menopausal women it was con-
sidered optimal to schedule the sequential biopsies one menstrual cycle apart, rather than
using a fixed window of time236, as there is clear evidence that menstrual changes in oe-
strogen levels caused significant changes in gene expression237. Underlying tumour het-
erogeneity is an inevitable variable when comparing any two tumour biopsies, and this
study suggests that the method of sample collection should be considered along with treat-
ment, time interval and clinicopathological features as an important potential confounding
factor. These considerations are of particular importance if a study’s purpose is the devel-
opment of a prognostic/predictive classifier or identification of a biomarker, with genes
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present in our NIT signature excluded from the analysis. Beyond the results highlighted
here, the NIT dataset represents a publicly available control, against which new findings
within the context of the neoadjuvant window can be compared and benchmarked.
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4 | Extended neoadjuvant therapy as
a model of breast cancer dor-
mancy and acquired endocrine
resistance, or extended endocrine
therapy
4.1 Context
The majority of invasive breast cancers present as oestrogen receptor positive. Therapeu-
tically this represents a double-edged sword, wherein a tumours addiction to oestrogen
and ER signalling both drives its proliferation but simultaneously renders it susceptible to
targeted therapies. For a majority of cases (50-70%), endocrine therapy is successful, tu-
mour volume decreases within the neoadjuvant setting and post-operative recurrence free
survival is extended104,238,239. However, for these same initially responsive tumours, the
likelihood of recurrence is in excess of ~30%, even for small node-negative tumours240,241.
This is in contrast to ER-negative disease, which, despite lacking targeted therapies, exhibits
a continuous reduction in recurrence risk beyond the first five years post diagnosis (Figure
4.1.1)153.
The potential for delayed recurrence in ER-positive disease following seemingly suc-
cessful treatment is currently difficult to understand, as well as to study experimentally.
It is conjectured that undetected residual disease is likely to seed future recurrences. This
residual disease may represent only a tiny fraction of the original tumour mass, and even
a single cell may be able to eventually proliferate and become detectable164. As a result,
tracking, biopsying and assaying residual and dormanti tumour cells is challenging, even
outside of the normal challenges of extended follow-up studies such as patient drop-out
and cost. Furthermore, prediction of when a tumour cell may emerge from its dormant
iThat is tumour cells that have, or are yet to, clinically re-emerge from a prolonged disease-free period
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state is equally obscure, with residual tumour cells able to remain dormant for a longer
duration than would be anticipated by normal cell doubling rates242. Studying breast can-
cer dormancy within the adjuvant setting is therefore fundamentally difficult and, to date,
studies have been restricted to cell line and animal models.
Figure 4.1.1: Distant metastasis hazard estimates for 1615 ER-positive (ERP) and 427 ER-
negative (ERN) breast cancers. ER-positive samples display a continued recurrence risk up
to at least 10-years (adapted from Demicheli et al. 2010).
In contrast, the neoadjuvant window offers an alternative setting to model the dor-
mancy trajectory in situ, that is:
(i) treatment → (ii) response → (iii) desensitisation and resistance or continued response
Within the framework of the Edinburgh Breast Unit’s biobanking activity, a cohort of pa-
tients undergoing extended neoadjuvant endocrine therapywas identified. Extended treat-
ment, in some cases reaching over 3.5-years, allowed multiple ultrasound measurements
and tumour biopsies to be collected sequentially. With these samples, breast cancer dor-
mancy had the potential to be experimentally interrogated. By confirming an initial re-
sponse to therapy, determined by a reduction in tumour volume, patients could be cate-
gorised as either one of two classes — dormant or desensitised— based on whether the
initially observed volume decrease eventually reversed. This chapterwill present an analy-
sis that first validates the appropriateness of extended neoadjuvant therapy as a model for
long-term breast cancer dormancy, before characterisation and classification of dormant
and desensitised patients based on their transcriptomic profiles.
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Figure 4.1.2: Dormancy classification and sampling scheme. Three time points (Diagnostic,
Early-on and Extended) characterise two tumour classes (Dormant and Desensitised).
4.2 Results
4.2.1 Extended neoadjuvant therapy as an appropriate model for acquired en-
docrine resistance
Key to studying long-termacquired endocrine therapy resistancewas demonstrating the ap-
propriateness of the extended neoadjuvant model. Considerations of treatment duration,
change in tumour volume and how thesewere reflected at themolecular level needed to be
carefully assessed. Critical was the demonstration of initial treatment sensitivity followed
by either continued sensitivity or eventual desensitivity. This would ultimately allow clas-
sification of patients as one of two classes — dormant or desensitised.
Ultrasound sonographic (USS) measurement taken in situ over the course of treatment
allowed tumour volume to be a read-out of treatment response. An initial decrease in tu-
mour volume of ≥40%within 120 days of treatment was required for inclusion in the study,
and a subsequent continuing decline or steady volume classified patients as dormant. Con-
versely, re-growth of at least 5% classified patients as desensitised (Figure 4.2.1A). Classifica-
tionbyUSSwas complicated, however, due to a proportion of patients having their final USS
measurements taken at least onemonth prior to their final tumour biopsy. This allowed the
possibility of treatment desensitivity occurring within this window to be missed. For these
patients (n = 46), transcriptomic measurement of 3 markers of proliferation (MKI67, PCNA,
and MCM2) were used to help guide dormant/desensitised classification (Figure 4.2.1B).
Average expression was compared across the three treatment time points, that is — pre-
treatment (Diagnostic); treatmentwithin the commonneoadjuvant study time frame (≤120
days, Early-on); and treatment beyond this (>120 days Extended) (4.1.2). Only where gene
expression classification greatly differed from USS measurement was classification recon-
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sidered, with USS otherwise being considered before gene expression measurements. Fol-
lowing classification, the Edinburgh dataset consisted of 40 dormant and 22 desensitised
patients.
Figure 4.2.1: Treatment response and class assignment. (A) Sequential USS measurements
taken over the course of the study allowed patients to be assigned as either dormant or desen-
sitised based on the following criteria: a ≥40% decrease in tumour volume followed by either
a subsequent ≥5% increase (desensitised) or continued reduction/stability (dormant). The
x-axis is limited to 450 days for visualisation. (B) For patients whose last USS measurement
was ≥1-month prior to their final biopsy, proliferation is used as a surrogate for changes in
tumour volume. (C) Time-to-recurrence is evident to be significantly shorter for desensitised
patients (p = .01, one-sided Wilcoxon rank sum test).
Classifications were benchmarked using both clinical and transcriptomic variables.
Firstly, time-to-recurrence was determined to be significantly earlier in desensitised
patients (Figure 4.2.1C; p = .01, one-sided Wilcoxon rank sum test). Then, to validate
dormant/desensitised classifications were reflected at the transcriptomic level, two
assumptions were tested, that (i) early-on treatment samples would demonstrate less
between-class diversity, under the selective pressure of treatment and (ii) dormant and
desensitised patients would display variable long-term prognoses. Despite no signifi-
cant differences evident in clinico-pathological features between classes (Table 6.5), the
comparative enrichment for 50 ‘biological hallmark’ genesets243 between dormant and de-
sensitised patients demonstrated significant variation in gene expression at the diagnostic
time point. This variation in between-class enrichments was greatly reduced at early-on
treatment time points, demonstrating an initial shared response to treatment. However,
by the extended treatment time point, renewed diversity was apparent mirroring the
expected variation in treatment trajectory outlined above (Figure 4.2.2A). Of the geneset
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evident to differ between classes, early and late oestrogen responses are differentially en-
riched at both diagnostic and extended time points, but not early-on treatment. Similarly,
oncogene-related hallmarks (MYC targets, KRAS signalling, angiogenesis, and DNA repair
amongst others) were all differentially enriched at diagnostic and extended time points.
In parallel, PAM50 subtyping revealed a general transition of subtypes only if a patient
had been classified as dormant (p = 2.25x10$ˆ{-6}, Fisher’s exact test). Anecdotally, this
trend appeared to be towards better prognosis subtypes (e.g. Luminal B > Luminal A; Lu-
minal A > Normal) by the extended time point. Desensitised patients on the contrary dis-
played no evidence of transition between subtypes, largely remaining as the predominant
class: Luminal B (p = 1; Figure 4.2.2B & Table 4.1).
Diagnostic Early-on Extended
Dormant
LumA 18 19 27
LumB 23 9 5
HER2 0 0 0
Basal 0 0 0
Normal 0 0 10
Desensitised
LumA 7 7 7
LumB 11 9 11
HER2 1 1 1
Basal 0 0 1
Normal 0 0 0
Table 4.1: Subtype variation over extended endocrine treatment. Dormant and desensi-
tised classes exhibit varying progression under treatment, here illustrated by subtype hetero-
geneity. As treatment continues, dormant patient subtypes and associated prognosis begin to
change (p= 2.25x10−6, Fisher’s exact test), transitioning from a majority Luminal B subtypes
to a majority of Luminal A/Normal subtypes. Desensitised patients on the other hand display
almost no change in subtype proportions (p = 1, Fisher’s exact test), typified as Luminal B
tumours remaining Luminal B.
These results confirmed the a priori assumptions regarding the dormant and desen-
sitised phenotypes. Classification was therefore considered successful and the extended
neoadjuvant model as a whole appropriate for further investigation.
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Figure 4.2.2: Molecular validation of extended endocrine class assignment. (A)
Normalised-enrichment scores (colour) demonstrate relative enrichment of hallmark geneset
between classes. Though patients initially differ for a number of hallmarks at diagnosis, early
treatment greatly reduces between-class variation. After extended treatment patients again
exhibit increasing variability. Scores are relative to dormant patients. (B) Class-wise PAM50
subtyping reveals a trend of improving prognosis for dormant patients and stable/worsening
prognosis for desensitised patients. (C) Though the distribution of subtypes are similar be-
tween classes at diagnosis, a clear shift from Luminal B → Luminal A → Normal subtypes
is apparent for dormant patients as treatment progresses. In contrast desensitised patients
transition from Luminal A to Luminal B or even Basal subtypes.
4.2.2 Class differences are most evident after extended treatment
Transcriptomic class differences were initially compared using unsupervised feature se-
lection and clustering. PCA analysis using the 500 highest-variance genes across all sam-
ples, revealed little suggestion of an obvious dormant/desensitised stratification, instead
samples clustered based on treatment duration, with treated samples effectively progres-
sively diverging from their diagnostic pairs in the 1st principal component (PC1; Figure
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4.2.3A). However, there was the suggestion that this effect was not shared between classes,
with only extended treatment dormant samples significantly separating from their their
untreated diagnostic pairs based on PC1 (p = 7.9x10-14 dormant; p = .1 desensitised; one-
way ANOVA; figure 4.2.3A lower). In essence the expected molecular effect of treatment
observed in dormant patients appeared disrupted for desensitised patients and, indeed,
the pairwise correlations between diagnostic and extended treatment samples was signifi-
cantly lower in dormant patients (p = .004, Figure 4.2.3B), suggesting that long-term varia-
tion in gene expressionmay have potential in predicting classmembership. For single time
points, unsupervised clustering largely failed in distinctly stratifying classes, though, con-
sistent with Figure 4.2.3A, extended treatment samples displayed some hint of class separa-
tion based on gene expression, at least for the right-most sub-cluster of potentially “easier-
to-call” dormant patients (4.2.3C). However this translated poorly to earlier time points and
may simply reflect that class differences are too slight to be resolved early during treatment,
or that they simply do not yet exist.
Figure 4.2.3: Class-wise effects of extended treatment. (A) PCA visualisation of the 500
highest-variance genes failed to explicitly stratify classes. Instead samples clustered by time
on treatment, most notably in PC1. This representation of treatment effect over time var-
ied by class, with desensitised extended treatment samples co-clustering with earlier treated
and diagnostic samples. (B) Quantification of this effect demonstrated a significantly higher
pairwise correlation between diagnostic and extended treatment samples for desensitised pa-
tients (*p* = .004). (C) Alternatively using the highest-variance genes of extended treatment
samples only is suggestive of class stratification based on transcriptomic features.
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Per-class differential expression (SAM, fdr < .05) between diagnostic and extended
treatment samples revealed further class-wise differences, specifically in the number of
genes called as differentially expressed (5466 dormant vs. 41 desensitised).i The greatly
reduced number of DEGs in desensitised patients further highlighted the apparent atten-
uation/reversal of a shared response to treatment (Figure 4.2.3A), and in fact only 4 of
the 41 desensitised DEGs (AATF, HBE1, MIR193BHG & RGS1) were not shared by dormant
patients. Moreover, of these 41 genes, 16 were apparent to overlap with the no-intervening
treatment signature geneset, raising the possibility that a sizeable proportion of desensi-
tised DEGs were simply as a result of comparing core and excision biopsies, rather than
any specific genetic reprogramming. The intuition here therefore remained that class
differences stemmed from the loss of a previously shared response to treatment, rather
than an obvious alternative mechanism or program of gene expression. Furthermore,
application of dormant paired DEGs to desensitised samples revealed that not only were
the dormant changes being attenuated, they were in fact being reversed, an effect that
appeared to increase with time-on-treatment (Figure 4.2.4).
Dormant differential expression was typified by the expected pathway involvement
derived from previous neoadjuvant endocrine studies, with proliferation, cell cycle and
senescence pathways all highlighted. That these changes were absent in desensitised pa-
tients againmakes intuitive sense and PCA of paired dormant differentially expressed gene
fold change was able to detail a reasonably well defined stratification of dormant and de-
sensitised patients (Figure 4.2.5A). Similar stratification was alternatively achieved using
DEGs from direct dormant and desensitised extended treatment sample comparisons (Fig-
ure 4.2.5B). Pathway analysis of the union of these significantly up- and downregulated
genes (n = 234) revealed a notable enrichment for Reactome epigenetic modification path-
ways at p < 0.05 (hypergeometric test), with several of these pathways being similarly en-
riched in the previous paired analysis, including ‘HDACs deacetylase histones’ and ‘DNA
methylation’, again implicating epigenetic modification as a potential determinant of dor-
mancy/desensitisation.
iDGEAwas additionally performedusing 50 randomsamplings of dormant patients. These sampleswere each
equal in size to the number of desensitised pairs, allowing for any discrepancies in differential expression




Figure 4.2.4: Treatment induced changes are reversed after extended treatment in desen-
sitised patients. Dormant differentially expressed genes (y-axis) over the course of treatment
are not shared by their desensitised counterparts. In fact the opposite effect is revealed, with
an increasing magnitude following longer treatment duration. Of the two major gene clusters
(light and dark greys), a significant difference in expression fold-change is observed between
classes (up: p = 1x10−6; down: p = 1.9x10−5, Wilcoxon rank sum test). Patients (x-axis)
are ordered by increasing time-on-treatment. Red = up-regulation, blue = down-regulation.
All comparisons are drawn between extended and diagnostic biopsies.
Description GeneRatio BgRatio
M Phase 158/2749 325/10281
Chromosome Maintenance 68/2749 110/10281
G2/M Checkpoints 92/2749 170/10281
PRC2 methylates histones and DNA 51/2749 75/10281
Cell Cycle Checkpoints 103/2749 202/10281
DNA methylation 46/2749 66/10281
RNA Polymerase I Promoter Opening 45/2749 64/10281
Signaling by Rho GTPases 187/2749 446/10281
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA
expression
50/2749 77/10281
HDACs deacetylate histones 57/2749 93/10281
Table 4.2: Paired differential expression pathway enrichment. Dormant gene expression
changes over the course of treatment. All pathways were significant to p < 1x10−35. Gen-
eRatio is the ratio between the number of DEGs in the pathway and the number of mapped
DEGs. BgRatio is the ratio between the number of genes in the pathway and the total exam-
ined background
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Description GeneRatio BgRatio
HDACs deacetylate histones 37/142 93/10281
RNA Polymerase I Promoter Opening 31/142 64/10281
DNA methylation 31/142 66/10281
PRC2 methylates histones and DNA 32/142 75/10281
Condensation of Prophase Chromosomes 32/142 75/10281
Activated PKN1 stimulates transcription of AR (andro-
gen receptor) regulated genes KLK3 and KLK3
31/142 68/10281
SIRT1 negatively regulates rRNA Expression 31/142 70/10281
HATs acetylate histones 38/142 143/10281
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA
expression
31/142 77/10281
Meiotic recombination 32/142 89/10281
Table 4.3: Class-wise differential expression pathway enrichment. Gene expression
changes between dormant and desensitised extended treatment samples. All pathways were
significant to p < 1x10−9. GeneRatio is the ratio between the number of DEGs in the path-
way and the number of mapped DEGs. BgRatio is the ratio between the number of genes in
the pathway and the total examined background
Figure 4.2.5: Class stratification and visualisation by DEGs. t-SNE visualisation of extended
treatment samples by dormant paired diagnostic→extended (A) and unpaired between-class





Building a class prediction model was therefore attempted using alternative approaches,
applying both the paired and unpaired feature subsets individually as well as in combi-
nation. A random forest model would be built using the discovery dataset and features
refined by variable importance. This model would be trained using a subset of the Ed-
inburgh discovery cohort that was repartitioned to redistribute replicate samples shared
by both the discovery and Georgetown validation datasets in an attempt to balance class
proportions and retain a sufficiently large validation set. In response to this, differential
expression was recalculated using the newly partitioned discovery samples only. Models
were trained on a subset of the discovery partition, evaluated using a withheld discovery
subset, before application to the validation data (Table 4.4). The aim here was to predict
desensitised patients suitable for an alternative treatment regimen.
Data Dormant Desensitised % Dormant
Discovery 24 9 73
Discovery Evaluation 6 3 67
Validation 18 8 69
Table 4.4: Discovery and validation dataset partitions.
On the whole class prediction was unable to predict class (Figure 4.5). The best accu-
racy (62%) was achieved using fold change values for the differentially expressed geneset
derived fromdormant patients’ paired diagnostic and extended treatment samples, though
this fell short of the benchmark accuracy achievable by calling no patients as desensitised
(69%). The shortfall in accuracy was driven by poor sensitivity (25%) that characterised the












Table 4.5: Validation confusion matrix. Random forest model prediction fell below a base-
line accuracy of 69%, largely driven by low sensitivity in the prediction of desensitised patients.
PPV/NPV = Positive/Negative Predictive Value.
4.2.4 Epigenetic modification may mediate desensitisation
Both paired and unpaired differential expression models had highlighted epigenetic-
associated genesets, including histone deacetylases, histone acetyl transferases and DNA
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methyltransferases, though in reality the overlap between these pathways was high.
Nonetheless, it was clear that epigenetic modification and regulation was integral to the
molecular variation observed between dormant and desensitised classes. Inspection
of the 13 genes shared by the highlighted pathways revealed a significant progressive
down-regulation of all 13 genes following treatment for dormant patients (Figure 4.2.6A;
one-way ANOVA). This effect was not shared by desensitised patients following extended
treatment, with HIST1H2AK in fact showing significant and opposite up-regulation. For
desensitised patients, there was a clear trend for an initial decrease at early-on treatment
time points before subsequent re-expression, an overall neutral effect, at least within the
study duration. This initial response followed by desensitisation to treatment mirrors the
USS and proliferative markers used to assign class membership and offers further evi-
dence to latent acquisition of the desensitised phenotype that is not apparent at diagnostic
or early-on treatment time points.
Figure 4.2.6: Class variation in epigenetic-related expression. (A) Thirteen epigenetic-
related HIST genes are significantly downregulated over the course of treatment in dormant
patients only, summarised in (B). Lines denote pairwise changes. *** = p < .001, * = p <
.05.
The pioneer factors FOXA1, GATA3, and PBX1 have each previously been linked with
influencing an alternative ER-signalling response via chromatin remodelling and activated
ER recruitment and both FOXA1 and GATA3 were evident only to significantly decrease in




Figure 4.2.7: Class variation in pioneer factor expression. (A) Two of three pioneer factors
associated with ER-chromatin interaction are significantly downregulated over the course of
treatment in dormant patients only, summarised in (B). Lines denote pairwise changes. ***
= p < .001.
4.3 Perspectives
The molecular affects of endocrine therapy have previously been demonstrated for intrin-
sically resistant and responsive patients102. Post-treatment alterations in proliferative (↓),
metabolic (↓), immune-responsive (↑) and extra-cellular matrix/stromal remodelling (↑)
pathways are essentially lost in resistant patients and, moreover, these effects are apparent
at 2-weeks on-treatment. Acquired, rather than intrinsic, resistance stands as a different
challenge, and patients initially present as ostensibly identical in terms of their sensitiv-
ity to endocrine therapy, typified by shared changes in the same pathways listed above.
Eventually, however, this sensitivity is lost at some undetermined future point in time.
Experimentally this makes acquired resistance particularly difficult to model, reflected in
the paucity of patient-derived models of acquired resistance and breast cancer dormancy.
Even within the context and normal time frame of the neoadjuvant window, tumours are
likely to have been surgically removed prior to desensitisation occurring, making molec-
ular characterisation challenging. However, through normal deviation from routine dis-
ease management, some patients forwent surgery for an extended period of time, allowing
neoadjuvant treatment to be continually administered and the possibility of desensitisa-
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tion to occur. Characterisation of this cohort confirmed that the expected trajectory of an
initially shared response followed by either continued sensitivity or desensitivity was con-
firmed by a number of approaches. At the clinical level, USS demonstrated a decrease in tu-
mour volume followed by stabilisation/subsequent increase and these phenotypic changes
were equally reflected at the molecular level. Rational biological differences, as demon-
strated using the hallmark geneset243, were evident between classes. Here it was expected
that class differences would be most evident after extended treatment time points and
this proved evident, often for logical facets of tumour biology, including cancer-related
signalling pathways, such as MYC, KRAS, WNT, and oestrogen signalling pathways (Fig-
ures 4.2.2). Proliferative, angiogenic, DNA repair and EMT components were similarly
differentially enriched, with angiogenesis in particular suggested to play a major role in
emergence from dormancy165. Perhaps the most obviously difference between classes was
simply xenobiotic metabolism, suggesting that the mechanism of endocrine resistance was
related to how drugs were metabolised by the tumour, with dysregulation of CYP2D6 pre-
viously previously being implicated in tamoxifen resistance115. Class-wise differential en-
richment of the hallmark genesets was clearly extensive after long-term treatment and,
working backwards, these changes were almost non-existent early on-treatment, likely as
a result of the initially shared response to therapy coercing all tumours to a single similar
phenotype before eventual deviation into distinct classes. Though differential enrichment
at diagnostic time points tantalisingly suggested the possibility of early class stratification,
this never truly manifested in subsequent unsupervised or supervised comparisons.
Intrinsic subtyping revealed similar class variation over the course of treatment,
demonstrating a clear trend towards better prognosis phenotype only in the case of
dormant patients. It was clear that each of these qualitative measures were evident to
progress over the course of treatment in a manner that fit with the dormant/desensitised
hypothesis and spoke to the validity of the model as a whole, encouraging further analysis.
Unsupervised characterisation of class variation reflected and reinforced this pattern
of molecular change over time. Here treatment was anticipated to inform amajority of the
variation observed within the extended endocrine dataset and this was evident, with sam-
ples clustering by time on treatment (Figure 4.2.3). Though the effect of treatment could
have overshadowed the likely more subtle class differences, in fact variation in the re-
sponse to treatment proved a major discriminating factor, fitting with the overall message
that desensitisation manifests as a reversal of the effects of treatment, where long-term
treated desensitised samples molecularly revert to an early-on or even pre-treatment state.
In illustrating the continued response to treatment itwas again clear that an initial response
to therapy was shared between classes, before reversion for desensitised patients, with
many of these genes hinting at potential mechanisms facilitating desensitisation, including
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epigenetic and cell-cycle regulation (Figure 4.2.4 & Table 4.2). It appeared that response to
therapy would be more informative than any single biopsy snapshot in time. Moreover,
it’s clear that desensitisation to endocrine therapy is not simply an attenuation of the anti-
tumour effects but that the continued changes seen in dormant are in fact entirely reversed,
up-regulation becomes down- and vice versa, and this effect becomes more predominant
the longer post-diagnosis a biopsy was taken (Figure 4.2.4). This suggests that desensitised
extended treatment samples may represent a more aggressive cancer than that at diagno-
sis.
Whilst this variation was highly promising it failed to generalise and accurately facili-
tate class prediction. Neither the most promising DEGs derived from dormant treatment-
induced changes, nor direct class comparisons following long-term treatment, alone or in
combination would translate effectively to the Georgetown validation dataset. Accuracy
(59%) was no better than the class proportions (62%), and therefore failed to perform bet-
ter than simply predicting all samples as dormant. Furthermore, class prediction was per-
formed using extended treatment samples, and performed worse on earlier time-points,
limiting any clinical applicability even if successful.
It is perhaps here that the utility of the extended endocrine dataset reaches its limit,
as a descriptive, rather than predictive, tool. The uniqueness of the cohort is reflected in
its relatively small sample size and a yet smaller still validation dataset. Furthermore, the
explicit classification of tumours as either dormant or desensitised is a convenience to al-
low comparison but likely does not represent to true reality of desensitisation to endocrine
therapy. Dormant tumours may simply be yet-to-become desensitised tumours and two
truly independent classes may not exist, with initially responsive patients likely to suffer a
recurrence up to at least a decade post-surgery. Therefore, though two explicit classes have
been considered in this analysis, the designation of dormant and desensitised could equally
be considered a single class: initially responsive patients who have had andwhowill have a
recurrence. As a result, uncovering clear divisions amongst the dormant and desensitised
classes would always be challenging, more akin to comparing yes and not-yet than yes and
no. Classification, here measured by USS would therefore always stand as a snapshot, sub-
ject to the effects of temporal heterogeneity, despite being taken as several measurements
over time, and a far greater neoadjuvant treatment time span would be necessary to truly
compare long-term dormant patients with their desensitised counterparts.
This, in turn, assumes that the use of USS can accurately determine the relatively subtle
changes in tumour volume that underpin the dormancy study. Though USS has been com-
monly used tomeasure in situ tumours, its resolution in finely assessing changes in volume
is unclear and the test/re-test accuracy is high though imperfect170. It appears that alterna-
tive approaches such as CT scan may offer greater confidence in determining tumour vol-
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ume, though this comes at the cost of efficiency and ease of use, both for the clinician and
the patient. Given that desensitisation was classified using an increase in volume of 5% un-
derlies the precariousness of classification, where to an extent it has been trusted that the
measurements are reliable. Despite this, the measurements themselves were performed
in a highly controlled manner, within a single centre and by the same clinician, at the very
least ruling out the opportunity for inter-observer disagreement. Moreover, though a 5%
increase may appear small, this proportion is relative to the original tumour volume and
therefore underestimates the regrowth. For example, if a tumour had decreased in size by
90%, then a regrowth of 10% is an increase of 100% from the perspective of the tumour at its
smallest point. Ascertaining the specific tolerance of USSwithin this study remains difficult,
being all of technology-, clinician-, and likely patient-dependent. Triplicate measurement
may have allowed a statistical confidence to be approximated, though this remains non-
trivial given the reality of the clinic, particularly for patients who are already undertaking
non-essential tests as part of their therapy. Classification by USS therefore remains a deli-
cate balance between assurance of correct class assignment and maximising study power,
particularly for the less prevalent desensitised class. In essence, for this study it’s been ac-
cepted that the likelihood of false-positives classification is increased in order to minimise
false-negative classification.
The extended endocrine dataset’s ability to inform future studies remains however, in
(i) encouraging and directing the collection of sequential biopsies as an effective method of
modelling acquired resistance and tumour dormancy, whether by less invasive and more
feasiblemethods such as cell-free DNA (cfDNA) or circulating tumour cells (CTCs), and in (ii)
revealing the potential role of epigenetic alteration in potentially inducing desensitisation
to endocrine therapy.
Epigenetic modification resulting in desensitisation to endocrine therapy is an attrac-
tive hypothesis, providing a logical explanation as to the de/sensitivity ‘switch’ from re-
sponsive to resistant phenotypes as well as previous evidence supporting its potential role
in a number of cancer types246,247. Moreover, DNA methyltransferase (DNMT) and histone
deacetylase (HDACs) inhibitors have shown promise in breast cancer management, and in
fact have demonstrated increased efficacy in combination248,249, though benefit in solid tu-
mours is not as well characterised as haematological malignancies250. In fact, in leukaemic
patients, HDAC inhibition has been demonstrated to be time-dependent, supporting epige-
netic modulation as a mechanism in acquiring resistance. Furthermore HDAC inhibition
appears to be tumour selective, demonstrating synthetic lethality251,252. Perhaps most en-
couragingly, a phase-II trial (ENCORE 301) combined the HDAC inhibitor entinostat with
exemestane to demonstrate both increased progression-free and overall survivals253, result-
ing in entinostat being classified as an FDA Breakthrough Therapy for hormone receptor-
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positive breast cancer and the development of an on-going phase-III trial (E21120)254. Epi-
genetic modification and alterations of chromatin structure may destabilise ER-responsive
gene expression and force a switch to alternative ER-signalling pathways255, and silencing
of EREs via promoter methylation has been demonstrated in vitro256. A number of pio-
neer factors (FOXA1, GATA3, and PBX1) have been suggested to dynamically restructure
chromatin and facilitate this alternative signalling244,245,257. FOXA1 in particular has been
associated with ER chromatin recruitment in metastatic disease258 and is evident to show
class-wise differential expression at extended treatment time points, warranting further
analysis.
Ultimately HDAC inhibition stands as particularly attractive opportunity in explaining
and managing acquired endocrine resistance, due to prior FDA approval for use in haema-
tological malignancies and its logical potential as a resistance ‘switch’. Direct validation of
an epigenetic role in acquisition of resistance is clearly necessary, whether by IHC staining
or more comprehensive sequencing approaches. Key to characterising this modulation is
in tracking alterations over time as sequential biopsies and, in fact, epigenetic biomark-




5 | Continuous biomarker assessment
by exhaustive survival analysis, or
survivALL
5.1 Context
Survival analysis comprises a collection of statistical procedureswherein the length of time
leading up to an event is of interest. Within oncology, occurrence of and time to metastasis,
local relapse or disease-specific death are frequently used to compare the relative survivals
of two or more distinct populations, for example treated vs. placebo arms within a clinical
trial. By demonstrating that a given event occurs later and/or less frequently within the
treatment arm is evidence in favour of that same treatment. Whilst qualitative biomarkers
can easily stratify cohorts into two or more groups for this purpose, the question of how
to divide a cohort using a quantitative measure is considerably more challenging, where
an obvious division is not apparent. Within a clinical context, dividing patients to allow
a tractable decision is important, where reduction to binary choices of “treat” or “do not
treat” are relevant, even though a greater number of subgroups may exist in reality. For
instance, in the case of a prognostic signature outputting a continuous risk score, transla-
tion into whether a given patient should or should not be treated is key, though frequently
an arbitrary division into two equal sized groups at a predefined level, such as the me-
dian, is employed.i However, this arbitrary-split approach is ignorant to the biomarker’s
distribution, as well as the composition of the cohort and any potential confounding clin-
ical factors. In essence, median stratification of a patient cohort, based on the expression
of an individual gene, would assume that for every high-risk patient there is an equivalent
low-risk patient. The heterogeneous reality of patient cohorts makes assessing the robust-
ness of a biomarker across several datasets problematic, with arbitrary dichotomisation
unlikely to produce consistently reliable results due to random differences in sampling. In
iThough other arbitrary splits, such as comparing upper vs. lower quartiles, are common median dichotomi-
sation will be highlighted throughout this chapter.
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short, identifying a significant association with outcome by median separation in cohort A
is unlikely to directly translate to a significant median separation in cohort B. The ultimate
risk here is that an otherwise functional biomarker may be deemed irrelevant.
The opportunity to evaluate quantitative biomarkers in silico is in principle becoming
easier, with increasing numbers of publicly available high-throughput molecular profil-
ing datasets also providing patient follow-up data. In practice however, these datasets
derived from cohorts of primary patient tissue are molecularly heterogeneous in their
compositions32, and are likely to exhibit varying proportions of multiple clinical factors as-
sociated with outcome (e.g. molecular subtypes, age, stage, grade and length of follow-up).
It’s therefore clear that this variationmust be considered if a biomarker is to be successfully
applied and validated in a meta-analysis, though these factors may be of unknown origin
and difficult to correct in a multivariate analysis.
Building upon previous best-of-split methods261–263, I developed survivALL (https:
//CRAN.R-project.org/package=survivALL) an R package to exhaustively calculate and
visualise hazard ratios (HRs) for all possible points-of-separation and assess the associa-
tion between a continuous measure and survival. As open-source software, survivALL
allows for reproducible exhaustive survival analysis using public or independent datasets,
in a highly transparent, automatable and extensible manner within the wider R pack-
age landscape. Complimenting survivALL is a companion web-based app — survivAPP
(pearcedom.shinyapps.io/survivapp/) — allowing non-programmatic, drag-and-drop
survivALL use. survivALL offers researchers the ability to perform exhaustive survival
analysis highly relevant to the current state of –omics research.
In practice, survivALL computes the hazard ratio (HR)264 for every possible point-of-
separation,i allowing themagnitude— and frequency of— significant points-of-separation
to be identified. Robust significance is determined using a non-parametric and dataset-
specific bootstrap, performed as a 10,000-fold repeated calculation of HRs for random sam-
ple orderings, producing a distribution of expected/random HRs for each individual point-
of-separation, to which observed true biological HRs are compared and significance cal-
culated. Dataset-specific best points-of-separation are then optimised by maximising the
desirability265 of a combined p-value and absolute HR magnitude. To avoid Type-II errors
associated with the multiple comparisons inherent in survivALL’s methodology, all exam-
ples are preceded by a single ancillary test of significance, performed using the biomarker
as continuous predictor. Following this initial single test, all subsequent downstream anal-
ysis is performed using a combination of individual point-of-separation p-values and HR
magnitude, and therefore no longer considers significance of an association with outcome,
but rather where this association is most pronounced. This allows for robust determina-
iHence, survival analysis + all possible points-of-separation = survivALL
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tion of prognostic association whilst avoiding overcorrection in determining the optimum
point-of-separation. survivALL is compared to arbitrary stratification approaches through-
out the chapter and, whilst these are equivalent regardless of the chosen method (e.g. me-
dian, quartile separation), only median-dichotomisation is demonstrated for brevity.
5.2 Results
5.2.1 Exhaustive and arbitrary approaches to survival analysis
To illustrate the value of exhaustive survival analysis, I considered over-expression of hu-
man epidermal growth factor 2 (HER2/ERBB2), a well-established biomarker associated
with poor prognosis in invasive breast cancer38,266, in the largest single breast cancer gene
expression dataset – METABRIC43 (n = 1971 samples with complete disease-specific survival
information). Importantly and unusually, METABRIC is split into two equally sized and
composition-matched subsets, allowing for independent discovery and validation. Hazard
ratio visualisation for all possible points-of-separation of ordered ERBB2 expressionwithin
the METABRIC discovery cohort (n = 980) established 283/980 points-of-separation as signif-
icant (p < .05), confirming the expectation that increased ERBB2 expression is associated
with poor prognosis (Figure 5.2.1A). The span and location of these significant points are
consistent with epidemiological evidence demonstrating that across the population ~20%
of breast cancers overexpress HER2267 and, importantly, none are located at the median.
The contrasting Kaplan-Meier plots resulting from using the median (p = .48) and the data-
driven most significant point-of-separation (p = 1x10−11) for this dataset are also shown in
Figure 5.2.1A.
The level of ERBB2 expression associated with the discovery cohort-derived most sig-
nificant point-of-separation was then applied to the validation cohort to predict its own
specific most desirable point-of-separation (n = 991, Figures 5.2.1B). Prediction accuracy
was measured as the number of patients alternatively classified compared to the valida-
tion cohort’s own most desirable point-of-separation. This same measure of accuracy was
also calculated using amedian approach for comparison (Figure 5.2.1B), before application
to the entire available transcriptome (19,628 genes, Figure 5.2.1C). As expected, survivALL
significantly outperforms the median approach (p = 2x10−16, Kolmogorov-Smirnov test),
demonstrating the ability of exhaustive survival analysis to robustly determine prognos-
tic classification in two suitably relatable datasets, without a priori knowledge of a gene’s
distribution within a population.
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Figure 5.2.1: Exhaustive survival analysis of a continuous biomarker. (A) The plotALL()
function allows hazard ratios (y-axis) and bootstrap significance (p < 0.05 colour scale; p
≥ 0.05 grey) for all possible quantitative biomarker cut-points to be examined. Patients are
ordered by increasing expression of the quantitative marker – in this example, ERBB2 expres-
sion. Events (distant metastasis-free survival) are indicated as vertical lines below the plot,
with darker colours indicating chronologically earlier events. Kaplan-Meier plots for ERBB2
stratified using median (n = 490 vs. 490) and survivALL (n = 924 vs. 56) approaches are
shown, comparing patients with expression lower (grey) or higher (black) than the points-of-
separation determined in A. (B) Comparison of survivALL and median approaches in predict-
ing optimal cohort separation for ERBB2. The expression values associated with both median
and the dataset-specific most significant points-of-separation derived from the discovery set
in A is applied to the validation dataset. Error (median = orange, survivALL = blue) is calcu-
lated as the number of patients who would be incorrectly assigned using these predictions,
in relation to the validation cohorts own best separation. (C) Distribution of prediction error
for all genes. survivALL significantly (p = 2x10−16) outperforms a median approach in terms
of predictive accuracy.
5.2.2 Reproducible determination of prognostic stratification using publicly available
datasets
Real-world datasets rarely have similar compositions to the degree of the METABRIC dis-
covery and validation cohorts, and it remained to determine if survivALL could perform
reliable prognostic stratification in more dissimilar and noisier datasets. To test this,
semi-random sub-samplings of the entire METABRIC dataset were simulated for three
pre-defined proportions of estrogen receptor alpha (ER) positivity — 25, 50 & 75%. Using
these dramatically variable compositions, the extent to which survivALL was able to track
these differences in terms of the dataset-specific best point-of-separation for GATA3, a
prominent luminal biomarker244 was determined (Figure 5.2.2A). It was evident that as
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the proportion of ER-positive and ER-negative samples shifted, the survivALL plots in
turn shift in response, with the most significant point-of-separation consistently falling
at the division between ER-positive and ER-negative samples. Importantly, although the
most significant point-of-separation shifts between datasets, the corresponding level of
expression that defined the ER+/- boundaries remained consistent (Figure 5.2.2B), indi-
cating that survivALL is robustly determining a reliable and reproducible level of GATA3
expression with which to stratify these patient cohorts, even across highly compositionally
dissimilar datasets. In essence, this reproducible value represented a dataset-nonspecific
or population best point-of-separation. Again, a median point-of-separation failed to
define a level of expression that reproducibly stratified the patient cohorts and would
therefore likely result in rejection of GATA3 as a novel biomarker, contrary to the accepted
literature (Figure 5.2.2B).
To further demonstrate the difficulty in deriving a reproducible point-of-separation
acrossmultiple datasets with variable compositions, I repeated this analysis using five pub-
licly available, ER-positive tamoxifen treated datasets (GSE299065, GSE6532207, GSE9195206,
GSE12093208, GSE17705209; 5.1).
Grade





GSE9195 77 100 77 0 47 13 14 20 24
GSE6532-p2 87 100 75 0 67 32 17 37 16
GSE6532-a 109 100 95 0 45 23 1 91 0
GSE12093 136 100 - 0 - 15 - - -
GSE2990 139 100 - 0 20 22 58 31 36
GSE17706 196 100 - 0 41 27 44 110 40
Table 5.1: ER-positive dataset compositions.
Each dataset was variable in its composition for several clinical factors including grade.
It was therefore logical that each dataset, containing variable proportions of grade 1, 2,
and 3 tumours would equally contain variable proportions of good and poor prognosis pa-
tients. Understandably any one arbitrary point-of-separation would fail to reflect this com-
positional variation, whereas exhaustive survival analysis could accurately reflect grade
boundaries (Figure 5.2.3A). In assuming that tumour grade is an objective measurement
that reflects prognosis equally for each of the 5 cohorts, each survivALL-derived dataset-
specific best point-of-separation was therefore expected to relate to a consistent level of
any biomarker correlated with grade. For this purpose, AURKA, a prominent biomarker of
proliferation, being well explored and referenced in the literature for breast cancer, and
known to be correlated with grade, was employed to explore the performance of a known
biomarker268,269. As expected, AURKA was able to successfully determine GGI-determined
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Figure 5.2.2: Determination of a reproducible cut-off for a continuous marker. (A) Analysis
of METABRIC subset with variable composition. Three equally sized subsets (n = 500) with
variable proportions of ER-positive samples (25, 50 and 75%) demonstrate the ability of
survivALL to track the ER+/ER- (blue/red) boundary for GATA3 expression, with the most
significant point-of-separation (low-high significance = blue-yellow gradient) existing at this
boundary for each subset. (B) Whilst the HR distribution changes with ER+ proportion, the
10% most significant points-of-separation consistently relate to the same level of GATA3
expression. For comparison, the median level of expression (dashed white line) for each
subset is also shown, which varies substantially between the three subsets.
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grade boundaries across our 5 compositionally variable datasets where arbitrary methods
would have otherwise failed (Figure 5.2.3B).
Figure 5.2.3: Continued analysis of compositionally variable datasets. Six ER-positive
breast cancer, tamoxifen treated affymetrix datasets demonstrate survivALL’s ability to track
the grade-defined boundaries (greyscale) for AURKA expression, with the most significant
point-of-separation (less-more significant = blue-yellow) existing at these boundaries for
each dataset. Whilst the HR distribution and dataset-specific best point-of-separation are
evident to change with grade composition, the 15% most significant points-of-separation
consistently relate to the same range of AURKA expression.
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5.2.3 Significance does not guarantee a robust association with significance in meta-
analysis
Whilst significant association of a biomarker can be determined in a meta-analysis using
gene expression as a continuous predictor, this methodology does not reveal the direction
of that association, i.e. good or poor prognosis. For a gene determined as significantly as-
sociated with prognosis in more than one dataset, the magnitude of these associations may
be highly variable and even opposite (Figure 5.2.4). For the METABRIC discovery and vali-
dation cohorts this was evident to occur for ten genes, several of which (ACY3270, LRRK2271,
NUPR1272 & UGT1A7273) have been previously associated with cancer risk. This therefore
represents a small but real quirk of survival analysis that must be considered in meta-
analysis, emphasizing that caution should be employed when interpreting the results of
quantitative biomarker evaluation to establish consensus findings.
Figure 5.2.4: Biomarker significance and direction. survivALL reveals a gene, NUPR1, sig-
nificantly associated with survival in both the discovery and validation METABRIC datasets,




This chapter addresses the issues of assessing quantitative biomarkers for survival analysis,
offering survivALL and survivAPP as tools to evaluate and overcome these challenges. Il-
lustrated are situations relevant and common to researchers evaluating potential quantita-
tive biomarkers in publicly available high-throughput datasets, using well established, but
likely compositionally distorted examples. As an R package, survivALL allows greater reso-
lution, transparency and flexibility compared to other online best-of-split tools, applicable
to any public or proprietary dataset and usable in larger-scale automated data operations.
Researchers are increasingly using approaches such as KMplotter274 and Cutoff
Finder275, either to median-split or highlight a dataset-specific best point-of-separation.
This approach presents a number of potential problems highlighted in this chapter, though
the single most notable problem with currently available survival analysis tools is the
restriction of what data is available to be analysed – either alone or in combination as a
meta-analysis – and the exact methods used. Furthermore, whilst a prognostic association
can be considered using a continuous marker as the classifier itself, this ignores a number
of informative factors, such as the direction and magnitude of association, as well as
the optimal value to allow patient stratification into binary treatment groups. Many
quantitative biomarkers and patient characteristics are associated with outcome. The
distributions of these inter-related factors are likely to vary considerably between datasets,
making the use of single arbitrary cut-points for stratification of prognostic groups highly
context dependent. Our results demonstrate the value of evaluating all possible points-of-
separation (using survivALL) to carefully consider whether and where to dichotomise a
patient cohort.
Importantly, whilst the examples presented here relate to individual genes in breast
cancer microarray datasets, survivALL is readily extensible to other diseases, data types or
any other quantitative measure, including signatures or scores based upon marker combi-
nations. Moreover, whilst this study focuses on dichotomisation, survivALL also allows for
additional sub-populations with varying survivals to be visualised, as well as revealing po-
tential confounding factors, producing multivariate analysis and demonstrating or uncov-
ering an otherwise unknown factor when considering multiple datasets. Fundamentally,
survivALL has been developed as open-source software, to flexibly integrate with other
popular R packages, including the popular visualisation tool ggplot2 for customisable and
scalable output. Most importantly, survivALL and survivAPP allows true biological effects
and their relationship to survival to be revealed and reliably compared, within and be-




survivALLwas published as a CRAN-distributed R package in 2017, detailing survivALL
functions, examples and workflow in addition to the key rationale highlighted throughout
this chapter. A pre-print article was made available to further detail the use and signifi-
cance of survivALL and, similarly to this chapter, avoided reporting exploratory findings,
instead using known biomarkers to illustrate the relative benefit of survivALL over arbi-
trary stratification approaches, where well-validated biomarkers are liable to be discarded.
In this way, a survivALL user can be confident that, for a novel biomarker of unknown con-
sequence, variation in composition between datasets, due to random sampling differences,
will not affect the results, evenwith no a priori knowledge of how these confounding factors
may manifest.
Consistent throughout the results here was a focus on dichotomisation, rationalised as
the need for simple clinical decisions — i.e. treat or don’t treat. It should be stressed, how-
ever, that the choice to analyse by dichotomisation removes information from a statistical
analysis, potentially underpowering it. Key to survivALL is therefore its role as a comple-
mentary analysis, following careful initial assessment of a biomarker to determine a signifi-
cant association with prognosis. Once statistical association has been satisfied, it is then ap-
propriate to interrogate where patients may best be stratified by a givenmarker. Similarly,
though dichotomisation has been highlighted, survivALL equally allows greater than two
subpopulations to be interrogated. This is apparent in figure 5.2.4-left, where GSEs 6532-
p2 and 17705 display a twin-peak of HRs that correlate with grade 1/2 and 2/3 boundaries.
Trichotomisation (and beyond) using survivALL has not been robustly explored as part of
this thesis, however. survivALL’s key utility is therefore in deriving these boundaries for
patient stratification, to inform clinical application. That these dataset-specific points-of-
separation can be tied back to consistent levels of expression (Figures 5.2.2 & 5.2.3) is highly
encouraging. That a value even slightly consistent can be derived from datasets originat-
ing frommultiple independent studies (purposefully left un-batch corrected) is even more
encouraging still.
Though the nominal survival suggests a specific application in the life sciences, sur-
vivALL and exhaustive survival analysis are equally applicable beyond the remit of on-
cology and even biological science as a whole, extending to other data-types and, in theory,
any continuous measure. However, whilst a logical assumption, this extended scope has
as-of-yet not been demonstrated in practice.
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Within this thesis I have characterised temporal heterogeneity in breast cancer by two com-
plimentary approaches — an examination of the role of tumour heterogeneity within the
neoadjuvant window for untreated sequential biopsies; and the use of this same setting
in characterising the molecular progression and regression of endocrine therapy and its
resistance. Supplementing this was an additional methodological study detailing an im-
proved method for appraising and comparing quantitative biomarkers. Taken together,
these threads have illustrated the realities, needs, challenges and potential avenues for fu-
ture research, which will be summarised here.
Neoadjuvant ‘window of opportunity’ studies make use of the pre-surgical nature of
the neoadjuvant window to collect tumour material over time. Crucially, with the tumour
still in situ, it is possible to molecularly profile these biopsies whilst accurately monitoring
the clinical phenotype of the tumour and to synthesise these sources of information. It is
important to remember that the ultimate aim for most of these studies is to characterise
existing tumours to better inform our understanding of any given newly presenting cancer
— both in terms of its likely response to therapy or its prognosis — as well as to pilot novel
or existing therapies as part of a clinical trial, all within a greatly reduced time frame than
would otherwise be possible. In the case of the latter, measurement of tumour volume,
or markers of proliferation, are utilised to benchmark treatment efficacy and a reduction
in size or proliferation (which to an extent can be considered synonymous) is evidence
of response, correlating with long-term outcome. However, the use of protein or mRNA
quantification of proliferative biomarkers, such as Ki67/MKI67, has long been confounded
by potential variation resulting from normal tumour evolution. Cancers are known to be
heterogeneous and they are known to vary in their composition over time but the use of
MKI67 as a measure of response to therapy ignores the potential that MKI67, along with
any other gene, may vary independently of therapy. Similarly, and perhaps even more
pertinent, is the idea that diagnostic classification may be changeable over the course of
weeks or months, raising questions as to when clinical classification could and should be
performed. It was therefore crucial to perform a control study characterising the variation
between sequential tumour biopsies to both inform future, and corroborate past, studies.
79
6 Conclusion
Chapter 2 reports now published findings detailing 74 paired breast cancer biopsies
from 37 patients taken at diagnosis and, between 14-53 days later, at surgery having re-
ceived no-intervening treatment1. Perhaps unsurprisingly, though at odds with previous
window study designs, variation was apparent between sample pairs taken from the same
tumour. This variation was small relative to that observed in response to therapy, with
a greatly reduced number of genes being significantly altered, but remained significant
and consistent across patients nonetheless. Moreover, the apparent changes represented
a number of genes previously reported as being involved in malignancy. This variation
was equally apparent in 6 additional treated datasets, specifically for a selection of genes
associated with response to surgical trauma and the induction of an early growth response.
Importantly, diagnostic classification and proliferation were not observed to alter signifi-
cantly between biopsies, suggesting that the use of MKI67 as an outcome measure appro-
priate in the context of the neoadjuvant window.
The no-intervening treatment study results serve to inform the practicalities of sam-
pling, highlighting the need to ensure that biopsies are performed in as uniform a manner
as possible in order to minimise technical variation that would otherwise confound results.
Moreover, they also strongly question the previously reported role of a core-needle biopsy
in inducing a poor outcome associated immune response and supports their continued use
as both a clinical and research tool197. That the information available within the neoadju-
vant window can be maximised by considering changes over time has been demonstrated,
and linking data from multiple biopsies to characterise tumour heterogeneity both high-
lights the importance of, and offers confidence for, the continued ethical use of sequential
biopsies within the neoadjuvant window.
Perhaps lacking from Chapter 2 was conclusive proof that it was indeed the act of sur-
gical excision that induced the characteristic early growth response, though this has fortu-
nately been subsequently validated by another group232, tying post-surgical excision biopsy
X-ray duration with induction of many of the NIT signature genes. Similarly, it stands to
reason that a score of treatment-unrelated affects could have been derived, to measure
sampling-induced technical bias. This could find use in datasets where clinical data as to
the exact protocol of how biopsies were taken and processed is missing. The long-term im-
plications of the no-intervening treatment responsewill likely lie in future studies, wherein
theNIT signature and datasetwill serve as negative controls towhich novel biomarkers can
be compared and validated against.
In Chapter 3, a second cohort of patients were identified to characterise acquired re-
sistance to endocrine therapy. Contrary to the NIT study, here patients with ER-positive
disease underwent extended letrozole endocrine therapy. Patients were tracked over the
course of years, and multiple sequential biopsies were collected over the course of treat-
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ment. Our group has previously demonstrated the added benefit of an on-treatment treat-
ment biopsy in tracking a dynamic response to therapy to classify ER-positive tumours as
responsive or non-responsive102. However, despite initial responsiveness, a subset of tu-
mours remain liable to develop resistance at a later date and, understandably, prediction
of this acquired resistance phenotype was warranted. The extended duration of endocrine
therapy throughout this study effectively allowed some tumours to stochastically become
desensitised to treatment, whilst others remained sensitive and dormant, qualified by se-
quential measurements of tumour volume by USS. By transcriptomically comparing pa-
tients who did and who did not become desensitised to endocrine therapy the extended
endocrine study attempted to first characterise whether patients could be separated based
on their molecular characteristics before developing a classifier that could be applied for
newly presenting patients. Indeed based on transcriptomic features, dormant and desensi-
tised patients did display differential expression, manifesting as a reversion of an initially
shared response to treatment, rather than two entirely independent genetic programs. This
is perhaps the key factor that precluded an effective gene expression classifier being de-
veloped for acquired endocrine resistance, due to the relative similarity between classes,
particularly at earlier on treatment time points where classification would be most desir-
able. However, despite this failure in developing a classification model, it remained ap-
parent that significant differences in the expression of a number of epigenetic regulatory
genes were repeatedly highlighted between classes. Though these genes remain to be con-
clusively validated, previous literature evidence, including an ongoing phase III trial253,254
and the availability of FDA approved HDAC inhibitors encourage further scrutiny276.
Though a generalisable classifier remains elusive, the extended endocrine study was
able to highlight that, whatever changes are apparent, these are likely to emerge only after
a length of time far beyond that of the normal neoadjuvant setting. The implications of
this are that, if a predictive classifier could hypothetically be developed, there would likely
be no tumour material left to test it on. Cell-free DNA and circulating tumour cells may of-
fer a solution to this problem, wherein any residual tumour material is able to be assayed,
in theory far beyond the time frame of the extended endocrine study. If desensitisation
is influenced epigenetically, cfDNA may be the ideal candidate biomarker, relatively eas-
ily collected, stable and with previously work demonstrating the potential for epigenetic
modifications from cfDNA to be identified in melanoma and colorectal cancers277–279.
A major question that remains unresolved is whether desensitisation to endocrine
therapy is through acquired alterations within cells under the conditions of treatment, or
whether small subclonal compartments of the primary tumour exhibit resistance that is
only revealed once a previously dominant clone is destroyed. Bulk tumour sampling, as
was the practice for both neoadjuvant studies, sacrifices intra-tumour spatial heterogene-
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ity for feasibility. However, purified as-of-yet unsequenced DNA exists for the extended
endocrine dataset that could serve to characterise changes in subclonal composition.
Emergence of a resistant clone is certainly an attractive hypothesis to explain desensiti-
sation to treatment, though it could be argued that it poorly explains extended periods of
tumour cell dormancy associated with late relapse in ER-positive disease. Single-cell RNA
sequencing approaches have equally been demonstrated to illustrate the clonal dynamics
of a tumour over time280, though this more in-depth approach comes with associated
increases in complexity and cost, as well as simply being a younger, less well validated
method.
Though Chapter 4 characterises extended neoadjuvant endocrine therapy, it is not a
perfect model. For instance, the time frame is notably less than the 5- or 10-years adjuvant
endocrine therapy is commonly administered for, during which desensitisation to therapy
can occur. The study duration, though extended, therefore does not characterise potential
longer-term variation between dormant and desensitised patients. This is especially per-
tinent considering that endocrine response genes appear to deviate between classes more
as time-on-treatment increases, even for extended time point samples. Moreover, acquisi-
tion of resistance in the real world would normally occur post-surgically, in the absence
of the primary tumour, and the fact that the tumour remains in situ during the extended
endocrine treatment study could be assumed to increase the likelihood of resistance occur-
ring, given that there is simply a larger pool of cells and greater subclonal diversity for
resistance to arise from.
Though validation of a predictive classifier and/or epigenetic involvement in desensiti-
sation to therapy remains inconclusive, it should be noted that the Georgetown validation
dataset was significantly smaller than the Edinburgh dataset and represents an underpow-
ered comparison. However, criticism of the validation data should not be misunderstood
as validation itself. It may prove that the Georgetown dataset could be better utilised in
integration with the Edinburgh dataset, maximising sample size for a purely exploratory
analysis and, indeed, the promise of similar extended neoadjuvant datasets may become
available in the near future. Despite these issues, I believe that the results from Chapter 4,
particularly those relating to the potential epigenetic influence on desensitisation to ther-
apy, deserve further investigation. Having already generated the hypothesis using the en-
tire transcriptome, validation could be achieved by smaller-scale approaches such as IHC.
Furthermore, whilst able to suggest a role for epigenetic regulation, gene expression re-
mains a poor way to quantify it, and alternative assays focussing on protein-chromatin
associations, including chromatin immunoprecipitation (ChIP), may prove more sensitive,
if combined with a long-term sequential monitoring program. Again the legacy of the ex-
tended endocrine therapy study lies both in its findings but also with the data itself, against
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which findings from cell line and animal models can be compared and validated.
The neoadjuvant window is clearly a useful tool for the investigation of breast cancer.
Whilst traditional neoadjuvant studies have focussed on assessing a response to treatment,
this thesis highlights the interesting and complex phenotypes that can be effectively mod-
elled, when combined with an expansive biobanking operation. Whilst breast cancer treat-
ment is built upon well-established recommendations, the realities of treatment are var-
ied and stochastic and, given enough patients and thoughtful planning, cohorts describing
poorly characterised phenotypes can be assembled and clinical translatability maximised.
Though, the benefits of tumour-derived over cell-line models are clear281,282, and patient-
derived tumourmaterial represents the pinnacle of human translatability, in practicework-
ing with patient-derived material is tricky and the opportunity for technical biases is high.
Chief amongst these is that for every non-ordinary cohort that is assembled, there may ex-
ist an unaccounted for confounding factor motivating its abnormality, for instance a com-
mon reason for delayed surgery combined with extended treatment, or indeed no treat-
ment at all. Furthermore, the practical complexities are greatly increased. Chapter 2’s no-
intervening treatment highlighted the effect of biopsy method and sample processing can
have on downstream data analysis, and there are many more opportunities for technical
distortion to occur. This is particularly consequential when analysing sequential biopsies,
where hybridisation failure of only one sample from a patient set can render the entire set
unusable and sample size is disproportionately affected. Difficulties arising from the clin-
ical, rather than laboratory, origin of neoadjuvant samples are countered by increasing
recruitment and the use of paired statistical methods however. Whilst sequencing costs
remain a bottle neck, investigations into human disease are likely to remain a compromise
between reliability, relatability, and size and the reality remains that there is no quick or
easy fix when it comes to cancer research—heterogeneity informs all stages of clinical and
research practice, consistently questioning how best to investigate and compare different
patients, or even tumour material from the same patient. Ultimately the results presented
here encourage the ever growing acceptance of the role of heterogeneity in influencing
and defining cancer research, highlighting the need for careful study design and analytical
approach (as well as a dose of healthy scepticism), in order to translate and inform how




Within the context of this thesis, reference to terms such as RNA, expression, and abundance are used inter-
changeably and in the context of mRNA expression and its quantification.
AI - aromatase inhibitor
ALTTO - adjuvant lapatinib and/or trastuzumab treatment optimisation
ATAC - arimidex, tamoxifen alone or combined
AURKA - aurora kinase A
CB - core-needle biopsy
cfDNA - cell-free DNA
ctDNA - circulating tumour DNA
CTC - circulating tumour cell
DNA - deoxyribonucleic acid
DNMT - DNA methyltransferase
EB - excision biopsy
EGFR - epidermal growth factore receptor
EMT - epithelial to mesenchymal transition
ER - oestrogen receptor
ERE - oestrogen response element
DGE(A) - differential gene expression (analysis)
FDA - US food & drug administration
FF - fresh frozen
FFPE - formalin-fixed and parafin-embedded
FIRST - fulvestrant first-line study comparing endocrine treatments
GSEA - geneset enrichment analysis
HDAC - histone deacetylase
HER2 - human epidermal growth factor receptor 2
HR - hormone receptor or hazard ratio
IHC - immunohistochemistry/chemical
IGF - insulin-like growth factor
IMPACT - immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen
Lum - luminal
MAPK - mitogen-activated protein kinase
MAQC - microarray quality control
METABRIC - molecular taxonomy of breast cancer international consortium
NIT - no-intervening treatment
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NCBI GEO - national centre for biotechnology information gene expression omnibus
NKI - national kaker instituut
NPI - nottingham prognostic index
NPV - negative predictive value
PCA - principle component analysis
PCR - polymerase chain reaction
PCNA - proliferating chain nuclear antigen
PDX - patient-derived xenograft
POETIC - peri-operative endocrine therapy for individualising care
PPV - positive predictive value
PR - progesterone receptor
ROR - risk of recurrence
RS - recurrence score
RNA - ribonucleic acid
RT-PCR - reverse transcription polymerase chain reaction
SAGE - serial analysis of gene expression
SAM - significance analysis of microarrays
SERD - selective oestrogen receptor downregulator
SERM - selective oestrogen receptor modulators
SSP - single sample predictor
TAM - tumour-associated macrophage
TNBC - triple-negative breast cancer
t-SNE - t-distributed stochastic neighbour embedding
UHRR - universal human reference RNA
USS - ultrasound sonography





























Table 6.1: No-intervening treatment dataset clinico-pathological features.
87
6 Appendices
Gene Mean log2 FC Gene Mean log2 FC
HBA2 -1.23 HBB -1.17
GOLGA6A 0.08 TMEM255B 0.09
LCA5L 0.11 C20orf141 0.11
ZNF565 0.11 LRCH1 0.14
APOLD1 0.14 ABL2 0.14
FAM86FP 0.15 EDNRB 0.15 gg
FLYWCH1 0.15 ABCA6 0.16
ITSN1 0.16 WDFY2 0.16
SPDYE3 0.18 GOLGA8K 0.19
PTGS2 0.20 KLF6 0.22
RASA3 0.22 SLC2A3P2 0.22
ATF3 0.22 GPR183 0.22
KRTAP19-6 0.23 NR4A3 0.24
NPIPA3 0.24 SIK1 0.25
NR4A2 0.26 ZSWIM4 0.30
NRP1 0.31 LAMB1 0.36
SRGN 0.36 C8orf4 0.39
SGK1 0.45 EGR3 0.52
GEM 0.53 SLC2A3 0.59
RASD1 0.61 MEG3 0.64
JUN 0.75 RGS1 0.76
NR4A1 0.77 ZFP36 0.83
CYR61 0.97 RGS2 1.02
FOS 1.13 EGR1 1.48
DUSP1 1.56 FOSB 1.60




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.5: Extended endocrine treatment class relationships by clinico-pathological fea-
tures. No significant differences in are apparent between classes (Fisher’s Exact test).
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Table 6.6: Extended endocrine therapy Edinburgh cohort tumour volume by USS informa-
tion.
Patient ID Biopsy taken Days post-treatment Volume Rel. volume
32 TRUE -1 31.68 100
32 FALSE 51 6.78 21.4
32 FALSE 63 15.82 49.94
32 FALSE 910 3.21 10.13
50 FALSE 0 12.92 100
50 FALSE 44 0.79 6.11
50 TRUE 86 5.18 40.09
50 FALSE 184 7.72 59.75
50 FALSE 231 1.32 10.22
109 FALSE 0 13.94 100
109 FALSE 52 8.65 62.05
109 FALSE 101 9.44 67.72
109 FALSE 192 2.72 19.51
109 FALSE 283 8.71 62.48
120 FALSE 0 36.87 100
120 FALSE 45 16.67 45.21
120 TRUE 87 5.65 15.32
120 FALSE 126 5.26 14.27
120 FALSE 169 4.84 13.13
139 FALSE 0 19.13 100
139 FALSE 49 3.18 16.62
139 FALSE 92 4.82 25.2
139 FALSE 162 0.98 5.12
147 FALSE 0 3.74 100
147 FALSE 84 0.98 26.2
147 FALSE 140 2.01 53.74
147 FALSE 196 3.35 89.57
171 TRUE -12 17.91 100
171 FALSE 44 6.73 37.58
171 FALSE 86 3.04 16.97
171 FALSE 205 6.21 34.67
181 FALSE 0 8.01 100
181 FALSE 45 3.04 37.95
181 FALSE 87 2.15 26.84
182 FALSE 17 4.91 100
182 FALSE 45 1.36 27.7
182 FALSE 80 1.14 23.22
182 FALSE 171 1.13 23.01
182 FALSE 371 0.17 3.46
182 FALSE 743 0.18 3.67
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188 FALSE -3 8.17 100
188 FALSE 42 7.83 95.84
188 FALSE 84 2.83 34.64
188 FALSE 175 3.87 47.37
188 FALSE 217 3.38 41.37
188 FALSE 441 3.22 39.41
195 FALSE 0 1.34 100
195 FALSE 43 0.11 8.21
195 FALSE 78 0.21 15.67
195 FALSE 148 0.13 9.7
214 TRUE 14 4.11 100
214 FALSE 47 4.52 109.98
214 FALSE 89 0.69 16.79
215 FALSE 0 4.98 100
215 FALSE 45 1.88 37.75
215 FALSE 108 0.44 8.84
225 FALSE 0 212.17 100
225 TRUE 88 124.79 58.82
225 TRUE 179 50.97 24.02
225 FALSE 333 50.97 24.02
226 FALSE 0 4.34 100
226 FALSE 45 2.39 55.07
226 TRUE 143 0.09 2.07
226 FALSE 434 0.15 3.46
226 FALSE 556 0 0
249 FALSE 0 394.37 100
249 FALSE 59 118.79 30.12
249 TRUE 108 75.73 19.2
249 FALSE 295 56.09 14.22
249 FALSE 393 65.42 16.59
251 FALSE 0 10.93 100
251 FALSE 52 1.42 12.99
251 FALSE 101 1.79 16.38
251 FALSE 204 1.42 12.99
268 TRUE -11 338.71 100
268 FALSE 45 243.6 71.92
268 FALSE 87 195.33 57.67
268 FALSE 157 87.07 25.71
269 TRUE -8 4.84 100
269 FALSE 45 2.27 46.9
269 FALSE 108 0.75 15.5
276 FALSE 0 1.72 100
276 FALSE 46 1.63 94.77
276 FALSE 98 0.83 48.26
279 FALSE 0 3.32 100
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279 FALSE 45 1.81 54.52
281 FALSE 0 3.69 100
281 FALSE 52 1.18 31.98
281 FALSE 101 0.65 17.62
289 FALSE 0 4.71 100
289 FALSE 45 3.59 76.22
289 FALSE 91 0.92 19.53
289 FALSE 189 1.51 32.06
289 FALSE 364 0 0
291 FALSE 0 15.39 100
291 FALSE 28 4.91 31.9
291 FALSE 98 3.14 20.4
298 FALSE 0 4.71 100
298 TRUE 22 0.82 17.41
299 FALSE 0 5.12 100
299 FALSE 64 0.47 9.18
299 FALSE 91 1.14 22.27
299 FALSE 133 0.48 9.38
300 TRUE -6 2.54 100
300 FALSE 42 1.28 50.39
300 TRUE 84 1.03 40.55
300 FALSE 182 1.26 49.61
302 FALSE 15 13.98 100
302 FALSE 50 7.48 53.51
302 FALSE 106 3.14 22.46
309 FALSE 0 2.09 100
309 FALSE 64 0.38 18.18
309 TRUE 156 0.35 16.75
311 FALSE 0 2.4 100
311 FALSE 42 1.92 80
311 FALSE 84 0.68 28.33
323 TRUE -15 5.56 100
323 FALSE 50 2.46 44.24
323 FALSE 91 1.07 19.24
325 FALSE 0 8.8 100
325 FALSE 57 6.01 68.3
325 FALSE 100 4.98 56.59
325 FALSE 211 2.54 28.86
328 TRUE -25 13.11 100
328 FALSE 42 3.92 29.9
328 FALSE 91 2.93 22.35
329 FALSE 0 2.27 100
329 FALSE 43 1.74 76.65
329 FALSE 85 0.69 30.4
330 FALSE 0 2.83 100
98
330 FALSE 42 1.38 48.76
330 FALSE 77 1.18 41.7
333 TRUE 22 19.11 100
333 FALSE 38 2.91 15.23
333 FALSE 78 0.99 5.18
334 FALSE 0 5.89 100
334 FALSE 66 0.38 6.45
334 FALSE 105 0.42 7.13
340 FALSE 0 5.26 100
340 FALSE 49 3.38 64.26
340 TRUE 91 2.71 51.52
340 FALSE 196 3 57.03
341 TRUE -11 4.05 100
341 FALSE 64 2.64 65.19
341 TRUE 106 0.75 18.52
341 FALSE 302 1.13 27.9
343 FALSE 0 16.53 100
343 FALSE 63 3.08 18.63
343 FALSE 273 0.28 1.69
346 FALSE 0 3.39 100
346 FALSE 49 3.04 89.68
346 FALSE 98 1.63 48.08
346 FALSE 196 3.52 103.83
347 TRUE -7 14.02 100
347 FALSE 88 7.08 50.5
350 FALSE 0 13.82 100
350 FALSE 64 1.26 9.12
350 TRUE 134 2.79 20.19
350 FALSE 225 3.97 28.73
355 FALSE 0 0.68 100
355 FALSE 57 0.25 36.76
357 FALSE 0 3.63 100
357 FALSE 63 2.08 57.3
357 FALSE 105 0 0
364 FALSE 0 60.85 100
364 FALSE 48 26.01 42.74
364 TRUE 90 20.98 34.48
369 TRUE 0 6.37 100
369 FALSE 43 2.46 38.62
369 FALSE 98 2.42 37.99
374 FALSE 0 3.38 100
374 FALSE 42 0.71 21.01
374 FALSE 91 0.26 7.69
378 TRUE 0 10.86 100
378 FALSE 42 3.18 29.28
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378 TRUE 106 0.95 8.75
378 FALSE 204 1.32 12.15
381 FALSE 0 15.86 100
381 FALSE 42 15.39 97.04
381 TRUE 106 6.36 40.1
381 FALSE 239 4.82 30.39
381 FALSE 358 2.98 18.79
382 FALSE 0 1.66 100
382 FALSE 78 1.34 80.72
382 FALSE 120 0.4 24.1
393 FALSE 0 5.83 100
393 FALSE 85 3.58 61.41
393 FALSE 148 2.01 34.48
394 TRUE -6 6.6 100
394 FALSE 42 4.15 62.88
394 FALSE 105 3.04 46.06
395 FALSE 0 1.21 100
395 FALSE 211 0.13 10.74
399 FALSE 0 4.85 100
399 FALSE 36 2.88 59.38
399 FALSE 182 2.08 42.89
399 FALSE 330 1.3 26.8
400 FALSE 0 2.93 100
400 FALSE 85 0.97 33.11
400 FALSE 183 1.13 38.57
405 FALSE 0 1.66 100
405 FALSE 36 0.31 18.67
405 FALSE 113 0.31 18.67
405 TRUE 253 0.18 10.84
409 FALSE 0 3.05 100
409 FALSE 50 0.69 22.62
409 FALSE 176 0.24 7.87
413 FALSE 0 1.41 100
413 FALSE 50 0.88 62.41
413 FALSE 92 0.57 40.43
416 FALSE 0 3.05 100
416 FALSE 78 2.28 74.75
416 FALSE 120 1.33 43.61
283L FALSE 0 5.73 100
283L FALSE 52 2.86 49.91
283L FALSE 101 1.03 17.98
373R FALSE -1 1.61 100
373R FALSE 41 0.88 54.66
373R FALSE 90 0.34 21.12
100
Table 6.7: Extended endocrine therapy Edinburgh cohort patient-level information.
Patient ID Sample ID Biopsy Time Treated T N M Grade Allred HER2 event.os time.os
109 109-1 1 -8 T2 N0 M0 3 8 NA 1 1083
120 120-1 1 -8 T4D N1 M0 3 8 NA 0 4244
139 139-1 1 -11 T3 NO M0 2 7 0 0 4697
171 171-1 1 -12 T3 N1 M0 2 7 NA 1 369
181 181-1 1 -8 T2 N0 M0 2 7 1 1 1793
182 182-1 1 -8 T2 N0 M0 2 8 0 1 1681
188 188-1 1 -11 T2 N1 M0 2 8 0 1 1323
195 195-1 1 -8 T4 N1 M0 2 7 0 NA NA
214 214-1 1 -12 T4b N0 M0 2 8 0 0 2854
215 215-1 1 -11 T2 N0 M0 3 6 0 0 3640
225 225-1 1 -10 T4b N0 M0 3 7 0 1 811
226 226-1 1 -11 T2 N0 M1 3 8 0 1 745
249 249-1 1 -8 NA NA NA NA 8 0 1 1377
251 251-1 1 -11 T4 N0 M0 2 8 0 1 486
268 268-1 1 -11 T3 N2 M0 3 8 1 NA NA
269 269-1 1 -8 T2 N1 M0 3 8 0 1 2470
276 276-1 1 -7 T2 N1 M0 3 8 0 1 2641
279 279-1 1 -15 T2 N0 M0 1 8 0 1 2660
281 281-1 1 -8 T2 N0 M0 2 8 0 1 1032
283L 283L-1 1 -11 T1 N0 M0 1 8 0 NA NA
289 289-1 1 -11 T4 N0 M0 2 7 0 1 3126
291 291-1 1 -6 T2 N1 MX 3 7 0 1 1448
298 298-1 1 -13 T2 N1 M0 2 8 0 0 2997
299 299-1 1 -11 T2 N0 M0 2 7 0 1 613
300 300-1 1 -6 T1 N0 M0 3 8 1 0 2857
302 302-1 1 -7 T1 N0 MX 2 7 0 0 3081
309 309-1 1 -11 NA NA NA 2 8 0 1 2796
311 311-1 1 -6 T1 N0 M0 3 8 1 1 2800
32 32-1 1 -1 NA NA NA NA 8 NA NA NA
323 323-1 1 -15 T2 N0 M0 1 8 1 0 2873
325 325-1 1 -11 T2 N0 M0 2 8 0 0 2755
328 328-1 1 -25 T2 N0 M0 3 8 0 0 2832
329 329-1 1 -18 T4b N0 M0 2 8 0 0 2680
330 330-1 1 -15 T2 N1 M0 2 8 0 0 2811
333 333-1 1 -15 T2 NX M0 2 8 1 0 2828
334 334-1 1 -15 T4b N1 M0 2 8 1 0 2822
340 340-1 1 -8 T4b N0 M1 1 8 0 1 1467
341 341-1 1 -11 T2 N1 M0 1 8 0 1 2582
343 343-1 1 -16 T3 N1 M0 2 8 0 0 2649
346 346-1 1 -11 T2 N0 M0 2 8 1 1 2425
347 347-1 1 -7 T2 N0 M0 2 8 0 0 2615
350 350-1 1 -11 T4 N2 M0 3 8 0 1 280
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355 355-1 1 -11 T1 N0 M0 2 8 0 0 2001
357 357-1 1 -11 T2 N0 M0 1 7 0 1 2706
364 364-1 1 -12 T2 N0 M0 2 8 0 0 2123
369 369-1 1 0 T2 N0 M0 2 8 1 0 2342
373R 373R-1 1 -9 T1 N0 M0 NA 8 0 NA NA
374 374-1 1 -11 T1 N0 M0 2 8 0 0 2356
378 378-1 1 0 T2 N1 M0 2 8 0 0 2155
381 381-1 1 -15 T4b N0 M0 2 8 0 0 534
382 382-1 1 -11 NA NA NA 2 8 0 0 1705
393 393-1 1 -12 T2 N0 M0 1 8 0 0 1572
394 394-1 1 -6 NA NA NA 2 8 0 0 1937
395 395-1 1 -13 T2 N0 M0 2 7 0 0 1885
400 400-1 1 -11 NA N0 NA 2 8 0 1 544
405 405-1 1 -11 T1 N0 M0 2 8 0 1 1705
409 409-1 1 -13 T2 N1 M0 3 8 0 0 1717
413 413-1 1 -12 T1 N0 M0 2 8 0 1 878
416 416-1 1 -8 T4 N0 M0 2 8 0 0 1673
50 50-1 1 -12 T4D N1 M0 2 8 NA 1 824
109 109-2 2 20 T2 N0 M0 3 8 NA 1 1083
120 120-2 2 17 T4B N1 M0 3 8 NA 0 4244
147 147-2 2 17 T4 N0 M0 NA 7 NA NA NA
171 171-2 2 16 T3 N1 M0 2 7 NA 1 369
214 214-2 2 14 T4b N0 M0 2 8 0 0 2854
215 215-2 2 15 T2 N0 M0 3 6 0 0 3640
225 225-2 2 18 T4b N0 M0 3 7 0 1 811
226 226-2 2 14 T2 N0 M1 3 8 0 1 745
268 268-2 2 17 T3 N2 M0 3 8 1 NA NA
269 269-2 2 17 T2 N1 M0 3 8 0 1 2470
291 291-2 2 14 T2 N1 MX 3 7 0 1 1448
298 298-2 2 22 T2 N1 M0 2 8 0 0 2997
299 299-2 2 21 T2 N0 M0 2 7 0 1 613
309 309-2 2 15 NA NA NA 2 8 0 1 2796
311 311-2 2 14 T1 N0 M0 3 8 1 1 2800
328 328-2 2 14 T2 N0 M0 3 8 0 0 2832
329 329-2 2 14 T4b N0 M0 2 8 0 0 2680
330 330-2 2 14 T2 N1 M0 2 8 0 0 2811
333 333-2 2 22 T2 NX M0 2 8 1 0 2828
334 334-2 2 22 T4b N1 M0 2 8 1 0 2822
340 340-2 2 21 T4b N0 M1 1 8 0 1 1467
343 343-2 2 21 T3 N1 M0 2 8 0 0 2649
346 346-2 2 22 T2 N0 M0 2 8 1 1 2425
347 347-2 2 39 T2 N0 M0 2 8 0 0 2615
350 350-2 2 29 T4 N2 M0 3 8 0 1 280
355 355-2 2 24 T1 N0 M0 2 8 0 0 2001
357 357-2 2 38 T2 N0 M0 1 7 0 1 2706
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364 364-2 2 13 T2 N0 M0 2 8 0 0 2123
369 369-2 2 14 T2 N0 M0 2 8 1 0 2342
373R 373R-2 2 20 T1 N0 M0 NA 8 0 NA NA
374 374-2 2 21 T1 N0 M0 2 8 0 0 2356
381 381-2 2 14 T4b N0 M0 2 8 0 0 534
382 382-2 2 28 NA NA NA 2 8 0 0 1705
393 393-2 2 42 T2 N0 M0 1 8 0 0 1572
394 394-2 2 13 NA NA NA 2 8 0 0 1937
395 395-2 2 14 T2 N0 M0 2 7 0 0 1885
400 400-2 2 29 NA N0 NA 2 8 0 1 544
409 409-2 2 14 T2 N1 M0 3 8 0 0 1717
413 413-2 2 14 T1 N0 M0 2 8 0 1 878
416 416-2 2 28 T4 N0 M0 2 8 0 0 1673
50 50-2 2 16 T4D N1 M0 2 8 NA 1 824
120 120-2e 3 87 T4B N1 M0 3 8 NA 0 4244
225 225-2e 3 88 T4b N0 M0 3 7 0 1 811
249 249-2 3 108 NA NA NA NA 8 0 1 1377
300 300-2 2 84 T1 N0 M0 3 8 1 0 2857
340 340-2e 3 91 T4b N0 M1 1 8 0 1 1467
341 341-2 3 106 T2 N1 M0 1 8 0 1 2582
343 343-2e 3 105 T3 N1 M0 2 8 0 0 2649
364 364-2e 3 90 T2 N0 M0 2 8 0 0 2123
378 378-2 2 106 T2 N1 M0 2 8 0 0 2155
381 381-2e 3 106 T4b N0 M0 2 8 0 0 534
50 50-2e 3 86 T4D N1 M0 2 8 NA 1 824
109 109-4 4 303 T2 N0 M0 3 8 NA 1 1083
120 120-4 4 184 T4B N1 M0 3 8 NA 0 4244
139 139-4 3 184 T3 NO M0 2 7 0 0 4697
147 147-4 4 219 T4 N0 M0 NA 7 NA NA NA
171 171-4 3 236 T3 N1 M0 2 7 NA 1 369
181 181-4 3 121 T2 N0 M0 2 7 1 1 1793
182 182-4 3 884 T2 N0 M0 2 8 0 1 1681
188 188-4 4 559 T2 N1 M0 2 8 0 1 1323
195 195-4 4 184 T5 N1 M0 2 7 0 NA NA
214 214-4 3 141 T4b N0 M0 2 8 0 0 2854
215 215-4 3 163 T2 N0 M0 3 6 0 0 3640
225 225-4 4 392 T4b N0 M0 3 7 0 1 811
226 226-4 4 143 T2 N0 M1 3 8 0 1 745
249 249-4 4 436 NA NA NA NA 8 0 1 1377
251 251-4 4 261 T4 N0 M0 2 8 0 1 486
268 268-4 4 209 T3 N2 M0 3 8 1 NA NA
269 269-4 3 149 T2 N1 M0 3 8 0 1 2470
276 276-4 3 136 T2 N1 M0 3 8 0 1 2641
279 279-4 3 135 T2 N0 M0 1 8 0 1 2660
281 281-4 3 121 T2 N0 M0 2 8 0 1 1032
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283L 283L-4 3 177 T1 N0 M0 1 8 0 NA NA
289 289-4 3 415 T4 N0 M0 2 7 0 1 3126
291 291-4 3 170 T2 N1 MX 3 7 0 1 1448
298 298-4 4 163 T2 N1 M0 2 8 0 0 2997
299 299-4 3 170 T2 N0 M0 2 7 0 1 613
300 300-4 3 219 T1 N0 M0 3 8 1 0 2857
302 302-4 3 177 T1 N0 MX 2 7 0 0 3081
309 309-4 3 156 NA NA NA 2 8 0 1 2796
311 311-4 3 121 T1 N0 M0 3 8 1 1 2800
32 32-4e 3 149 NA NA NA NA 8 NA NA NA
32 32-4 4 1366 NA NA NA NA 8 NA NA NA
323 323-4 3 142 T2 N0 M0 1 8 1 0 2873
325 325-4 3 359 T2 N0 M0 2 8 0 0 2755
328 328-4 3 128 T2 N0 M0 3 8 0 0 2832
329 329-4 3 149 T4b N0 M0 2 8 0 0 2680
330 330-4 4 205 T2 N1 M0 2 8 0 0 2811
333 333-4 3 209 T2 NX M0 2 8 1 0 2828
334 334-4 3 128 T4b N1 M0 2 8 1 0 2822
340 340-4 4 275 T4b N0 M1 1 8 0 1 1467
341 341-4 4 387 T2 N1 M0 1 8 0 1 2582
343 343-4 4 380 T3 N1 M0 2 8 0 0 2649
346 346-4 3 233 T2 N0 M0 2 8 1 1 2425
347 347-4e 3 158 T2 N0 M0 2 8 0 0 2615
347 347-4 4 262 T2 N0 M0 2 8 0 0 2615
350 350-4e 3 134 T4 N2 M0 3 8 0 1 280
350 350-4 4 247 T4 N2 M0 3 8 0 1 280
355 355-4 3 121 T1 N0 M0 2 8 0 0 2001
357 357-4 3 188 T2 N0 M0 1 7 0 1 2706
364 364-4 4 232 T2 N0 M0 2 8 0 0 2123
369 369-4 3 191 T2 N0 M0 2 8 1 0 2342
373R 373R-4 3 183 T1 N0 M0 NA 8 0 NA NA
374 374-4 3 121 T1 N0 M0 2 8 0 0 2356
378 378-4 3 349 T2 N1 M0 2 8 0 0 2155
381 381-4 4 373 T4b N0 M0 2 8 0 0 534
382 382-4 3 167 NA NA NA 2 8 0 0 1705
393 393-4 3 219 T2 N0 M0 1 8 0 0 1572
394 394-4 3 141 NA NA NA 2 8 0 0 1937
395 395-4 4 366 T2 N0 M0 2 7 0 0 1885
399 399-4 4 359 T4 N3 M0 2 8 0 0 1863
400 400-4 4 350 NA N0 NA 2 8 0 1 544
405 405-4 4 282 T1 N0 M0 2 8 0 1 1705
409 409-4 4 209 T2 N1 M0 3 8 0 0 1717
413 413-4 4 163 T1 N0 M0 2 8 0 1 878
416 416-4 4 170 T4 N0 M0 2 8 0 0 1673
50 50-4 4 232 T4D N1 M0 2 8 NA 1 824
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Table 6.8: Extended endocrine therapy Georgetown cohort patient-level information A.
Patient ID Sample ID Timepoint Days treated Age Surgery performed T N M ER Grade
109 109-1 diagnosis -8 78 WLE T2 N0 M0 8 3
109 109-2 on-treatment 20 78 WLE T2 N0 M0 8 3
109 109-4 long-term 303 78 WLE T2 N0 M0 8 3
120 120-1 diagnosis -8 64 WLE T4d N1 M0 8 3
120 120-2 on-treatment 17 64 WLE T4d N1 M0 8 3
120 120-3 on-treatment 87 64 WLE T4d N1 M0 8 3
120 120-4 long-term 184 64 WLE T4d N1 M0 8 3
124 124-1 diagnosis -6 73 WLE T2 N0 M0 8 3
124 124-2 on-treatment 24 73 WLE T2 N0 M0 8 3
124 124-3 on-treatment 94 73 WLE T2 N0 M0 8 3
124 124-4 long-term 1019 73 WLE T2 N0 M0 8 3
135 135-1 diagnosis -8 63 WLE NA NA NA 8 2
135 135-4 NA NA 63 WLE NA NA NA 8 2
146 146-1 diagnosis -8 73 no surgery NA NA NA 7 3
146 146-3 NA NA 73 no surgery NA NA NA 7 3
146 146-4 long-term 737 73 no surgery NA NA NA 7 3
159 159-1 diagnosis -11 88 WLE T2 N0 M0 8 2
159 159-4 long-term 198 88 WLE T2 N0 M0 8 2
163 163-1 diagnosis -11 84 WLE T1 N1 M0 8 1
163 163-2 on-treatment 10 84 WLE T1 N1 M0 8 1
163 163-4 NA NA 84 WLE T1 N1 M0 8 1
166 166-1 diagnosis -18 73 WLE T2 N0 M0 7 3
166 166-2 on-treatment 17 73 WLE T2 N0 M0 7 3
166 166-4 long-term 293 73 WLE T2 N0 M0 7 3
184 184-1 diagnosis -11 92 WLE T4b N0 M0 8 2
184 184-4 long-term 268 92 WLE T4b N0 M0 8 2
187 187-1 diagnosis -6 81 no surgery NA NA NA 8 2
187 187-4 long-term 1139 81 no surgery NA NA NA 8 2
188 188-1 diagnosis -11 85 WLE T2 N1 M0 8 2
188 188-4 long-term 559 85 WLE T2 N1 M0 8 2
195 195-1 diagnosis -8 67 NA T4 N1 M0 7 2
195 195-4 long-term 184 67 NA T4 N1 M0 7 2
208 208-1 diagnosis -11 84 WLE T3 N1 M0 8 2
208 208-2 on-treatment 45 84 WLE T3 N1 M0 8 2
208 208-3 on-treatment 87 84 WLE T3 N1 M0 8 2
208 208-4 NA NA 84 WLE T3 N1 M0 8 2
226 226-1 diagnosis -11 78 no surgery T2 N0 M1 8 3
226 226-2 on-treatment 14 78 no surgery T2 N0 M1 8 3
226 226-4 NA NA 78 no surgery T2 N0 M1 8 3
248 248-1 diagnosis -22 88 mast T4 N0 M0 8 3
248 248-3 long-term 266 88 mast T4 N0 M0 8 3
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248 248-4 NA NA 88 mast T4 N0 M0 8 3
251 251-1 diagnosis -11 76 WLE T4 N0 M0 8 2
251 251-4 long-term 261 76 WLE T4 N0 M0 8 2
257 257-1 diagnosis -6 61 WLE T2 N1 M0 8 1
257 257-4 NA NA 61 WLE T2 N1 M0 8 1
268 268-1 diagnosis -11 72 mast T3 N2 M0 8 3
268 268-2 on-treatment 17 72 mast T3 N2 M0 8 3
268 268-4 long-term 209 72 mast T3 N2 M0 8 3
279 279-1 diagnosis -15 73 WLE T2 N0 M0 8 1
279 279-4 NA NA 73 WLE T2 N0 M0 8 1
283 283-1 diagnosis -11 80 WLE T1 N0 M0 8 2
283 283-4 long-term 177 80 WLE T1 N0 M0 8 2
298 298-1 diagnosis -13 69 WLE T1 N0 M0 8 2
298 298-2 on-treatment 22 69 WLE T1 N0 M0 8 2
298 298-4 long-term 163 69 WLE T1 N0 M0 8 2
304 304-1 diagnosis -8 83 WLE T2 N0 M0 8 2
304 304-4 long-term 247 83 WLE T2 N0 M0 8 2
312 312-1 diagnosis -11 57 WLE T2 N0 M0 8 3
312 312-2 on-treatment 14 57 WLE T2 N0 M0 8 3
312 312-4 NA NA 57 WLE T2 N0 M0 8 3
313 313-1 diagnosis -6 80 no surgery NA NA NA 8 2
313 313-4 NA NA 80 no surgery NA NA NA 8 2
319 319-1 diagnosis -8 59 WLE T2 N0 M0 8 2
319 319-4 NA NA 59 WLE T2 N0 M0 8 2
32 32-1 diagnosis -1 61 WLE T4 N0 M0 8 3
32 32-3 long-term 149 61 WLE T4 N0 M0 8 3
32 32-4 long-term 1366 61 WLE T4 N0 M0 8 3
330 330-1 diagnosis -15 71 WLE T2 N1 M0 8 2
330 330-2 on-treatment 14 71 WLE T2 N1 M0 8 2
330 330-4 long-term 205 71 WLE T2 N1 M0 8 2
341 341-1 diagnosis -11 79 WLE T2 N1 M0 8 1
341 341-3 on-treatment 106 79 WLE T2 N1 M0 8 1
341 341-4 long-term 387 79 WLE T2 N1 M0 8 1
343 343-1 diagnosis -16 63 WLE T3 N0 M0 8 2
343 343-2 on-treatment 21 63 WLE T3 N0 M0 8 2
343 343-3 on-treatment 105 63 WLE T3 N0 M0 8 2
343 343-4 long-term 380 63 WLE T3 N0 M0 8 2
343 343-5 NA NA 63 WLE T3 N0 M0 8 2
343 343-6 NA NA 63 WLE T3 N0 M0 8 2
347 347-1 diagnosis -7 75 WLE T2 N0 M0 8 2
347 347-2 on-treatment 39 75 WLE T2 N0 M0 8 2
347 347-3 long-term 158 75 WLE T2 N0 M0 8 2
347 347-4 long-term 262 75 WLE T2 N0 M0 8 2
350 350-1 diagnosis -11 89 WLE T4 N2 M0 8 3
350 350-2 on-treatment 29 89 WLE T4 N2 M0 8 3
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350 350-3 long-term 134 89 WLE T4 N2 M0 8 3
350 350-4 long-term 247 89 WLE T4 N2 M0 8 3
353 353-1 diagnosis -11 84 no surgery NA NA NA NA 2
353 353-2 on-treatment 21 84 no surgery NA NA NA NA 2
353 353-4 NA NA 84 no surgery NA NA NA NA 2
395 395-1 diagnosis -13 75 WLE T2 N0 M0 7 2
395 395-2 on-treatment 14 75 WLE T2 N0 M0 7 2
395 395-4 long-term 366 75 WLE T2 N0 M0 7 2
400 400-1 diagnosis -11 73 WLE NA N0 NA 8 2
400 400-2 on-treatment 29 73 WLE NA N0 NA 8 2
400 400-4 long-term 350 73 WLE NA N0 NA 8 2
405 405-1 diagnosis -11 65 WLE T1 N0 M0 8 2
405 405-4 long-term 282 65 WLE T1 N0 M0 8 2
409 409-1 diagnosis -13 60 WLE T2 N1 M0 8 3
409 409-2 on-treatment 14 60 WLE T2 N1 M0 8 3
409 409-4 long-term 209 60 WLE T2 N1 M0 8 3
413 413-1 diagnosis -12 84 WLE T1 N0 M0 8 2
413 413-2 on-treatment 14 84 WLE T1 N0 M0 8 2
413 413-4 long-term 163 84 WLE T1 N0 M0 8 2
416 416-1 diagnosis -8 84 WLE T4 N0 M0 8 2
416 416-2 on-treatment 28 84 WLE T4 N0 M0 8 2
416 416-3 NA NA 84 WLE T4 N0 M0 8 2
416 416-4 long-term 170 84 WLE T4 N0 M0 8 2
428 428-1 diagnosis -10 85 WLE T2 N1 M0 8 3
428 428-2 on-treatment 15 85 WLE T2 N1 M0 8 3
428 428-3 long-term 199 85 WLE T2 N1 M0 8 3
434 434-1 diagnosis -11 75 WLE T2 N1 M0 8 2
434 434-2 on-treatment 22 75 WLE T2 N1 M0 8 2
434 434-3 on-treatment 92 75 WLE T2 N1 M0 8 2
434 434-4 long-term 261 75 WLE T2 N1 M0 8 2
50 50-1 diagnosis -12 78 WLE T4b N1 M0 8 2
50 50-2 on-treatment 16 78 WLE T4b N1 M0 8 2
50 50-3 on-treatment 86 78 WLE T4b N1 M0 8 2
50 50-4 long-term 232 78 WLE T4b N1 M0 8 2
64 64-1 diagnosis -8 89 Mast T4 N2 M0 7 3
64 64-4 NA NA 89 Mast T4 N2 M0 7 3
Table 6.9: Extended endocrine therapy Georgetown cohort patient-level information B.
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Tumour sampling method can 
significantly influence gene 
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Patient-matched transcriptomic studies using tumour samples before and after treatment allow inter-
patient heterogeneity to be controlled, but tend not to include an untreated comparison. Here, Illumina 
BeadArray technology was used to measure dynamic changes in gene expression from thirty-seven 
paired diagnostic core and surgically excised breast cancer biopsies obtained from women receiving no 
treatment prior to surgery, to determine the impact of sampling method and tumour heterogeneity. 
Despite a lack of treatment and perhaps surprisingly, consistent changes in gene expression were 
identified during the diagnosis-surgery interval (48 up, 2 down; Siggenes FDR 0.05) in a manner 
independent of both subtype and sampling-interval length. Instead, tumour sampling method was 
seen to directly impact gene expression, with similar effects additionally identified in six published 
breast cancer datasets. In contrast with previous findings, our data does not support the concept of a 
significant wounding or immune response following biopsy in the absence of treatment and instead 
implicates a hypoxic response following the surgical biopsy. Whilst sampling-related gene expression 
changes are evident in treated samples, they are secondary to those associated with response to 
treatment. Nonetheless, sampling method remains a potential confounding factor for neoadjuvant 
study design.
Gene expression profiling of carcinomas has been widely used for molecular subtyping and prognostic predic-
tion1–9 producing a diverse library of gene classifiers. However, these signatures may be limited by the particular 
dataset used to produce the signature10 and by the inherent cellular heterogeneity of tumours and the practical 
considerations of how samples are collected – in short the heterogeneity of the cohort and the heterogeneity of 
sampling.
A more informative and considered approach when performing molecular studies is to use matched biopsies 
from the same patient, allowing for both inter-patient variation to be controlled and changes occurring within a 
given tumour or organism to be more accurately modelled11–13. Matched sample pairs coupled with careful cohort 
selection should ensure that changes related to a given drug represent the largest source of variation, avoiding any 
unwanted contribution from confounding factors known or unknown and allow for greater statistical power with 
a smaller sample size14,15.
Acquisition of multiple biopsies from an individual patient has been simplified by the more common use of 
neoadjuvant therapy for breast cancer, an increasingly popular treatment option for initially large, inoperable or 
locally advanced breast tumours, as well as operable cancers susceptible to specific treatments16. Pre-operative 
treatment with chemotherapy, or endocrine therapy in ER+ disease, not only increases rates of breast conserving 
surgery17, but also allows a unique in vivo observation of tumour response to treatment12,18. This so-called ‘win-
dow of opportunity’ permits sequential biopsies of the same cancer to be taken at different time points during the 
course of the pre-operative treatment, allowing assessment of molecular changes in the tumour long before clini-
cal evidence of response can be determined11,13. This has allowed the molecular effects of an administered drug to 
be studied and enabled biomarkers predictive of response or resistance to therapy to be identified at an increased 
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rate. Recently our own group has demonstrated the added value of additional on-treatment measurements of 
gene expression to characterise and accurately predict the response to treatment13,19.
Whilst the benefits of this ‘window of opportunity’ approach are certainly attractive for translational research, 
matched samples have commonly been collected under the assumption that variation observed between pairs 
will have occurred as a result of treatment – i.e. the results apparent are due to the drug alone. A control group 
is often not included in these studies and those that do are commonly limited to a handful of samples (n = 820, 
n = 1521) or are confounded by concurrent treatments. Conversely, studies that have compared multiple biopsies 
from the same patient in lieu of treatment are limited to only a fraction of the total molecular repertoire, most 
often focussing on hormone receptor status by IHC and not full transcriptomic profiling22–25. Whilst oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) exhibit high 
concordance between sample pairs in these studies, the growing understanding of breast cancer as an increasingly 
heterogeneous and polygenic disease necessitates a high-throughput approach.
Previous work26 that has utilised larger-scale assays (a panel of 147 cancer related genes) investigated molec-
ular variation under conditions of no-intervening treatment (NIT) in 21 paired core needle biopsy (CB) and 
excision biopsy (EB) samples. Here the diagnostic core biopsy was implicated in initiating an immune response, 
hypothesised to then be detected in a later surgically extracted excision biopsy. Potential stimulation of 
tumour-associated macrophages (TAMs) in response to CB was also reported, itself associated with poor prog-
nosis in human breast cancer, raising concerns of taking multiple repeated biopsies from the same patient, under-
lining the importance of considering the full repertoire of genetic expression under conditions of no treatment.
Here we present the largest dataset to-date of untreated patient-matched breast cancer samples to determine 
whether, and to what extent, sample pairs exhibit molecular heterogeneity independent of treatment, and what 
the implications of any variation are in terms of the interpretation of patient-matched gene expression profiling 
studies. We explore possible causes of consistent differential expression and whether these reflect a wounding or 
immune response to the first biopsy, a hypoxia- or stress-induced response following blood supply interruption27 
or the normal growth and evolution of tumours over time28.
Methods
Patient selection. Paired diagnostic core biopsies and surgical excision biopsies were identified from 37 
patients with a primary histologically confirmed invasive breast cancer that did not receive any preoperative or 
neoadjuvant treatment at the Western General Hospital, Edinburgh, between 2003 and 2011. All patients gave 
informed consent to be included in the study, which was approved by the Lothian Regional Ethics Committee 
(2001/8/80 and 2001/8/81) and we confirm can that all experiments were performed in accordance with relevant 
guidelines and regulations. A summary and complete clinicopathological characteristics of the patients diagnostic 
core biopsies are given in Supplementary Tables S1 and S2.
Sample collection, RNA processing and microarray hybridisation. Core biopsies were taken at 
diagnosis in all patients using a 14-gauge automated needle device. Multiple cores were taken per tumour and 
combined as individual samples. Surgical excision biopsies of breast tumour were collected between 13 and 53 
days later (mean interval = 27.5 days). Samples were snap frozen in liquid nitrogen and stored at − 80 °C before 
homogenisation and RNA extraction using the RNeasy Mini Kit with RNAse Free DNAse treatment (Qiagen). 
RNA quantity and quality was assured using a Nanodrop 2000 c spectrophotometer (Thermo Scientific). RNA 
was reverse transcribed and amplified using the WT-Ovation FFPE System Version 2 (NuGEN), purified using 
the Qiaquick PCR purification Kit (NuGEN), biotinylated using the IL Encore Biotin Module (NuGEN), and 
purified using the minElute Reaction Cleanup Kit (Qiagen). At each step RNA/cDNA quantity and quality was 
assured by repeat assessment with the Nanodrop 2000 c prior to advancing to the next stage. Labelled cDNA was 
hybridized to Illumina Human HT-12 version 3 and version 4 whole-genome expression bead arrays according to 
the standard protocol for NuGEN labelled samples. Data was extracted using GenomeStudio software (Illumina).
Data analysis. All analysis was conducted in R (http://www.r-project.org) using software packages avail-
able via CRAN (http://cran.r-project.org/) and Bioconductor (http://www.bioconductor.org/). Data was 
pre-processed using the lumi package29. Log2 transformation, quantile normalisation and summarisation was 
performed for all Illumina probe profiles. Probe expression information was extracted and detected probes were 
standardised, firstly by passing a detection p-value threshold (≤ 0.05) and then by being called present in ≥ 3 
samples. This was carried out three times, once each for three processing batches that comprised the dataset. A 
common feature list was determined by those probes common to all three dataset batches before re-mapping to 
Ensembl gene sequences using the biomaRt package30,31. Multiple probes-per-Ensembl ID were resolved by mean 
averaging. Batch correction was performed using ComBat32 to integrate processing batches for further analysis 
(Supplementary Fig. S2). Sample groupings were compared using Pearson product-moment correlations. All sig-
nificances were calculated by a two-tailed Wilcoxon rank sum test and corrected for multiple testing (FDR), unless 
otherwise stated. Intrinsic subtype assignment was performed using the genefu package33. Pairwise differential 
gene expression was calculated using significance analysis of microarrays (SAM), part of the siggenes package34. 
Hierarchical clustering was performed on pairwise fold change expression values using a complete linkage 
method. SAM analysis of treated data was performed using a hundred 18-sample permutations, to fairly match 
sample size between subsets, with the intersecting significant genes being taken as a mean average. The raw and 
processed data from this study can be accessed from NCBI GEO under the accession GSE76728.
Results
Consistent treatment-independent gene expression changes between diagnostic and surgical 
paired samples. Unsupervised clustering using the 500 most variable genes across the patient-matched 
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samples demonstrated high concordance, with 25/37 pairs observed to cluster at the first level of the dendro-
gram (Fig. 1a upper). In order to assess whether core biopsy and surgical excision sample pairs varied from 
one another, Pearson correlations were calculated between intra-tumour (paired) and inter-tumour (non-paired) 
samples (Fig. 1B). Intra-tumour differences were more significantly (p = 7e-11) correlated (median r = 0.92 range 
r = 0.60–0.97) than the mean inter-tumour variations (median = 0.87, range r = 0.77–0.90). Technical interfer-
ence due to sample processing is expected to decrease correlation between samples, though only nominally35. 
Correlations below r ≃ 0.97 are likely due to underlying tumour heterogeneity, implicating a biological cause to 
the variation.
To determine the impact of differences in gene expression apparent between diagnostic core and excision 
biopsy pairs, pairwise SAM analysis identified 50 significantly differentially expressed genes (48 upregulated, 
2 downregulated; FDR = 5%), between the surgical excision and diagnostic core biopsies (Supplementary Table 
S3). Clustering using these genes was able to separate samples by their sampling method in 31/37 cases (Fig. 1a 
lower). Five subtyping signatures (PAM50, Sorlie 2003, Hu 2006, Desmedt 2008, Wirapati 2008) were applied 
to each sample individually and concordant (subtype agreement between pairs with > 3 subtype classifiers) vs. 
discordant (≤ 3 pair subtype agreements) results recorded (Fig. 1c (PAM50 only) and S5 (all methods)). Pairwise 
correlation between concordant and discordant assignments, revealed a trend (p = 0.08, Wilcoxon) between 
decreased pairwise correlation and greater discordance (Fig. 1d).
Pathway analysis of the 50 gene NIT signature revealed enrichment for MAPK signalling (DUSP1, JUN, 
NR4A1 and FOS), cancer specific (COX-2, PGE2, JUN and FOS), apoptosis induction (FOS and JUN) and 
genomic reformatting following (brain) ischaemia (EGR1 and JUN) pathways. A number of these genes are 
examples of ‘early’ or ‘primary’ growth response genes induced by both cell-extrinsic and cell intrinsic signals that 
do not require de novo protein synthesis for their expression36.
Figure 1. Evidence of treatment independent variation between breast cancer diagnostic core biopsies 
and surgical excision samples. (a) Hierarchical clustering of the 37 patient-matched diagnostic core and 
excision biopsy samples using the 500 most variable genes (upper) and a SAM derived signature of 50 genes 
consistently differentially expressed between core and excision biopsies (lower). Bars represent IHC status 
(ER+ /Her2− = Blue; ER+ /Her2+ = Pink; ER-/Her2− = Red) or biopsy method. Lower-most bar indicates 
where sample pairs have co-aggregated. Two-thirds (25/37) of the pairs cluster at the first level of the upper 
dendrogram, whereas pairwise association is lost in 31/37 cases for the lower. (b) There is a significantly 
stronger correlation between biopsy pairs (intra-tumour) than between different tumours (mean inter-tumour). 
* * * p < 0.001. (c) Discordance in molecular subtype assignment between core and excision biopsies. Patients are 
ranked left to right by pairwise correlation. Colours represent SSP subtypes (Luminal A = Dark blue; Luminal 
B = Light Blue; Her2 = Pink; Basal = Red; Normal = Green). (d) Sample pairs were called discordant when 
Biopsy A ≠ Biopsy B for at least 4/5 classifiers. Comparison of concordant vs. discordant pairwise correlations 
then revealed an inverse relationship between correlation and discordancy.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:29434 | DOI: 10.1038/srep29434
Patient-matched gene expression changes may be associated with either time or biopsy 
methodology. Having determined significant and consistent changes in gene expression exist 
between diagnostic core and surgical excision pairs we sought to identify the underlying cause. Several hypothe-
ses were immediately apparent – greater changes may occur following a shorter time interval between sampling 
if consistent gene expression changes reflect a wounding/immune response to the diagnostic core biopsy26; or it 
may be anticipated that expression patterns diverge over time to reflect tumour evolution; this may in turn be 
driven by tumour subtype28. However, comparisons of pairwise correlations defined by either IHC status subtype 
(ER+ /Her2− , ER+ /HER2+ or ER-/HER2− ), PAM50 subtype (cross-table comparing IHC and PAM50 subtype 
assignment in Supplementary Table S4) or as a function of time interval between biopsies revealed no trend asso-
ciated with either factor (p = 0.43 and p = 0.32 respectively) (Fig. 2a). This suggested that a progression in breast 
cancer-related biological changes were unlikely to be the root cause of the observed pairwise variation. To further 
investigate whether breast cancer biology could be responsible for the observed pairwise variation, we compared 
7 breast cancer-related expression modules37 between core and excision biopsies (Supplementary Fig. S3), which 
revealed no contrasting trend in gene expression. In conjunction to assigning cause, it remained equally impor-
tant to determine whether our NIT signature genes were evident to alter in an equivalent treated data set. Using a 
patient-matched cohort treated with letrozole, collected and processed within our group in a manner analogous 
to the NIT data13, there appeared to be a strong relationship between the time interval between biopsies and a 
Figure 2. Factors associated with consistent gene expression changes between diagnostic core biopsy and 
surgical excision of breast tumours in the absence of treatment. (a) Pairwise correlations between biopsy 
pairs are not explained as either a function of time between biopsy (p = 0.32) or IHC status (p = 0.43). ER+ 
/Her2− = Blue; ER+ /Her2+ = Pink; ER-/Her2− = Red. (b) Heatmap showing differential expression of 
NIT signature genes in NIT and letrozole treated cohorts. Colours represent gene expression fold changes 
(up = yellow; down = blue) between samples and their subsequent patient-matched biopsies. Samples are 
ordered by increasing time between biopsies and reveal a pattern associated with either extraction method - CB 
(grey) or EB (dark grey) - or time. (c) Frequency distribution of biopsy time intervals. For further analysis, the 
letrozole treated data was split into three subsets – 2-week CB (2wCB), 3-month CB (3 mCB) and 3-month 
EB (3 mEB) – to investigate the effects of biopsy method and/or time on gene expression. (d) Mean expression 
fold changes since previous biopsy for 2 week, 3 month and NIT samples. 3 month subsets closely resemble 
NIT expression changes, though SAM analysis revealed a greater intersection of differentially expressed genes 
between NIT and 3 mEB samples than between NIT and 3 mCB samples.
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subset of our NIT gene signature (Figs 2b and S4), with treated samples biopsied after 3 months exhibiting signifi-
cant differential expression of these NIT genes. In these instances however, time interval almost wholly coincided 
with the final biopsy method and we therefore sought to determine which factor, if either, was dominant. Dividing 
the treated data into 3 subsets determined by the time since previous biopsy (Fig. 2c) as 2-week CB (2wCB, 
n = 95), 3-month CB (3 mCB, n = 18) and 3-month EB (3 mEB, n = 70), allowed comparison of changes assumed 
to result from treatment by both time interval and sampling method. Biopsy time interval was apparent as the fac-
tor most associated with the genes altered in our NIT data, with 3-month samples alone exhibiting expression fold 
changes similar to those observed in the NIT data, implying time on treatment as the defining factor (Fig. 2d). 
However, in tandem, global GSEA analysis was able to demonstrate that our NIT signature could significantly 
define the differences between untreated and treated data only when sampling method differed (NIT vs. 2wCB, 
p = 0; NIT vs. 3 mCB, p = 0.02; NIT vs. 3 mEB, p = 0.25). Similarly, only in the instance of excision biopsy was 
SAM analysis able to recapitulate > 30% of the genes differentially expressed in the NIT data (mean = 47%). More 
so, out of 3955 differentially expressed treated-EB genes, seven of those common to NIT differential expression 
were amongst the top 15 in terms of fold change magnitude. Taken together, this implies both time on treatment 
as well as biopsy method are able to impact upon NIT signature gene expression.
Multiple patient-matched datasets also demonstrate changes in NIT early growth response 
genes. To further investigate the evident relationship between sampling method, time on treatment and NIT 
signature expression, we selected a panel of four genes (DUSP1, EGR1, FOS, FOSB) that were observed to be most 
representative of these factors, as well as being well characterised in the literature, for comparison in six external 
validation datasets (Table 1, Fig. 3). Significant differential gene expression was consistently observed to a greater 
degree only when an excision biopsy followed a previous core biopsy for these four genes.
Neoadjuvant treatment n
Biopsy Time Interval/days Extraction Method
Dataset/Referencemedian range 1st On- Final
None 37 27 13–53 CB – EB This study
Letrozole 122 107 13–884 CB CB CB EB Turnbull et al.13
Celecoxib/none 22 15 unspecified 14–21 CB – EB (Brandão et al.21
Anastrozole 81 On-18 Final 14 14–112 CB CB CB (Smith et al.57
RAD001 21 14 14 CB – EB (Sabine et al.58
Anthracycline-based Chemotherapy 69 unspecified unspecified CB CB EB (Magbanua et al.59
None 56 14 14 CB EB Lopez-Knowles et al.47
Table 1.  Composition of patient-matched neoadjuvant breast tumour datasets used within our study.
Figure 3. Multiple patient-matched datasets demonstrate shared changes in NIT early growth response 
genes. Pairwise analysis of four early growth response genes among the NIT signature in six validation datasets. 
These genes potentially represent an association between gene expression and sampling method, with surgically 
excised samples (EB) showing greater expression fold-change than their core biopsied (CB) counterparts.  
* p ≤ 0.05; * * p ≤ 0.01; * * * p ≤ 0.001; − = not significant.
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Tumour sampling appears independent of an immune or wound-healing response. It remained 
important to determine whether gene expression changes in lieu of treatment were able to elicit either an immune 
or wound-healing response that may be detrimental to a patient’s health or directly confound gene expression 
profiling results. Evaluation of both a published immune-related 9 gene panel, suggested to be upregulated in 
response to a diagnostic CB26 and a 589 gene signature representative of a wound-healing response38 failed to 
show any association with sampling method or time between biopsy, with sample expression unlikely to have 
been affected in terms of these biological categories (Supplementary Fig. S2).
Discussion
Our study reports gene expression changes in the largest cohort of sequential samples from patients receiving 
no-intervening treatment yet assembled to demonstrate the molecular variation that occurs independent of treat-
ment in the neoadjuvant and preoperative setting. Significant pairwise changes in gene expression were observed 
and a 50 gene signature identified comprised of genes associated with a number of cell growth, cell stress and 
cancer related signalling pathways, including ATF3, EGR1, FOS, FOSB and JUN, each of which have been pre-
viously implicated in prognostic discrimination and pathogenesis of breast cancer39–43 as well as other cancers44.
We report that sampling method, specifically core versus excision biopsy, has a direct impact on gene expres-
sion and has the potential to introduce a confounding factor to downstream analysis. The most probable expla-
nation of this expression variation between sample pairs is the technical issue of warm ischemia before newly 
biopsied samples are processed, when the cellular metabolic machinery attempts to mount a survival or apoptotic 
response before all metabolic activity ceases. Tissue ischemia may result from exclusion of the vascular supply or 
simply from handling by the surgeon, scrub nurse, pathologist and tumour bank personnel before the sample is 
frozen in liquid nitrogen. This time delay is likely (on average) to be significantly longer for surgical excision spec-
imens than core biopsy samples. The effects of ischemia on gene expression has been described previously45 and 
warm ischemia associated with the surgical extirpation of human tissues has significant effects on gene expres-
sion. These data support the careful monitoring of ischemic time for tissues harvested for the purpose of gene 
profiling. Similarly, Dash et al.46 demonstrated significant changes in the expression of FOS, JUN, ATF3 in a study 
to examine the effect of processing time on prostate cancer samples.
Similar conclusions are proposed in a recent study published during the review process47, where CB and 
EB pairs were also analysed in terms of correlation and differential gene expression. Variation between sample 
pairs was found to be evident though modest and those genes found to be differentially expressed intersected 
with those highlighted in this study (34% of our NIT signature genes). Of particular interest, the overlapping 
genes included the four genes highlighted in Fig. 3 as well as several others indicative of a stress or early growth 
response (RGS1, RGS2, ATF3, JUN), similarly proposed as a reaction to surgery-associated ischaemia. Indeed, 
the rationale of the study stemmed from a desire to investigate post-operative processing time and its effect on 
gene expression, citing two smaller studies which both highlighted ischaemia as a potential source of molecu-
lar variation48,49. Again, key molecules including FOSB were highlighted as being demonstrative of this effect. 
Importantly, the investigators additionally compared excision biopsies placed into RNAlater either immediately 
post-surgery or following an interval, and again observed early growth and stress response associated genetic 
expression to increase.
In a second analogous study, of 147 breast cancer-related genes measured by Nanostring in 21 patients, 
Jeselsohn et al.26 proposed that sequential breast cancer biopsies reveal activation of an immune response, char-
acterised by a panel of 9 immune-related genes, of which CD68 is known to activate tumour-associated mac-
rophages and implicated in increasingly severe prognosis50, as well as being present in the clinically available 
Oncotype DX® breast cancer assay8. However, none of these genes were found to be significantly differentially 
expressed in our larger, whole genome cohort (Supplementary Fig. S1). Conversely, a number of studies have 
demonstrated a high degree of concordance between classical IHC markers for breast cancer, namely oestrogen, 
progesterone and HER2 receptors24,25 between diagnostic core and excision biopsies, suggesting discordance may 
be limited to the level of transcription. Our study demonstrates that pairwise variation at the transcriptome level 
is not limited to the classical markers of breast cancer, though in some cases paired samples may be classified dif-
ferently using molecular signatures (Figs 1c and S5). The causative factor behind this variation is most likely due 
to sampling method in our NIT cohort, with surgical resection resulting in gene expression in response to stress. 
It remains unclear whether this effect translates to samples following treatment, with time on treatment being 
observed to mediate molecular changes against the background of the sampling method.
It is important that results from preoperative window or neoadjuvant studies are carefully scrutinised, as a 
study by Morrogh et al.51 - using a 502 cancer-related gene panel to examine 16 paired patient samples, 8 of which 
were untreated controls - claimed that window trials are influenced by the wound-healing process. They proposed 
that upregulation of MLL and FOSB was evidence of this, irrespective of treatment. This mirrored our own find-
ings, though it is necessary to note that Morrogh et al. were limited by sample size and inconsistencies in the effect 
direction of proliferation markers (increased Ki67, but decreased PCNA). Nonetheless it remains likely that the 
overall pathway level message within our study - upregulation of proliferation - was a consequence of an early 
growth response to the biopsy itself. It is crucial to determine whether there is a genuine immune response asso-
ciated with biopsy type as inflammatory signatures have been associated with poor anti-proliferative responses to 
aromatase inhibitors13,52. Clear evidence of both an immune or wound response signature53 was completely absent 
in our untreated samples, implying that any contribution of biopsy methodology to an inflammatory response is 
likely to be minor.
With the potential for pairwise variation irrespective of treatment, our study raises potential concerns of 
the suitability of the neoadjuvant window in gene expression profiling studies. Recent results of the ALTTO 
(Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) clinical trial were, however, found to be con-
sistent with the predicted benefits from the neoALTTO trial. This supported the utility of the neoadjuvant setting 
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as a suitable and important window for evaluating promising new targeted agents54, as well as the continued use of 
patient-matched samples to assess intervention studies for translational research. Nonetheless it remains critical 
to understand that whilst patient-matched samples reduce variation due to individuals, all possible sources of 
variation must be considered for an optimal experimental design. For example, in an intervention study to assess 
dietary changes on normal breast tissue from pre-menopausal women it was considered optimal to schedule 
the sequential biopsies one menstrual cycle apart, rather than using a fixed window of time55, as there is clear 
evidence that menstrual changes in oestrogen levels caused significant changes in gene expression56. Underlying 
tumour heterogeneity is an inevitable variable when performing neoadjuvant or window studies, however our 
study suggests that the method of sample collection should be considered along with treatment, time interval and 
clinicopathological features as an important potential confounding factor. These considerations are of particular 
importance if a study’s purpose is the development of a prognostic/predictive classifier or identification of a bio-
marker, with genes present in our NIT signature excluded from the analysis.
Our study demonstrates that consistent molecular changes arise in tumours in the absence of treatment and 
these can impact upon classification. These changes appear to be an artefactual ischemic response resulting from 
the sampling methodology itself, rather than reflecting the effects of a previous biopsy. Careful consideration 
should be given in future studies that seek to illustrate molecular changes between paired biopsies in the neoadju-
vant setting for breast cancer and likely other cancers that make use of the same experimental design.
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ABSTRACT
Publicly available high-throughput molecular data can enable biomarker identification and eval-
uation in a meta-analysis. However, a continuous biomarker’s underlying distribution and/or
potential confounding factors associated with outcome will inevitably vary between cohorts and
is often ignored. The survivALL R package (https://CRAN.R-project.org/package=survivALL)
allows researchers to generate visual and numerical comparisons of all possible points-of-
separation, enabling quantitative biomarkers to be reliably evaluated within and across
datasets, independent of compositional variation. Here, we demonstrate survivALL’s ability
to robustly and reproducibly determine an applicable level of gene expression for patient prog-
nostic classification, in datasets of similar and dissimilar compositions. We believe survivALL
represents a significant improvement over existing methodologies in stratifying patients and
determining quantitative biomarker(s) cut-points for public and novel datasets.
INTRODUCTION
Biomarker performance is traditionally assessed by estimating survival benefit over time, often
summarized by Kaplan-Meier plot1,2. Whilst qualitative biomarkers can easily stratify cohorts
into two or more groups, the question of how to divide a cohort with a quantitative measure
is considerably more challenging. Multiple subgroups may exist within a given patient pop-
ulation, but a need for simple and tractable clinical decisions (i.e. treat or don’t treat) have
often encouraged division into two classes. The most obvious, common, yet arbitrary approach
for this is to divide a cohort into two equal sized groups at the median level. However, this
median-split approach ignores a marker’s distribution and any potential confounding factors
relating to the composition of the dataset, clinical or otherwise. This heterogeneity makes as-
sessing the robustness of a biomarker across datasets problematic, with median dichotomisation
unlikely to produce reliable results due to random sampling differences. In short, a significant
median separation in cohort A is unlikely to translate to cohort B. Given the public availabil-
ity of high-throughput molecular profiling datasets providing outcome data, the opportunity to
evaluate biomarkers in silico, as part of extended meta-analyses, is in principle becoming easier.
In practice however, datasets derived from cohorts of primary patient tissue are molecularly
heterogeneous in their composition3, are likely to exhibit varying proportions of multiple clini-
cal factors associated with outcome (e.g. node and receptor statuses, grade, molecular subtypes
and age). It is therefore clear that this variation must be accounted for if a biomarker is to be
successfully applied and validated in a meta-analysis.
1
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/208660doi: bioRxiv preprint first posted online Oct. 25, 2017; 
Building upon previous best-of-split methods4–6 we have developed survivALL (https://CRAN.R-
project.org/package=survivALL) an R package implementation to exhaustively calculate and
visualise hazard ratios (HRs) for all possible points-of-separation and assess the association
between a continuous measure and survival. As open-source software, survivALL allows for
researchers to reproducibly perform exhaustive survival analysis using public or independent
datasets, in a highly transparent, automatable and extensible manner within the wider R
package landscape. Complimenting survivALL is a companion web-based app – survivAPP
(pearcedom.shinyapps.io/survivapp/) – allowing non-programmatic, drag-and-drop survivALL
use. We believe that survivALL allows researchers to perform exhaustive survival analysis
relevant to the current state of –omics research.
MATERIALS AND METHODS
survivALL computes hazard ratio statistics for every point-of-separation possible, allowing the
magnitude, and frequency of, significant cut-points to be identified (Video S1)x. To more ro-
bustly determine significance, a non-parametric and dataset-specific bootstrap is applied, defin-
ing reliable confidence intervals. Bootstrapping is performed as a 10,000-fold repeated calcula-
tion of HRs for random sample orderings, producing a distribution of expected/random HRs for
each individual point-of-separation, to which observed true biological HRs are compared and
significance calculated. Dataset-specific best points-of-separation were optimised by maximising
desirability of combined p-value and absolute HR magnitude7.
All analysis was performed using the R statistical environment using CRAN and Bioconductor
hosted packages8–10. survivALL p-values were calculated using the bootstrapping procedure
described above, whilst median approach p-values were calculated using the Cox-proportional
hazards model1. To avoid overcorrection of the multiple comparisons inherent in survivALL,
all survivALL analysis is preceded by a single ancillary test of significance (Cox-proportional
hazards model), performed using the biomarker as a continuous variable. Code and session
information necessary to reproduce the analysis is included as supplementary material.
RESULTS
To illustrate the value of the survivALL package, we considered over-expression of human epider-
mal growth factor 2 (HER2/ERBB2), a well-established biomarker associated with poor prog-
nosis in invasive breast cancer11,12, in the largest single breast cancer gene expression dataset
– METABRIC13 (n=1971 samples with complete disease specific survival information). Im-
portantly and unusually, METABRIC is split into two equally sized and composition-matched
subsets, allowing for independent discovery and validation. The survivALL plotALL() func-
tion enables visualisation of hazard ratios for all possible separations (n-1) of ordered ERBB2
expression for the METABRIC discovery cohort (n=980) (Figure 1A). It establishes 283/980
points-of-separation as significant, confirming the established expectation that increased ERBB2
expression is associated with poor prognosis. The span and location of these points are consistent
with epidemiological evidence demonstrating that across the population ~20% of breast cancers
overexpress HER214. Contrasted in Figure 1B are two Kaplan Meier plots resulting from using
the median (p=0.48) and the data-driven most significant point-of-separation (p=1.25x10-11)
for this dataset.
In considering the issue of dataset composition, the highly similar METABRIC subsets enabled
us to first evaluate whether survivALL could derive and validate the point-of-separation which
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most clearly distinguishes (lowest p-value) between good and poor prognosis groups from one
cohort to the other (Figure 1B). For all 19,628 genes, survivALL was used to calculate the point-
of-separation with the lowest p-value in the discovery cohort and the gene expression value at
this point was used to divide the validation cohort (n=991). Prediction accuracy was measured
as the number of patients incorrectly classified compared to the validation cohort’s own dataset-
specific most significant point-of-separation. This same measure of accuracy was additionally
calculated using a median approach for comparison (Figure 1B & 1C).
As expected, survivALL significantly outperforms a median approach (p=2.2x10-16,,
Kolmogorov-Smirnov test), demonstrating survivALL’s applicability in robustly determin-
ing prognostic stratification in two suitably relatable datasets, with no a priori knowledge of a
gene’s population level distribution.
However, real-world datasets are rarely compositionally matched in the way that the
METABRIC discovery and validation cohorts are, and it remained to determine if survivALL
could perform this applied prognostic stratification in more dissimilar and noisier datasets.
To test this, we simulated semi-random sub-samplings of the entire METABRIC dataset for
three pre-defined proportions of estrogen receptor (ER) positivity – 25, 50 & 75%. Using
these dramatically variable compositions, we determined the extent to which survivALL was
able to track these differences in terms of the datasets-specific best point-of-separation of
GATA3, a mediator of ER binding15 (Figure 2A). It was evident that as the proportion of
ER+ and ER- samples shifted, the survivALL plots in turn shifted in response, with the
most significant point-of-separation consistently falling at the division between ER+ and ER-
samples. Importantly, though these plots changed, the corresponding level of expression that
defined the ER+/- boundary remained consistent (Figure 2B), indicating survivALL’s ability to
robustly determine a reliable level of GATA3 expression to stratify our patient cohorts, even in
highly compositionally dissimilar datasets. We repeated this analysis for 5 publically available,
ER-positive and tamoxifen treated datasets (GSE2990, GSE6532, GSE9195, GSE12093,
GSE17705), for grade and AURKA expression, demonstrating similarly consistent results
between datasets (Figure S1).
Finally, whilst significant association of a biomarker can be determined in a meta-analysis using
expression as a continuous variable, this does not reveal the direction of that association, i.e. good
or poor prognosis. Beyond the added information revealed therein, there additionally remains
the possibility that a gene determined as significantly associated with prognosis in more than one
dataset may in fact demonstrate variable, or even opposite, directions of association (Figure S2).
For the METABRIC discovery and validation cohorts this was evident to occur for ten genes,
several of which (ACY316, LRRK217, NUPR118 & UGT1A719) have been previously associated
with cancer risk. This therefore represents a small but real danger that must be considered in
meta-analysis.
DISCUSSION
In this study we have highlighted the issue of assessing quantitative biomarkers for survival
analysis, offering survivALL and survivAPP (Video S2) as tools to evaluate and overcome these
challenges. We have attempted to illustrate situations relevant and common to researchers in
the current environment of publically available large datasets, using well established but likely
compositionally distorted examples. As an R package, survivALL allows greater resolution,
transparency and flexibility compared to other online best-of-split tools, applicable to any pub-
lic or proprietary dataset and usable in larger-scale automated data operations. Researchers
are increasingly using approaches such as KMplotter20, either to median-split or highlight the
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dataset-specific best point-of-separation in a single or combined dataset. This approach presents
a number of potential problems, most notably the restriction of what data is available to be
analysed – either alone or in combination as a meta-analysis – and the exact methods used.
Furthermore, whilst a prognostic association can be considered using a continuous marker as
the classifier itself, this ignores a number of informative factors, such as the direction and mag-
nitude of association, as well as the optimal value to allow patient stratification into treatment
groups.
Importantly, whilst the examples presented here relate to individual genes in breast cancer
microarray datasets, survivALL is readily extensible to other diseases, data types or any other
quantitative measure, including signatures or scores based upon combinations of markers. More-
over, whilst this paper has largely considered dichotomisation, survivALL also allows for addi-
tional sub-populations with varying survivals to be visualised, including those related to clinical
factors such as grade (Figure S1), as well as revealing potential confounding factors, produc-
ing multivariate analysis and demonstrating or uncovering an otherwise unknown factor when
considering multiple datasets. Fundamentally, survivALL has been developed as open-source
software, to flexibly integrate with other popular R packages, including the popular visualisation
tool ggplot2 for customisable and scalable output.
Most importantly, survivALL and survivAPP allows true biological effects and their relationship
to survival to be revealed and reliably compared, within and between datasets, to move towards
determining real-world clinically applicable biomarker cut-offs.
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Figure 1: A) The plotALL function allows hazard ratios (y-axis) and bootstrap significance
(p<0.05 colour scale; p￿0.05 grey) for all possible quantitative biomarker cut-points to be ex-
amined. Patients are ordered by increasing expression of the quantitative marker – in this
example, ERBB2 expression. Events (distant metastasis-free survival) are indicated as vertical
lines below the plot, with darker colours indicating chronologically earlier events. Kaplan-Meier
plots for ERBB2 stratified using median (n = 490 vs. 490) and survivALL (n = 924 vs. 56)
approaches are shown, comparing patients with expression lower (grey) or higher (black) than
the points-of-separation determined in A. B) Comparison of survivALL and median approaches
in predicting optimal cohort separation for ERBB2. The expression values associated with both
median and dataset-specific best points-of-separation derived from the discovery set in 1A is ap-
plied to the validation dataset. Error (median = orange, survivALL = blue) is calculated as the
number of patient who would be incorrectly assigned using these predictions, in relation to the
validation cohorts own best separation. This process is repeated in 1C for all genes. survivALL
significantly (p=2.2x10-16) outperforms a median approach in terms of predictive accuracy.
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Figure 2: A) Analysis of compositionally unmatched METABRIC subsets. Three equally sized
subsets (n=500) with variable proportions of ER+ samples (25, 50 and 75%) demonstrate sur-
vivALL’s ability to track the ER+/ER- (blue/red) boundary for GATA3 expression, with the
most significant point-of-separation (low-high significance = blue-yellow gradient) existing at
this boundary for each subset. B) Whilst the HR distribution is evident to change with ER+
proportion, the 10% most significant points-of-separation consistently related to the same level
of GATA3 expression. For comparison, the median level of expression (dashed white line) for
each subset is also shown.
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neoadjuvant letrozole treatment of breast
cancer: distinguishing acquired resistance
from dormant tumours
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Abstract
Background: The risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades
following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherently
difficult to investigate; previous efforts have been limited to in-vitro or in-vivo approaches. In this study, sequential tumour
samples from patients receiving extended neoadjuvant aromatase inhibitor therapy were characterised as a novel clinical
model.
Methods: Consecutive tumour samples from 62 patients undergoing extended (4–45months) neoadjuvant aromatase
inhibitor therapy with letrozole were subjected to transcriptomic and proteomic analysis, representing before (≤ 0), early
(13–120 days), and long-term (> 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. Patients with at least a
40% initial reduction in tumour size by 4months of treatment were included. Of these, 42 patients with no subsequent
progression were classified as “dormant”, and the remaining 20 patients as “acquired resistant”.
Results: Changes in gene expression in dormant tumours begin early and become more pronounced at later time
points. Therapy-induced changes in resistant tumours were common features of treatment, rather than being specific
to the resistant phenotype. Comparative analysis of long-term treated dormant and resistant tumours highlighted
changes in epigenetics pathways including DNA methylation and histone acetylation. The DNA methylation marks 5-
methylcytosine and 5-hydroxymethylcytosine were significantly reduced in resistant tumours compared with dormant
tissues after extended letrozole treatment.
Conclusions: This is the first patient-matched gene expression study investigating long-term aromatase inhibitor-
induced dormancy and acquired resistance in breast cancer. Dormant tumours continue to change during treatment
whereas acquired resistant tumours more closely resemble their diagnostic samples. Global loss of DNA methylation
was observed in resistant tumours under extended treatment. Epigenetic alterations may lead to escape from
dormancy and drive acquired resistance in a subset of patients, supporting a potential role for therapy targeted at
these epigenetic alterations in the management of resistance to oestrogen deprivation therapy.
Keywords: Dormancy, Oestrogen deprivation therapy, Epigenetics, Letrozole, Sequential samples, Resistance,
Microarray, Proteomics
* Correspondence: andrew.sims@ed.ac.uk
1Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research
UK Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Selli et al. Breast Cancer Research            (2019) 21:2 
https://doi.org/10.1186/s13058-018-1089-5
Background
Approximately 70% of breast cancer patients who have
oestrogen receptor (ER) alpha-positive tumours receive
adjuvant oestrogen deprivation therapy. Five years of
aromatase inhibitor therapy produces a 40% reduction in
10-year mortality [1]. However, while the annual risk of
mortality for ER-negative breast cancer decreases follow-
ing the first 5 years after diagnosis, the annual rate re-
mains constant for ER+ patients [2]. In fact, women with
ER+ early-stage disease treated with 5 years of adjuvant
endocrine therapy have a persistent risk of recurrence
and death from breast cancer for at least 20 years after
diagnosis [3]. Molecular studies have demonstrated that
nodal and distant metastases are highly similar to their
matched primary tumours, implicating a continuation of
the original cancer [4–6]. However, the time between
treatment and recurrence is often greater than that
which can be explained by normal cell-doubling rates
[7], implying cancer cells remain dormant in the body
before re-awakening.
Residual dormant cancer cells are hypothesised to per-
sist either by withdrawing from the cell cycle and transi-
tioning to a quiescence state or by continuing to
proliferate at a reduced rate, counter-balanced by cell
death [8]. Reawakened dormant cells may become de-
tectable after reaching a detection threshold or reacti-
vated via increased angiogenesis, and/or escape from the
inhibitory microenvironment or immune effects [9, 10].
Dormancy is therefore considered a major mechanism
underlying resistance to therapy, where dormant cells
survive despite anti-proliferative oestrogen deprivation
therapy.
Resistance to oestrogen deprivation therapy may occur
at disease inception (de novo or innate resistance), but a
larger proportion of patients acquire resistance during
treatment (acquired/secondary resistance) [11]. Several
mechanisms of resistance to oestrogen deprivation ther-
apy have been described previously [12, 13]. However,
the majority of these findings are based on preclinical
data obtained from cell lines and animal models. It is
therefore difficult to know if these accurately reflect mo-
lecular changes in patient tumours.
Expression profiling of clinical samples, measuring the
effect of, or predicting response to, treatment has re-
cently become feasible. However, experimental design is-
sues, such as the difficulty in obtaining paired samples
for comparison, particularly for longer time intervals,
makes it difficult to study changes within tumours [14].
For example, a previous study investigating tamoxifen
failure compared samples from patients requiring sal-
vage surgery with pre-treatment samples from an unre-
lated group of disease-free patients [15]. More recently,
sequential patient-matched samples have been success-
fully utilised to determine treatment-induced dynamic
changes in tumours at 2 weeks to 3 months, demonstrat-
ing the effectiveness of this approach [16–18].
For a variety of reasons, including being unfit for sur-
gery, a proportion of patients receiving pre-surgical
oestrogen deprivation therapy do not have their tumours
excised following 3–4 months of treatment. These
long-term endocrine-treated tumours represent a unique
group that can inform how tumours respond to ex-
tended oestrogen deprivation in situ. Having initially
shrunk in size, some tumours remain at a steady volume
and appear dormant, whilst others subsequently begin to
regrow. We have utilised this unique cohort of sequen-
tial samples from patients receiving extended neoadju-
vant oestrogen deprivation therapy to characterise
luminal breast cancer dormancy and acquired resistance
as a novel clinical model.
Methods
Patients and samples
Breast cancer patients were treated with neoadjuvant
aromatase inhibitor therapy with letrozole (Femara, 2.5
mg; Novartis Pharma AG, Basel, Switzerland) for a mini-
mum of 4 months; tumours were not removed either be-
cause patients declined or were unfit for surgery. The
study was approved by the local regional ethics commit-
tee (07/S1103/26, August 2007) and all patients gave in-
formed consent. Clinical characteristics of the tumours
are given in Table 1. A consort diagram detailing inclu-
sion and exclusion criteria is provided in Additional file 1
(Figure S1). Patients with > 40% initial decrease in
tumour size by 4months of treatment were included in
the study. Those with no subsequent progression on im-
aging by the latest biopsy were classified as “dormant”;
otherwise, they were classified as “acquired resistant”
(Fig. 1a, b). For patients whose latest ultrasound scan
(USS) measurement was taken more than a month be-
fore surgery, changes in gene expression (mean relative
change) of three widely used proliferation markers
(MKI67, PCNA, and MCM2) were used to assist classifi-
cation. Tumours with an increase in proliferation marker
expression (either after an initial decrease or not) were
classified as “acquired resistant”, otherwise there were
classified as “dormant”. Sequential tumour biopsies were
taken with a 14-gauge needle before and after letrozole
treatment and at the time of surgery. Fresh samples were
snap-frozen in liquid nitrogen and each tumour sample
was confirmed to contain ≥ 50% cellularity and at least
60% tumour tissue using haematoxylin and eosin (H&E)
sections. Following pulverisation of tissue with a mem-
brane disruptor (Micro-Dismembrator U, Braun Bio-
tech), phase separation was performed by guanidinium
thiocyanate-phenol-chloroform extraction (Qiazol Lysis
Reagent).
Selli et al. Breast Cancer Research            (2019) 21:2 Page 2 of 15
Table 1 Patient characteristics
Dormant, n (%) Resistant, n (%) Total, n p valuea
Total no. of patients 42 20 62





1 6 (14.3) 1 (5.0) 7
2 27 (64.3) 10 (50.0) 37
3 8 (19.0) 6 (30.0) 14
NA 1 (2.4) 3 (15.0) 4
Tumour size 0.71
T1 5 (11.9) 4 (20.0) 9
T2 19 (45.2) 9 (45.0) 28
T3 2 (4.8) 2 (10.0) 4
T4 11 (26.2) 4 (20.0) 15
NA 5 (11.9) 1 (5.0) 6
Nodal status 0.36
N0 27 (64.3) 11 (55.0) 38
N1 8 (19.0) 7 (35.0) 15
N2 1 (2.4) 1 (5.0) 2
N3 1 (2.4) 0 1
NX 1 (2.4) 0 1
NA 4 (9.5) 1 (5.0) 5
Metastasis status 1.00
M0 34 (80.9) 18 (90.0) 56
M1 2 (4.8) 0 2
MX 1 (2.4) 1 (5.0) 2
NA 5 (11.9) 1 (5.0) 6
ER score (Allred) 0.18
6 1 (2.4) 0 1
7 6 (14.3) 6 (30.0) 12
8 35 (83.3) 14 (70.0) 49
HER status 0.69
Negative 35 (83.3) 12 (60.0) 47
Positive 6 (14.3) 3 (15.0) 9
NA 1 (2.4) 5 (25.0) 6
Histological type 0.73
IDC (no special type) 18 (42.9) 6 (30) 24
ILC 8 (19.0) 4 (20) 12
Mucinous 1 (2.4) 0 1
NA 15 (35.7) 10 (50) 25
Molecular subtypeb 1.00
Luminal A 21 (50.0) 9 (45.0) 30
Luminal B 20 (47.6) 9 (45.0) 29
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Gene expression profiling and analysis
RNA was extracted from the aqueous phase by
column-based purification (RNeasy mini kit, Qiagen)
and then labelled and hybridized (HumanHT-12 v4 Illu-
mina BeadChip) according to the manufacturer’s proto-
col (NuGEN) as previously described [19, 20]. Raw data
were detection (p < 0.05, ≥ 3 samples) and quality fil-
tered, log2 transformed, and quantile normalized using
the Bioconductor lumi package [21]. Data are publicly
available from NCBI GEO under accession GSE111563.
The analysis also includes data from 14 patients (42
samples, GSE59515) and 9 patients (24 samples,
GSE55374) from previous studies [16, 19] which meet
the criteria defined above; the relationship between the
samples from these datasets is indicated in Add-
itional file 2 (Table S1). Hierarchical clustering analysis
was performed using a complete linkage method and
Euclidean distance. Pathway enrichment analysis and
visualisation were performed using ReactomePA [22].
Differential gene expression analysis was performed with
Rank Products [23]. The significance of differences was
evaluated by using unpaired Wilcoxon test for two
groups and analysis of variance (ANOVA) with post-hoc
Tukey HSD for multiple comparisons.
Proteomics analysis
Proteins were isolated from the organic phase of Qiazol
[24]. Pellets were sonicated and dissolved in 1% SDS.
Proteomics was performed using Thermo Q Exactive
plus and Label-free Quantitation (LFQ). Peptides ob-
tained from samples were analysed in mass spectrometry
runs; serial samples from the patients were run on the
same day. A modified version of Filter Aided Sample
Preparation (FASP) was performed using serial digests
with lysC and trypsin to generate two orthogonal frac-
tions per sample [25, 26]. The mass spectrometry spec-
tra generated in each run were used for relative
quantitation of individual peptides. Normalization and
quantifications of peptides were performed using
MaxLFQ and MaxQuant [27]. A total of 6251 protein
groups were identified. Data was log2 transformed and
missing values were imputed as the minimum observed
value in each sample. The data have been deposited to
the ProteomeXchange Consortium via the PRIDE [28]
partner repository with the dataset identifier
PXD009328.
Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded (FFPE) sections were
processed using an automated stainer (Leica Biosystems,
Bond III). Heat-induced epitope retrieval for both anti-
bodies was performed by 30-min incubation in
citrate-based pH 6.0 epitope retrieval (ER1) solution
followed by incubation in 3.5 N HCl for 15 min at room
temperature as suggested by Haffner et al. [29]. For
5-methylcytosine (5-mC) and 5-hydroxymethylcytosine
(5-hmC) detection, mouse monoclonal 5-methylcytosine
specific (33D3; Abcam, ab10805) and rabbit polyclonal
5-hydroxylmethylcytosine (Active Motif, 39,769) anti-
bodies were used, respectively. Both antibodies were
used at 1/1000 dilution and were incubated for 15 min.
Detection was performed using secondary
antibody-horseradish peroxidase (HRP) conjugates and
substrate-chromogen (3,3’-diaminobenzidine (DAB)).
After staining, slides were counterstained with haema-
toxylin. Nuclear staining in epithelial cells was evaluated
using an H-score obtained by multiplying the intensity
of the stain (0: no staining; 1: weak staining; 2: moderate
staining; 3: intense staining) by the percentage of cells
(H-score range, 0 to 300).
Results
Long-term oestrogen deprivation therapy as a model of
dormancy and acquired resistance
A cohort of 62 primary breast cancer patients receiving
at least 4 months of oestrogen deprivation therapy
(Fig. 1a) and initially responding were stratified into two
groups, ‘dormant’ and ‘acquired resistant’ based on dy-
namic changes in tumour size and proliferation (see
methods and Fig. 1b). Patient-matched sequential sam-
ples were available at three time points: before (≤ 0 days),
early (13–120 days), and long-term (> 120 days) treat-
ment. Dormant and acquired resistant samples were dis-
tributed uniformly with respect to time on treatment,
and duration at each time point was not significantly dif-
ferent between response groups (Table 1). For long-term
treatment, the mean and range were 186 (121–884) days
Table 1 Patient characteristics (Continued)
Dormant, n (%) Resistant, n (%) Total, n p valuea
HER2 enriched 0 1 (5.0) 1
Basal-like 0 0 0
Normal-like 0 0 0
NA 1 (2.4) 1 (5.0) 2
ER oestrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NA not available
aFisher exact test (p < 0.05, two-tailed)
bAt diagnosis by PAM50 (genefu)
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Fig. 1 (See legend on next page.)
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and 226 (121–1366) days for patients with dormant and
acquired resistant tumours, respectively (Fig. 1c).
There were no significant differences in patient
clinico-pathological features between response classes
before treatment (Table 1). However, prediction ana-
lysis of microarray (PAM)50 intrinsic molecular sub-
types were found to change during oestrogen
deprivation therapy (Fig. 1d). These changes were
consistent with known associations with outcome,
with all dormant tumours either remaining the same
or switching to better prognosis luminal A or
normal-like tumours. For resistant tumours, however,
25% (5 out of 20) switched to a subtype of worse
prognosis (Fig. 1d). The proportion of luminal B tu-
mours characterised by reduced endocrine sensitivity
and higher proliferation was higher in resistant tu-
mours compared with dormant tumours under early
(35% versus 27%) and long-term (50% versus 12%)
treatment (Fig. 1d; stacked bar graphs on the right).
The PAM50 defines breast cancer into four intrinsic
molecular subtypes: luminal A, luminal B, HER2-
enriched, and basal-like [30]. PAM50 intrinsic subtyp-
ing has been shown to provide additional prognostic
value to standard clinicopathological factors where lu-
minal A tumours had a significantly better outcome
than luminal B, HER2-enriched, and basal-like tu-
mours [31].
As expected, Kaplan-Meier survival analysis demon-
strated significantly worse outcomes for patients with
resistant tumours compared with patients with dor-
mant tumours (log rank, p = 0.026; Fig. 1e). Recur-
rence rates for patients with dormant and resistant
tumours were 21% (9/42) and 45% (9/20), respect-
ively. Moreover, patients with resistant tumours suf-
fered significantly earlier recurrences compared with
patients with dormant tumours (p = 0.05; range 26–
947 versus 136–2042 days; Fig. 1f ). Disease-free sur-
vival and time to recurrence were defined from time
of surgery, not from the time of diagnosis, since pa-
tient classification was performed based on change in
tumour size by USS and proliferation by gene expres-
sion at on-treatment and surgery time points.
Distinct transcriptomic changes under long-term letrozole
treatment
Unsupervised analysis was performed to consider
whether sequential samples displayed greater similarity
between response classes or treatment duration. Hier-
archical clustering using the 500 genes with the highest
variance across all samples revealed two main subclasses,
seemingly driven by time on treatment, with resistant
and dormant tumours indistinguishable (Fig. 2a). The
dominant pattern was that the samples of the same pa-
tient usually clustered together (Fig. 2a).
When long-term treated samples were considered
alone, two clusters did emerge, the larger of which con-
tained mostly dormant samples (79%), whilst the second
had a roughly even proportion of dormant (48%) and re-
sistant (52%) samples (Fig. 2a). Similarly, a multidimen-
sional scaling (MDS) plot for the 500 genes with the
highest variance across all time points revealed consist-
ent changes over time in response to treatment for both
dormant and acquired resistant samples (Fig. 2b), al-
though long-term dormant samples were much more
distinguishable from pre-treatment samples than the
long-term acquired resistant samples (Fig. 2b).
Correlations between tumours from different individ-
uals (inter-patient) remained similar at each time point
and were not different between response classes (data
not shown) as corroborated by hierarchical clustering
analysis with all samples and across all the time points.
However, correlations of the transcriptome between
matched sequential samples (intra-patient) revealed that
pre-treatment samples were significantly (p = 0.01) less
similar to their long-term treated pairs (median 0.89,
range 0.74–0.95) than their early treatment pairs (me-
dian 0.91, range 0.84–0.95) (Fig. 2c). However, when di-
vided by dormancy status this finding was only
significant (p = 0.01) for dormant tumours (Fig. 2c), sug-
gesting that dormant tumours continue to diverge tran-
scriptionally whereas acquired resistant tumours do not
consistently differ after initial or extended treatment, as
mirrored in the MDS representation (Fig. 2b).
Perhaps surprisingly, oestrogen, progesterone, and an-
drogen receptors and their target genes [32] were not
(See figure on previous page.)
Fig. 1 Long-term oestrogen deprivation therapy as a clinical model to investigate breast cancer dormancy and acquired resistance. a Extended (4–45months)
letrozole treatment was exploited as a clinical model of breast cancer dormancy and acquired resistance. Sequential clinical samples from the same patient
with no surgery and extended treatment were used to model clinical breast cancer dormancy and resistance. Before (pre, ≤ 0 days), early-on (early, 13–120
days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. b Dynamic change in tumour size by ultrasound scan (USS) and
mean expression of proliferation markers MKI67, PCNA, and MCM2 were used to classify patients into two categories: dormant (blue) and resistant (red). Overall
comparisons of classifications per patient based on USS and mean change in proliferation markers with final classification are shown. c The duration of letrozole
treatment (days) for samples from dormant (blue) and resistant (red) patients. Each bar represents a sample. Samples are ordered by time on treatment. d
Intrinsic subtype classification by PAM50 of samples at each time point. Stacked bar graphs on the right show the percentage of each subtype of samples from
dormant and resistant patients. e Kaplan-Meier plot showing disease-free survival probability in patients with dormant versus resistant tumours (log-rank test).
Disease-free survival was defined from time of surgery. f Density plot showing the distribution of time to recurrence (in years; defined from time of surgery) in
patients with dormant and resistant tumours. CI confidence interval, HR hazard ratio, LumA luminal A, LumB luminal B
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differentially expressed between long-term treated dor-
mant and resistant tumours (data not shown).
Changes in gene expression/pathways following long-
term letrozole treatment
To consider whether the gene expression changes due to
treatment in the dormant and acquired resistant tumours
were the same or distinct we initially considered them
separately. Pairwise rank product analysis (pre- versus
long-term treatment, false discovery rate (FDR) < 0.01)
identified 2319 genes significantly differentially expressed
(1063 downregulated and 1256 upregulated) between
long-term treated and pre-treatment dormant tumours
(Additional file 2: Table S2). These genes were significantly
enriched (p < 0.01) for a total of 62 and 26 pathways, re-
spectively (Additional file 2: Table S3), including reduc-
tions in cell cycle, senescence, DNA methylation, and an
increase in extracellular matrix (ECM) organization. These
findings are consistent with previous studies of
patient-matched sequential samples treated with
Fig. 2 Distinct transcriptomic changes during long-term aromatase inhibitor treatment. a Unsupervised hierarchical clustering with most variant 500
genes across all samples and long-term treated samples. ER6, ER7, ER8 correspond to oestrogen receptor (ER) Allred scores 6, 7, and 8, respectively. b
Multidimensional scaling (MDS) plot using the 500 genes with the highest variance across all time points. Each dot corresponds to a sample and sizes
represent the duration of treatment. c Intra-patient (comparison of samples from the same patient) correlations of transcriptome are shown. Dormant
(blue); resistant (red); before (pre, ≤ 0 days), early-on (early, 13–120 days), and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy
with letrozole. ***p < 0.001; **p < 0.01; *p < 0.05. NA not available, Rec+ recurrence, Rec– recurrence free
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oestrogen deprivation therapy [16–18]. Acquired resistant
tumours displayed much fewer consistently differentially
expressed genes (238; 63 downregulated and 175 upregu-
lated) between long-term treated and pre-treatment sam-
ples (Additional file 2: Table S4). Genes that were
upregulated in resistant tumours (pre-treatment versus
long-term treatment) were enriched for several of the
same pathways as dormant tumours (ECM organization,
elastic fibre formation, and platelet degranulation), but
downregulated genes were much more variable
(Additional file 2: Table S5; Fig. 3a, b).
Having determined that dormant and acquired resist-
ant tumours have somewhat distinct changes during
treatment at the molecular level, the question remained
as to whether these changes tend to occur at earlier time
points or were specific to long-term treatment. For dor-
mant tumours, differential expression begins early on,
but becomes more pronounced at later time points
(Fig. 3a). Downregulated genes (pre-treatment versus
long-term treatment) were most evident at early-on
treatment for resistant tumours, consistent with their
initial response to treatment, whilst upregulated genes
(pre-treatment versus long-term treatment) were most
changed after long-term treatment, potentially suggest-
ing that these genes may mediate acquired resistance
(Fig. 3b). We further examined whether differentially
expressed genes between pre-treatment versus
long-term treatment identified in each response class
(dormant and resistant) were shared (Fig. 3c, d). Both
downregulated and upregulated genes identified in re-
sistant tumours were significantly changed (p < 0.01) in
dormant tumours (Fig. 3d). However, only upregulated
genes identified in dormant tumours were significantly
upregulated in resistant tumours without any change in
downregulated genes (Fig. 3c), implicating a partial lack
of response to treatment at the molecular level in ac-
quired resistance patients.
A potential role of epigenetic regulation in acquired
resistance
The above findings suggest that therapy-induced dy-
namic changes in gene expression and pathways are
common features of long-term treatment, rather than
being specific to dormant or resistant phenotypes. This
led us to perform comparative analysis of dormant and
acquired resistant tumours at the long-term time point
to identify any specific differences. Unpaired rank prod-
uct analysis (FDR < 0.01) revealed a total of 419 genes
(170 downregulated and 249 upregulated) to be differen-
tially expressed between long-term treated dormant and
resistant tumours (Additional file 2: Table S6; Fig. 4a).
These genes were significantly enriched in 27 pathways
(p < 0.05), including several epigenetics-related pathways,
including “DNA methylation”, “PRC2 methylates
histones and DNA”, “histone acetyl transferases (HATs)
acetylate histones”, and “epigenetic regulation of gene
expression”, as well as senescence and cell cycle (Add-
itional file 2: Table S7; Fig. 4b). Examination of the ex-
pression of these genes alone demonstrated that they
could partially separate dormant from the majority of re-
sistant tumours (Fig. 4c). Single-sample gene set enrich-
ment analysis (ssGSEA) [33] was performed to
quantitatively score the activity of differentially
expressed genes in every sample. The score of differen-
tially upregulated genes between long-term treated dor-
mant and resistant tumours was significantly higher in
acquired resistant compared with dormant tumours
under early treatment (p < 0.05) as well as long-term
treatment (p < 0.001) (Fig. 4d).
Our results prompted us to examine whether the changes
we observed in clinical samples were similarly changed in ex-
perimental models of resistant breast cancer cells. Oestrogen
receptor-positive MCF7 cells stably transfected with the aro-
matase gene (MCF7aro cells) and long-term
oestrogen-deprived (LTED) breast cancer cells have been
widely used to understand mechanisms of aromatase inhibi-
tor resistance in vitro. Examining two publicly available gene
expression datasets (GSE10879 and GSE10911) demon-
strated that genes differentially expressed (upregulated) be-
tween acquired resistant and dormant tumours (a total of
249) were significantly enriched in aromatase inhibitor-resist-
ant cells compared with sensitive/control cells (Fig. 5a). A
total of 211 and 174 out of 249 genes were present in
GSE10879 and GSE10911, respectively. In two out of three
in-vitro studies with dynamic gene expression data from
LTED MCF7 cells, an initial decrease in ssGSEA scores
mimicking the dormancy/responsive state was followed by a
later increase representing acquired resistance (Fig. 5b), fur-
ther validating our results and emphasizing the utility of
these in-vitro models. Interestingly, no significant difference
was observed in tamoxifen- and fulvestrant-resistant MCF7
cells compared with drug-sensitive control cells (Fig. 5c) sug-
gesting the specificity of the results to resistance to aroma-
tase inhibitor therapy.
In addition, proteomic analysis of a subset of samples
was performed which revealed differential expression in
656 proteins (279 downregulated, 377 upregulated) be-
tween long-term treated dormant and resistant tumours
(rank product; p < 0.05; n = 10; Additional file 2: Table
S8; Fig. 5d). A total of 36 features including S100P and
HIST2H3A (H3.2) overlapped between proteomics and
transcriptomics, validating the results with a different
approach.
Furthermore, differentially expressed genes were
uploaded to Enricher (ENCODE Histone modification
2015 dataset) [34] to determine histone modification
enrichment. Two H3 lysine methylation modifications
(H3K27me3 and H3K4me1) were enriched
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significantly (adjusted p = 0.0003 and p = 0.004, re-
spectively) whereas no enrichment for histone acetyl-
ation was determined.
To further validate the gene expression results, im-
munohistochemical evaluation of FFPE sections re-
vealed significantly lower global 5-mC and 5-hmC
levels in resistant tumours compared with dormant
tumours under extended treatment (Fig. 6a, b). Sig-
nificantly lower 5-hmC levels in acquired resistant
compared with dormant tumours were also observed
at early treatment (Fig. 6b), suggesting hypomethyla-
tion may be predictive of emergence from dormancy.
Fig. 3 Long-term oestrogen deprivation therapy is associated with cell cycle, senescence, epigenetic regulation, and extracellular matrix
(ECM)-associated pathways. Differentially expressed genes between pre-treatment and long-term treated dormant (a) and resistant (b)
tumours were determined. Heat-maps showing change in downregulated and upregulated gene expression in dormant (a) and
resistant (b) samples. Each column represents a sample and each row a gene. Colours are log2 mean-centred values with red
indicating high values and blue indicating low expression. Bar plots on top of heat-maps represent the time on treatment (days) for
each sample. c,d Graphs show dynamic changes in mean expression of differentially expressed genes in response classes. ***p < 0.001;
**p < 0.01; *p < 0.05
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Discussion
Understanding the mechanisms underlying the mainten-
ance of and escape from dormancy have great import-
ance considering that most cancer-related deaths are
caused by metastasis rather than the primary tumour. In
this study, we describe the first sequential
patient-matched clinical dataset of extended oestrogen
deprivation therapy in breast cancer. The results high-
light the difficulty of distinguishing dormant and resist-
ant tumours, with dynamic molecular changes of
treatment being highly similar between the groups.
However, comparative analysis revealed a set of genes
significantly upregulated in resistant tumours compared
with dormant tumours within the first months of letro-
zole treatment suggesting a predictive role for changes
in DNA methylation.
Failure to reduce proliferation after 2 weeks of
oestrogen deprivation therapy [16, 35] may well identify
patients that are innately resistant; however, acquired re-
sistance remains a greater challenge in terms of identify-
ing biomarkers and appropriate alternative or
combination therapies [36]. Many of the transcriptomic
changes identified in long-term treated dormant tu-
mours are shared by some, but not all, resistant
Fig. 4 Comparative analysis of dormant and resistant tumours. a Volcano plot showing differentially expressed genes between long-term treated
dormant and resistant tumours (dormancy versus resistance genes). Some upregulated and downregulated genes in resistant tumours are
highlighted in red and blue, respectively. b Significantly enriched pathways for dormancy versus resistance genes (p < 0.01; ReactomePA). Grey
edges connecting the nodes indicates genes shared between the nodes/pathways, and the width of the edge is scaled by the number of
common genes. Colours indicates the significance (p value) where red is a lower p value. c Heatmap showing partial separation of long-term
treated dormant and resistant samples using dormancy versus resistance genes (a total of 419; 170 downregulated and 249 upregulated genes).
Colours are log2 mean-centred values with red indicating high and blue indicating low expression. Genes are sorted by fold-change (FC) values
from most to least up/downregulated. Samples are sorted by sum expression of upregulated genes. ER6, ER7, and ER8 correspond to oestrogen
receptor (ER) Allred scores 6, 7, and 8, respectively. d Comparison of single sample gene enrichment analysis (ssGSEA) scores of dormancy versus
resistance upregulated genes between dormant and acquired resistant tumours. Dormant (blue); resistant (red); before (pre, ≤ 0 days), early-on
(early, 13–120 days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. ***p < 0.001; *p < 0.05. NA not
available, Rec+ recurrence, Rec– recurrence free
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tumours, providing further evidence of resistance het-
erogeneity [37] where dormant tumours share similar
molecular changes, but there are likely to be a variety of
escape mechanisms that lead to acquired resistance.
In the present study, paired differential expression
analysis demonstrated that dormant tumours continue
to change under long-term treatment. Some of the iden-
tified dormancy-related pathways such as cell cycle
arrest and senescence have established roles in metasta-
sis dormancy [38], further supporting the relevance of
our clinical model, with the senescence-associated
secretory phenotype (SASP) recently suggested to regu-
late breast cancer dormancy and relapse [39]. As in
short-term responsive tumours [16], ECM organization
and degradation were significantly upregulated in dor-
mant tumours. ECM remodelling and its degradation by
Fig. 5 Validation of results using in-vitro gene expression data from resistant cell lines and proteomics analysis. a Normalised enrichment scores
of differently upregulated genes (a total of 249) between long-term treated dormant and resistant tumours calculated using single sample gene
set enrichment analysis (ssGSEA) in aromatase inhibitor-resistant cells. Scores were significantly higher (**p < 0.01, ***p < 0.001) in two aromatase
inhibitor-resistant cell lines, MCF7:2A and MCF7:5C, which were clonally derived from MCF7 breast cancer cells following long-term oestrogen
deprivation (LTED) compared with control/sensitive MCF7 cells (n = 4). Anastrozole-resistant (Ana_R) and exemestane-resistant (Exe_R) MCF7aro
cells had significantly higher scores compared with control (n = 3). b Dynamic changes in enrichment scores of LTED MCF7 cells in three different
datasets. c Scores in tamoxifen-resistant (Tam_R) and fulvestrant-resistant (Fulv_R) and drug-sensitive (control) MCF7 cells (n = 4, n = 10). d
Volcano plot showing differentially expressed proteins between long-term treated dormant and resistant tumours (p < 0.05). Some overlapping
features between transcriptomics and proteomics analysis and the most upregulated and downregulated proteins are highlighted in red and
blue, respectively. FC fold-change, sc subclone
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matrix metalloproteases (MMP) have previously been
suggested to regulate the switch between dormancy and
metastatic growth [40]. Despite histological confirmation
that each tumour sample contained at least 60% tumour,
we acknowledge that the results presented are of intact
whole tissue and potentially limited by minor variations
in tumour cellularity or the proportion of stoma which
could affect gene expression.
The most transcriptionally upregulated gene in resist-
ant tumours S100P, previously shown to be an inducer
of breast cancer metastasis correlated with decreased
survival [41]. S100P, a small calcium-binding protein
mediating Ca2+-dependent signalling pathways, has dis-
tinct functions in normal tissue and cancer, including
human embryonic development and breast cancer initi-
ation [42]. Recently, S100P hypomethylation in blood
was demonstrated to be inversely correlated with tissue
S100P expression and significantly associated with breast
cancer, implicating S100P as a potential diagnostic
marker [43]. High plasma S100P levels have also been
correlated with poor prognosis in metastatic breast can-
cer patients, with levels decreasing following treatment,
suggesting a role of S100P in dynamic monitoring of re-
sponse [44]. In the present study, S100P gene expression
and protein levels were significantly higher in resistant
tumours after long-term treatment, as well as being dif-
ferentially expressed before treatment, supporting its po-
tential role as a therapeutic target [45] and a predictive
marker.
Comparative analysis of dormant and resistant samples
after extended treatment revealed enrichment for a set
of genes with a role in DNA methylation and histone
Fig. 6 Immunohistochemical evaluation of methylation markers. a 5-methylcytosine (5-mC) and b 5-hydroxymethylcytosine (5-hmC) levels were
determined in FFPE sections from letrozole-treated samples. Representative images in dormant and resistant tumours are shown. Boxplots show
distributions of semi-quantitative intensity scores of 5-mC (*p < 0.05, ***p < 0.001; n = 5–12) and 5-hmC (***p < 0.001; n = 5–13) levels in dormant
and resistant tumours. Early-on (early, 13–120 days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole
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acetylation/deacetylation. Epigenetic alterations are rec-
ognized to occur in breast cancer. DNA methyltransfer-
ase (DNMT) and histone deacetylase (HDAC) inhibitors
have been shown to exert encouraging effects on the dis-
ease [46]. Recently, the potential role of epigenetic
changes in regulating dormancy and reactivation state
has been suggested to explain the reversible (on/off ) na-
ture of dormancy [47].
Breast cancer “CpG island methylator phenotype”
(CIMP), as revealed by genome-wide methylation ana-
lysis of metastatic breast cancers where a large number
of genes are hypermethylated, has been suggested to be
informative for metastatic potential [48]. A significant
correlation between pre-treatment global DNA methyla-
tion with neoadjuvant chemotherapy response in rectal
cancer has been reported [49]. Although DNA hypome-
thylation was the first epigenetic alteration identified in
cancer, its molecular process and effects are not yet well
understood [50]. In addition, 5-hmC levels were shown
to correlate with differentiation status, with higher levels
when more differentiated [29]. In addition, alterations in
DNA methylation in LTED MCF7 cells have been previ-
ously reported [51]. Our results provide evidence for the
loss of a global DNA methylation process in resistant tu-
mours and strengthen the case to use these models for
further study. The global decrease in 5-mC may account
for the observed reduction in 5-hmC levels since 5-mC
is converted to 5-hmC. On the other hand, at the
early-on time point, 5-hmC levels were significantly re-
duced with no significant change in 5-mC levels, sug-
gesting an independent role of the 5-hmC mark.
Hypomethylated cancer cells have been suggested to be
selected to form tumours with increased malignancy
[50]. We suggest that hypomethylation in resistant tu-
mours may reflect a de-differentiation process inducing
stem cell-like cell formation. Determining the time point
at which that hypomethylation starts, which would allow
intervention before it starts to prevent resistance to ther-
apy, needs further investigation.
The main genes significantly enriched for
epigenetics-associated pathways in the present study are
core histone (H3, H4, H2B) genes. Well-known
epigenetics-associated genes such as DNMT were not
differentially expressed in the present study. Therefore,
it might be suggested that observed changes in histone
gene levels may simply reflect the high proliferation rate
in resistant tumours since transcription of these histone
genes are replication-dependent and their mRNA levels
increase during DNA replication [52]. However, deregu-
lation of histone H2A and H2B was associated with
anthracycline resistance in breast cancer cells and re-
versed by HDAC small molecule inhibitors [53]. Further-
more, upregulation of replication-dependent core
histone proteins has been suggested to be a selective
indicator of ER-mediated MCF7 cell proliferation re-
gardless of the proliferation rate [54]. Also, observed glo-
bal loss of DNA methylation in resistant tumours
suggests dynamic regulation of gene transcription under
letrozole therapy. Therefore, histone upregulation and
alterations in epigenetic pathways observed in our study
may play a role in resistance to endocrine deprivation
therapy, rather than simply mirroring the degree of
proliferation.
Our results indicate alterations both in DNA methyla-
tion and histone modifications. HDAC inhibitors, which
have been shown to regulate DNA methylation [55],
may be successful clinically as second-line drugs alone
or in combination following oestrogen deprivation ther-
apy failure as there is growing evidence for their tumour
selective action [56, 57]. A time-dependent role for
HDACs in leukaemia has been shown [58] and may also
be critical in determining when to start HDAC inhib-
ition therapy to successfully treat tumours resistant to
oestrogen deprivation therapy. Whether or not the epi-
genetic alterations are triggers of re-awakening and if
the timely use of epigenetic drugs can prevent acquired
resistance warrants further investigation.
Conclusions
We have performed the first study of sequential tumour
samples from breast cancer patients receiving extended
neoadjuvant oestrogen deprivation therapy as a clinical
model of dormancy and acquired resistance. Our ana-
lysis suggests that molecular differences between dor-
mant and resistant tumours are initially subtle,
becoming more obvious only after extended treatment.
This study emphasizes that alterations in DNA methyla-
tion in the first months of treatment may predict which
patients will eventually develop acquired resistance.
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